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Malaria is a mosquito-borne infection caused by Plasmodium parasites. This disease occurs 
predominantly in tropical and sub-tropical regions causing 216 million clinical cases annually 
and resulting in 655 000 deaths.   It is estimated that more than 90% of the deaths due to 
malaria infection occur in Africa with children younger than 5 years of age and pregnant 
women being most susceptible to infection, disease progression and death.  Due to 
antimalarial drug resistance and other disease compounding factors such as poor socio-
economic conditions and patient compliance, there is a need to discover and develop effective 
novel antimalarials with a unique mode of action. However the discovery and development of 
new drugs is an expensive and time consuming venture therefore the use of drug formulation 
to improve and/or enhance existing antimalarial chemotherapy is a cost-effective and feasible 
alternative strategy in eradicating malaria. 
Artemisinin based combination therapy‟s (ACTs) are recommended as first line treatment for 
uncomplicated malaria. ACTs combine a rapid acting antimalarial such as artemisinin or a 
derivative, to reduce parasite load, with a longer acting partner antimalarial to eliminate 
residual parasites thus curing infection as well as preventing the selection of drug resistant 
parasites. Lumefantrine (LF) is a long acting antimalarial; it is co-formulated with artemether 
and available commercially as the ACT, Coartem
®
. LF is a highly lipophilic drug resulting in 
poor and variable oral bioavailability.  The primary aim of this study is to improve the 
bioavailability of LF with the application of Pheroid
™
 formulation technology. A further 
intention is to determine if the Pheroid
™
 formulated LF eliminates the positive „food effect‟ 
associated with LF and improves in vivo antimalarial efficacy.  




, LF was predicted to have low aqueous 
solubility (LogP = 9) and good membrane permeability. The oral absorption of compounds 
with low aqueous solubility is typically limited by the dissolution rate in the GI tract resulting 
in erratic absorption and variable bioavailability. Pheroid
™
 technology was applied to 
improve the solubility of LF after oral administration. A bioavailability study of LF was 
conducted in a mouse model to compare LF in Pheroid
™
 formulation with LF in reference 
(aqueous) solution and LF in canola oil. LF was quantitated in mouse whole blood and 
plasma using high performance liquid chromatographic separation coupled with tandem mass 















volume of 20 µl and an isotopic labelled internal standard, for the quantitation of LF over a 
concentration range of 15.6 – 4000 ng/ml, were validated according to FDA guidelines.  
For the bioavailability experiment the mice were divided into treatment groups each receiving 
LF in one of the three test formulations. The three treatment groups were further divided into 
the fed group and starved group. LF was tested at a 10 mg/kg dose concentration, 
administered to the experimental mice by oral gavage. Blood (and plasma) samples were 
collected via tail bleeding over a 24 hour test period and subsequently extracted using a 
protein precipitation method and analysed using LC-MS/MS. The concentration-time data 
was used to develop a population pharmacokinetic (PPK) model to describe and compare the 
bioavailability of the test group administered LF in Pheroid
™ 
formulation to the reference and 
canola oil groups. The bioavailability of LF in reference formulation heavily depended on 
food intake resulting in a 2.7 times higher bioavailability in the fed state when compared to 
the starved state. The bioavailability of LF, calculated using the PPK model was 3.2 times 
higher when formulated using the Pheroid
™
 technology as compared to LF in the reference 
solution (fasting state). For LF in Pheroid
™
 formulation, the between subject variability 
(BSV) for bioavailability was ~15% compared to ~44% for LF in reference solution, under 
fasting conditions.  
In vitro and in vivo antimalarial experiments were also performed to determine if LF when 
formulated using Pheroid
™
 technology would show enhanced efficacy compared to LF in the 
reference solution. The antimalarial efficacy of LF in Pheroid
™
 and reference formulation 
was tested against a chloroquine sensitive (D10) strain of Plasmodium falciparum using a 
colorimetric pLDH assay. LF in reference and Pheroid
™
 formulation had an IC50 value of 
50.9 and 27.1 nM respectively. The results indicated that LF in Pheroid
™
 formulation 
exhibited improved antimalarial activity in vitro by 46.8%, when compared to the reference 
formulation.   
A Peters‟ 4-day suppressive test was conducted to assess and compare the efficacy of LF in 
Pheroid
™
 and reference formulation to chloroquine (positive control). LF was tested at 10, 5 
and 1 mg/kg dose concentrations. The experimental mice were inoculated intra-peritoneally 
with parasitized erythrocytes and administered a dose of LF, by oral gavage, for four 
consecutive days. The results of the experiment indicated no significant difference in the 
efficacy or mean survival time of the mice in the Pheroid
™ 
formulation and reference 















Thus it may be concluded that using the Pheroid
™ 
formulation improves the bioavailability of 
LF, eliminates the food effect associated with LF as well as significantly reducing the 
between subject variability in bioavailability when compared to the reference formulation. A 
similar effect can be obtained after the oral administration of LF in canola oil. LF in 
Pheroid
™
 formulation showed improved in vitro efficacy when compared to the reference 
formulation, however the improved bioavailability of LF in Pheroid
™
 formulation did not 
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1.1 Malaria: Cause and Effect 
Malaria is a dual-host hematoprotozoan parasitic infection, transmitted by certain species of 
the female anopheline mosquitoes. In humans, malaria is caused by four parasite species; 
Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale and Plasmodium malariae 
(Hoffman et al., 2012). In recent years, Plasmodium knowlesi, a species that causes malaria 
among monkeys, has also caused human cases of malaria. P. falciparum is the most virulent 
of the species and largely responsible for severe morbidity and mortality (WHO; malaria fact 
sheet, 2012). The life cycle of the P. falciparum parasite will be discussed in detail in Section 
1.2.  
Malaria is an infectious disease that is preventable and curable yet 216 million clinical cases 
occur annually with 655 000 people succumbing to infection (WHO; malaria fact sheet, 
2012). Approximately half of the world‟s population live at risk of infection in the 99 
countries and territories affected by malaria. The risk of death as a result of P. falciparum 
infection is higher in Africa than other malaria endemic countries (Snow et al., 1997, Prusty 
and Das, 2001, Snow et al., 2005). Extensive areas of Latin America, Africa and South-East 
Asia, some of the poorest economies, have high prevalence of malaria infection (WHO; 
malaria fact sheet, 2012, Snow et al., 2005) as seen in Figure 1.1. 
 
Figure 1.1:  Global distribution of malaria endemic areas. The light green shaded areas have low 
levels of transmission with a childhood infection prevalence of <10%. Medium green shaded areas 
have an infection prevalence between 11% and 50%. Dark green shaded areas have an infection 















It is estimated that 90% of deaths caused by malaria occur in Africa, children under the age of 
5 years and pregnant women being most susceptible to infection (WHO, world malaria report 
2011). Although the malaria mortality rates have been reduced by more than 25%, globally, 
the burden of malaria extends well beyond morbidity and mortality. Malaria is closely 
correlated with poor socio-economic conditions. Malaria endemic countries may benefit less 
from foreign investment, market trade and industrial development due to the excessive cost of 
infection prevention, treatment and loss of labour (Gallup and Sachs, 2001, Malaney et al., 
2004). High child mortality leads to increased fertility rates which affect the demographic 
structure of a country and discourages investment in education. Malaria in childhood has also 
been shown to permanently affect development and reduce cognitive performance (Serouri et 
al., 2000, Holding and Snow, 2001). The magnitude of the disease burden caused by endemic 
malaria is evident in the prevalence of a potentially fatal genetic modification which causes 
sickle cell disease in 130 000 infants annually (Malaney et al., 2004, Natarajan et al., 2010). 
As a result of the protective nature of the sickle cell trait against malaria infection, the disease 
is still prevalent in malaria endemic areas. Due to the geographical overlap, malaria and 
Human Immunodeficiency Virus (HIV) co-infection has major public health and economic 
implications, especially in Sub-Saharan Africa where comorbidity causes increased 
prevalence of both diseases (Abu-Raddad et al., 2006). In summation, malaria is a global 
health threat that causes substantial morbidity, mortality, negative socio-economic growth 
and diminished quality of life for the populations living in endemic regions.  
1.2 Life cycle of P. falciparum 
The life cycle of the malarial parasite incorporates stages in both the mosquito vector and the 
human host. As depicted in Figure 1.2, the infective sporozoites present in the mosquito‟s 
saliva is transferred to the human host during a blood meal. In the human host the sporozoites 
develop in the parenchymal cells of the liver (exo-erythrocytic cycle) to produce merozoites 
which are released into the blood stream (erythrocytic cycle) to infect and reproduce in red 
blood cells (RBCs). Most antimalarials eliminate the parasite from infected red blood cells, as 
indicated in Figure 1.2, malaria diagnosis also occurs when the parasite is in the blood stage 
or erythrocytic cycle. The sporogonic, exo-erythrocytic and erythrocytic stages of P. 
















Figure 1.2: A diagram depicting the life cycle of the malaria parasite, detailing the A. Exo-
erythrocytic cycle, B. Erythrocytic cycle and C. Sporogonic cycle. (Diagram sourced from: 
http://dpd.cdc.gov/dpdx/html/Malaria.htm) 
 
A. Exo-erythrocytic cycle 
Malaria infection is transmitted to a human host when an infectious female Anopheles 
mosquito bites and injects saliva, containing anti-coagulant agents and infective sporozoites, 
into the blood stream of the human host. The sporozoites circulate in the bloodstream before 
actively entering the liver of the host. In the liver they invade the hepatocytes and initiate the 
asexual exo-erythrocytic cycle. The sporozoites transform into mature shizonts that reproduce 
asexually generating extensive numbers of merozoites. After 5-20 days the merozoites 
rupture the hepatic cells, enter the blood stream and invade the red blood cells. 
Only P. vivax and P. ovale produce hypnozoites which remain dormant, for varying periods 

















B. Erythrocytic cycle 
The blood stage cycle of the parasite replication is responsible for the pathology associated 
with malaria. The merozoites released from the liver into the blood stream recognize, attaches 
and enters the RBC. The blood stage parasite grows, feeds and undergoes periodic (24-72 
hour) cycles of asexual replication; producing and releasing daughter merozoites. Within the 
RBC, the merozoite matures from a ring-stage trophozoite to a pigmented trophozoite and 
then undergoes multiple rounds of nuclear division to form a shizont. A mature shizont 
generates merozoites which rupture the host RBC, enter the blood circulatory system and 
infect other RBCs.  Instead of undergoing cycles of asexual replication, merozoites may also 
develop into sexual forms of the parasite; male and female gametocytes. These gametocytes 
are the precursor cells of the male and female gametes, once formed they exit the RBC and 
circulate in the bloodstream. These gametocytes are ingested by a mosquito when it bites and 
takes a blood meal from the infected human host (Hoffman et al., 2012).  
C. Sporogonic cycle 
The female anopheline mosquito serves as a vector for the transmission of Plasmodium 
parasites among human hosts. In the event of a mosquito taking a blood meal from a malaria 
infected human, it also takes up mature gametocytes, this is the start of the sporogonic cycle. 
In the midgut of the mosquito, the microgametes (male gametes) fertilize the macrogametes 
(female gametes) producing zygotes which in turn develop into ookinetes. The ookinete 
penetrates the epithelium of the midgut, settles beneath the outer gut wall and develops into 
an oocyst. The oocyst then matures over a period of approximately 14 days and produces 
sporozoites. The sporozoites are actively mobile; they migrate to the salivary glands and 
settle in the salivary duct of the mosquito. During subsequent blood meals, the salivary fluid 
and its content of infective sporozoites are injected into the human host and initiate another 
asexual replicative stage (Hoffman et al., 2012). 
1.3 Strategies to control malaria 
The effective control of malaria is threatened by many factors; including drug-resistant 
parasites, poor patient compliance, counterfeit drugs, poor health care systems, insecticide 
resistant anopheline mosquitos and inaccurate diagnostic methods.  As a result, any 
successful malaria control program needs to be multi-faceted, incorporating methods for 















The current interventions implemented for the control of malaria includes the distribution and 
use of insecticide-impregnated bed nets (ITNs), particularly long-lasting insecticidal nets 
(LLINs), indoor residual insecticide spraying (IRS) using dichloro-diphenyl-trichloroethane 
(DDT), rapid diagnostic tests (RDTs), intermittent preventative antimalarial therapy during 
pregnancy (IPTp) and infancy (IPTi), and antimalarial chemotherapy (WHO; World Malaria 
Report, 2011).  
1.4 Vector control 
Integrated vector management (IVM) is a new „adaptive‟ and cost-effective strategy for the 
control and prevention of malaria. IVM incorporates the knowledge of local vector ecology 
and patterns of disease transmission in selecting the most appropriate method for vector 
control. IVM attempts to minimize health risks from acute exposure to toxic pesticides and 
the development of vector resistance to widely-used insecticides by combining environmental 
management and chemical tools. Environmental management strategies (reducing water 
logged areas) to reduce mosquito breeding grounds and biological controls (bacterial 
larvicides and larvivorous fish) to target and eliminate mosquito larvae may be used to 
replace chemical methods of vector control. The IVM system has been successfully used in 
Asia and Africa to reduce the transmission and incidence of malaria (WHO; Malaria control, 
2011).  
1.5 Diagnostic tools 
Inaccurate clinical (declared fever) or self-diagnosis of malaria contributes to the 
misdiagnosis of malaria and the misuse of antimalarial drug resources. The clinical signs and 
symptoms of malaria are non-specific and resemble many other febrile illnesses 
(Luxemburger et al., 1998, WHO; Guidelines for the treatment of malaria, 2011). Light 
microscopy; the direct examination of intracellular parasites on stained blood films, is 
regarded as the gold standard for diagnosis. It is inexpensive but is time-consuming, requires 
adequate equipment, maintenance and trained personnel; however it still remains an 
important diagnostic tool. RDTs are quick and easy to perform, sensitive and specific for P. 
falciparum and have less investigator-related variation than microscopy (Guerin et al., 2002). 
The drawbacks of RDTs include cost, lack of sensitivity to detect malaria caused by other 
Plasmodium species and heat instability (Guerin et al., 2002, Chiodini et al., 2007). 















endeavour against the onslaught of malaria that requires financial investment for continuous 
research and development. 
1.6 Antimalarial chemotherapy 
Chemotherapy is essentially used for prophylaxis and the effective treatment of malaria in 
order to prevent disease progression and transmission of infection. The current antimalarials 
available for clinical use are: the 4-aminoquinolines (e.g. chloroquine, amodiaquine), 8-
aminoquinolines (e.g. primaquine), arylaminoalcohols (eg. halofantrine, lumefantrine), 
artemisinin and its derivatives (e.g. artemether, artesunate, etc.), antifolates (e.g. 
pyrimethamine, sulfadoxine, etc.), antibiotics (e.g. azithromycin) and combination therapies 
such as artemisinin based combination therapy (ACT).  
ACTs are recommended as first line therapy for uncomplicated malaria and are discussed in 
detail in this chapter. Parenteral artesunate is recommended as first line treatment for severe 
malaria caused by P. falciparum (WHO; World Malaria Report, 2011).  In malaria endemic 
areas with high transmission, the World Health Organisation (WHO) recommends 
intermittent preventive treatment with sulfadoxine-pyrimethamine (SP) for pregnant women 
and infants (WHO; World Malaria Report, 2011). 8-aminoquinolines such as primaquine are 
the only drugs used for effective elimination of liver stage parasites and dormant stage P. 
vivax and P. ovale hypnozoites found in the liver. These dormant hypnozoites may cause 
recurrent malaria infections (Krotoski et al., 1982, Greenwood et al., 2008). Inhabitants of 
malaria endemic areas naturally develop immunity (after at least one or two episodes of 
infection) to blood stage infections; curtailing parasitemia and preventing the development of 
severe disease (Gupta et al., 1999). Likewise, antimalarial vaccines, which elicit long term 
immunity, may be imperative to counteract the malaria parasite at all life stages, preventing 
transmission and facilitating the eradication of malaria (Richie and Saul, 2002).    
The concurrent use of vector control measures, accurate diagnosis and chemotherapy has 
been shown to be effective in reducing malaria morbidity and mortality (Barnes et al., 2005). 
The WHO global malaria programme, the Roll Back Malaria partnership (RBM) and 
Medicines for Malaria Venture (MMV) are some examples of initiatives dedicated to the 
eradication of malaria through research and development (Nabarro and Tayler, 1998, 
Bathurst and Hentschel, 2006). The discovery and development of antimalarials with a long 
















1.7 Antimalarial drug resistance 
Drug resistance develops when malaria parasites subjected to sub-therapeutic drug levels 
acquire spontaneous genetic mutations that confer diminished drug susceptibility. The 
resulting parasite strain, possessing the drug resistant genotype may survive, replicate and 
cause treatment failure in the host despite optimal dosing ( Bloland, 2001, Wilairatana et al.,  
2001, WHO; malaria fact sheet, 2012). The selection for drug resistant parasites may be 
compounded by inappropriate antimalarial prescribing, poor patient compliance, counterfeit 
drugs and variable drug pharmacokinetics (Wilairatana et al., 2001). Understanding the 
genetic and molecular factors underlying the development of parasite drug resistance is 
imperative in sustaining the lifespan of the current antimalarials in clinical use, including 
ACTs (Hyde, 2005, Greenwood et al., 2008).  Chloroquine (CQ) was introduced in the 
1940‟s and was considered the „gold standard‟ treatment for malaria. Parasite resistance to 
CQ emerged in South-East Asia during the late 1950‟s and spread to Africa in the late 1970‟s 
(Harinasuta et al., 1965, Campbell et al., 1979, Fogh et al., 1979). Sulfadoxine-
pyrimethamine (SP) then replaced CQ as first-line therapy for uncomplicated malaria but 
drug resistant parasites soon emerged (Mita et al., 2009, Petersen et al., 2011). With reference 
to Figure 1.3, P. falciparum resistant to CQ and SP is now predominant in nearly all malaria 
endemic areas (Black et al., 1981, Bjorkman et al., 1990, Wongsrichanalai et al., 2002). 
 
















Parasite resistance has however recently emerged to all antimalarials including the 
artemisinin derivatives and effective treatment policies are necessary to prevent the spread of 
resistance (Anderson et al., 2010, Dondorp et al., 2010). 
Compounds that can reverse resistance to CQ in the parasites, known as chemosensitizers, 
may be used to improve or reinstate the clinical response to CQ (Zishiri et al., 2011). Many 
compounds such as imipramine (anti-psychotic) and verapamil (calcium channel blocker), 
have been shown to reverse CQ resistance (Krogstad et al., 1987, Martin et al., 2009). There 
are currently no drugs to replace ACTs thus strategies to prevent artemisinin-resistant malaria 
will depend on optimizing the partner drugs of existing ACTs. For future reference triple 
therapy, including an artemisinin derivative and two partner drugs may be considered as an 
alternative treatment strategy (Dondorp et al., 2010).  ACTs however are still the most 
effective antimalarial treatment option in most malaria endemic areas.  
 
1.8 Artemisinin based Combination Therapy (ACT) 
During the 1990‟s P. falciparum developed widespread resistance against Chloroquine (CQ) 
and Sulfadoxine-Pyrimethamine (SP) drug therapies, causing an increase in disease 
transmission and mortality due to diminished treatment efficacy (Price and Nosten, 2001, 
Mita et al., 2009, WHO, malaria fact sheet). Effective drug therapy to combat malaria as well 
as prevent parasite resistance was required. The additional problem of cross-resistance, where 
the development of parasite resistance to one drug may relay parasite resistance to other 
antimalarials with similar modes of action, may also be overcome and prevented by using 
combination therapy instead of monotherapy (WHO, Global report, 2010). The rationale for 
combining two antimalarials with independent modes of action is that the probability of the 
parasite developing resistance to two drugs simultaneously is significantly reduced compared 
to developing resistance to one drug (White and Olliaro, 1996). The WHO recommended the 
deployment of ACTs for the treatment of uncomplicated malaria in November 2000 (WHO, 
malaria fact sheet). ACTs combine a rapid acting antimalarial such as artemisinin or a 
derivative, to reduce parasite load with a partner antimalarial that has a long half-life which 
eliminates remaining parasites and prevents recrudescence (White et al., 1999, WHO; 
antimalarial combination therapy, 2001). Recrudescence is a recurrent infection that usually 
occurs after inadequate treatment due to parasite drug resistance, variable drug 















The artemisinin derivative and partner antimalarial may offer mutual protection against the 
development of drug resistant parasites, as resistant parasites to one of the drugs may be 
eliminated by the partner drug (Nosten et al., 2012). Artemisinin derivatives also eliminate 
young parasite gametocytes. Combination therapy may thus safeguard the therapeutic 
longevity of the constituent drugs and decrease parasite transmission (White et al., 1999, 
Greenwood et al., 2008). The effective ACTs, as recommended by the WHO are Artemether-
Lumefantrine (AL, Coartem
®
), Artesunate-Amodiaquine, Artesunate-Mefloquine, 
Artesunate-Sulfadoxine/Pyrimethamine and Dihydroartemisinin-Piperaquine (WHO; 
Antimalarial combination therapy, 2001). A more recent combination; Pyronaridine-
Artesunate has also demonstrated clinical efficacy when compared to Artemether-
Lumefantrine (AL) in a randomized non-inferiority clinical trial (Tshefu et al., 2010). AL is 
the first and only fixed dose (both active dugs in one tablet) ACT recommended by the WHO 
and has been adopted as first-line therapy for uncomplicated malaria in more than 20 African 
countries (Premji et al., 2008, WHO, world malaria report, 2011). ACTs in a fixed dose 
formulation may facilitate patient adherence to full treatment course (Price et al., 2006). 
1.9 Lumefantrine 
The chemical structure of lumefantrine (LF), shown in Figure 1.4, is a racemic fluorene 
derivative originally called benflumetol. It was synthesized in the 1970‟s by the Academy of 
Military Medical Sciences in Beijing and registered in China for use as an antimalarial drug 
in 1987 (White et al., 1999, Ezzet et al., 2000).  
               
Figure 1.4: Chemical structure of lumefantrine. Chemical name: (1RS)-2-(dibutylamino)-1-{(9Z)-2, 7-
dichloro-9-[(4-chlorophenyl)methylidene]-9H-fluoren-4-yl}ethanol.  
Molecular formula: C30H32Cl3NO 















Due to LFs chirality, it occurs in a laevorotatory and dextrorotatory form both of which have 
similar activity against P. falciparum as well as very low toxicity (Zeng et al., 1996, 
Wernsdorfer et al., 1998). LF is a hydrophobic and highly lipophillic compound with a 
terminal half-life of 3-4 days in malaria infected patients (White et al., 1999). Absorption of 
LF is influenced by lipids and food intake. As a result, high variability of therapeutic LF 
plasma levels has been observed in clinical trials (Wernsdorfer et al., 1998, White et al., 
1999, Ezzet et al., 2000). LF is available commercially as part of a co-formulated ACT called 
Coartem
®
 (Artemether + Lumefantrine) manufactured by Novartis Pharma AG, Basel, 
Switzerland. Coartem
® 
is safe, well tolerated and effective for treating multi-drug resistant 
malaria (Stohrer et al., 2004, Ratcliff et al., 2007). In 2010, Coartem
®
 accounted for more 
than 70% of the overall ACT supplies to the public sector. The price for Coartem
®
 ranges 
between 0.36-1.3 United States dollars (USD) per treatment course and drug accessibility 
may be increased in poor socio-economic areas due to the efforts of the WHO and the Global 
Health Fund (WHO, World Malaria Report, 2011). 
Coartem
®
 needs to be administered with food to ensure adequate oral bioavailability (White 
et al., 1999, Davis et al., 2005, Lindergardh et al., 2005). Poor drug pharmacokinetics and 
inefficient parasite elimination can prove to be disadvantageous, leading to the development 
of parasite drug resistance as a result of sub-therapeutic levels and eventually treatment 
failure (WHO; Global report 2010). The ideal antimalarial drug should have a rapid onset of 
the antiparasitic effect and a slow elimination to prevent recrudescence but not encourage the 
development of parasite resistance due to prolonged exposure to sub-therapeutic drug levels 
(Winstanly et al., 2002).  
1.10 Lumefantrine pharmacokinetics and the food effect 
Pharmacokinetics (PK) is a study of what the body does to the drug, after administration, 
involving the processes of drug absorption, distribution, metabolism and excretion (ADME) 
(Smith et al., 2001). A drug may be administered orally, parenterally (intravenous, 
intramuscular, subcutaneous), transdermally, rectally or via nasal spray. The route of drug 
administration and site (gastrointestinal tract (GIT), nasal cavity, conjunctiva, etc.) of drug 
absorption has a direct effect on its PK (Benedetti et al., 2009).  
Oral administration is the preferred and most frequently used route for drug administration; it 
is convenient, non-invasive, safe and eases patient compliance (Gomez-Orellana, 2005, Kerns 















GIT. In the body, absorption is the process whereby a drug is transported from the site of 
administration to the systemic blood circulation. Once the orally administrated drug is 
absorbed across the intestinal membrane it enters the blood circulation via the hepatic portal 
vein, which collects the blood supply from the GIT and passes through the liver, where a 
portion of the absorbed drug may be extracted and altered by enzymes. A drug may bind to 
proteins within the blood and only unbound or free drug may impart a therapeutic effect, be 
metabolised or excreted. Extraction occurs predominantly in the liver or kidneys and refers to 
the irreversible excretion or metabolism (chemical alteration by enzymes generating 
metabolites) of the drug. „First pass metabolism‟ occurs when the drug passes from the GIT 
to the liver for the first time after being absorbed and a fraction of the drug is extracted by 
enzymes in the GI membranes and liver before re-entering the blood circulation system. First 
pass metabolism may substantially reduce the amount of drug that eventually enters the 
systemic circulation (Smith et al., 2001, Benedetti et al., 2009).  
           
Figure 1.5: Schematic illustration of the disposition of an orally administered drug within the body 
and the organs involved in the ADME process (Figure sourced from Smith et al., 2001). 
 
The most relevant PK parameter for characterizing drug absorption is bioavailability. 
Bioavailability describes the fraction of the administered dose that reaches the systemic 
circulation. A bioavailability study is performed to elucidate the time course of the 
disposition of a drug within a biological system, by measuring concentration levels in blood 
or plasma over a period of time (Smith et al., 2001).   
Many factors may influence the oral bioavailability of a drug, including aqueous solubility, 
dissolution rate, membrane permeability and food (Gomez-Orellana, 2005, Kerns & Di, 
2008). Orally administered drugs need to dissolve in the gastric fluid before traversing the GI 















bioavailability (Ezzet et al., 2000). LF is also subject to the „food effect‟, as detailed in 
clinical research papers, with a reported 16-fold increase in bioavailability when administered 
with food compared to administration under fasted conditions (White et al., 1999, Ezzet et 
al., 2000).  A food effect may be defined as an observed relative difference in systemic 
exposure or bioavailability, of a drug when administered orally in a fed state as compared to 
when the same drug formulation is administered in a fasted or starved state (Singh, 1999).  
It is thought that the fat content in digested food may increase the solubility of the lipophilic 
drug thereby facilitating its dissolution, absorption and oral bioavailability. Food may 
decrease a drugs oral bioavailability by delaying absorption due to slow gastric emptying and 
input into the intestine, where most of the drug absorption takes place. Food may increase the 
absorption of lipophilic drugs by stimulating bile salt secretion and changing the pH 
conditions of the gastric fluid. In the presence of food there is less pre-systemic metabolism 
or loss of drug due to metabolism by gastric enzymes which means that, a larger fraction of 
the drug is thus absorbed into the blood stream (Kerns & Di 2008). 
1.11 Clinical Evidence 
The bioavailability of LF is the principal determinant of treatment efficacy of AL (artemether 
+ lumefantrine) (Ezzet et al., 1998, Price et al., 2006). Clinical evidence suggests that 
variable inter-individual bioavailability can be attributed to the food effect associated with 
AL, predominantly in the case of LF and to a lesser extent, Artemether (White et al., 1999, 
Ezzet et al., 2000, Ashley et al., 2007, Premji et al., 2008 and Borrman et al., 2010).  It is 
thus recommended that AL be administered after meals. This may pose a potential problem 
as patients with malaria often present with symptoms such as fever, nausea, vomiting and 
anorexia, and therefore eat very little during the acute phase of the disease. The affected 
people living in the malaria endemic areas in Africa are also often very poor and may not be 
able to eat a meal before every dose (White et al., 1999).   
A study done by Ashley et al. to determine how much ingested fat is necessary to obtain 
optimum LF exposure found that a meal containing 1.6 g of fat eaten before dose 
administration of AL would be sufficient (Ashley et al., 2007). The average fat consumption 
of children living in Sub-Saharan Africa is in the range of 30-60 g/day and the content of 
African diets is adequate to achieve optimum LF exposure when administered fixed-dose AL 
(Premji et al., 2008). This finding was reiterated in a study done by Piola et al., in a 















cure rate, >96%, irrespective of supervised food intake or routine outpatient conditions (Piola 
et al., 2005).  
Borrmann et al. conducted a randomized, multi-centre study in children in five different 
African countries to assess the food effect on the bioavailability and efficacy of AL. The 
study included 621 children and also evaluated the dispersible form of AL compared to the 
crushed tablet. It was concluded that the consumption of milk or traditional African food was 
sufficient to achieve adequate LF absorption, from both formulations, in children and that the 
increase in LF plasma concentration as a result of the „food effect‟ had no direct influence on 
the 28-day cure rate. The cure rate in the study was reported to be 98.2% and treatment 
failure was not related to food intake (Borrmann et al., 2010). 
Price et al. performed a clinical trial in Thailand to characterize the molecular and 
pharmacological determinants of therapeutic failure when using AL to treat multi-drug 
resistant P. falciparum malaria. The study enrolled 1588 patients and evaluated the 4-dose 
regimen of AL versus the 6-dose regimen in curing malaria and preventing recrudescence. 
South-East Asia is recognized as the „hot spot‟ for the development of drug resistant malaria 
parasites. Thailand has established P. falciparum drug-resistance to CQ, SP and mefloquine 
(MQ). It has been discovered that the P-glycoprotein pump encoded by the P. falciparum 
multi-drug resistant gene (pfmdr1) regulates the in vitro and in vivo parasite response to 
mefloquine, halofantrine, quinine and artesunate (Price et al., 2004). Gene amplification of 
pfmdr1 is the main molecular determinant of MQ resistance and there is in vitro evidence of 
cross-resistance between LF and MQ (Duraisingh et al., 2000). Results showed that gene 
amplification of pfmdr1 in P. falciparum isolates from study patients increased the risk of 
treatment failure in patients treated with the 4-dose regimen but not the 6-dose regimen of 
AL.  The study found that 24% of patients with a LF plasma concentration <175 ng/ml on 
day 7, post treatment, developed recrudescent infections as compared to the 1.1% of patients 
with LF plasma concentrations ≥175 ng/ml. The oral bioavailability of LF is the main 
pharmacological determinant of efficacy of AL and the 4-day regimen did not provide 
consistent LF levels to overcome susceptible parasites. The 6-day regimen provided sufficient 
drug levels to treat multi-drug resistant P. falciparum malaria (Price et al., 2006). 
Slower acting antimalarials such as LF, which serve as partner drugs to the fast acting 
artemisinin derivatives, may play an essential role in preventing recrudescent infections and 
parasite drug resistance (Ezzet et al., 1998). However for LF to be clinically effective it has 















be used to improve the solubility of lipophilic drugs and thereby improve the drugs oral 
bioavailability and clinical efficacy. 
1.12 Strategy to overcome poor oral bioavailability and food effect 
There are many strategies that may be employed to improve drug absorption and 
bioavailability including chemical modification (e.g. cyclodextrine inclusion) and drug 
formulation using colloidal drug delivery systems (e.g. self-emulsifying drug delivery 
systems). For this study Pheroid
™
 technology was used to enhance the bioavailability of LF. 
Pheroid
™
 technology is a patented, novel fatty-acid based drug delivery system that may 
enhance drug bioavailability and therapeutic efficacy (Grobler et al., 2008). With the use of 
Pheroid
™
 based formulation, we may improve the solubility and subsequently the absorption 
and bioavailability of LF (du Plessis et al., 2010, Steyn et al., 2011). The formulation may 
eliminate the „food effect‟ associated with LF and shorten dosage regimens (White et al., 
1999, Ezzet et al., 2000). Pheroid
™ 
technology and its application as a drug delivery system 


























The primary aim of this project is to improve the in vivo bioavailability of the antimalarial, 
LF using novel Pheroid
™
 drug formulation technology. A further intention is to determine if 
the Pheroid
™
 formulated LF eliminates the „food effect‟ associated with LF and assess in 
vitro and in vivo antimalarial efficacy.  
 
Objectives 
For the purpose of comparing LF in Pheroid
™
 formulation to LF in reference formulation (LF 
dissolved in a DMSO:water (1:9 v/v) solution), pre-clinical antimalarial in vitro and in vivo 
assays will be performed. 
 
1. Determine the physicochemical properties of LF using in silico (computational) tools. 
2. Determine the in vitro activity of LF with Pheroid
™
 formulation as compared to the 
reference formulation. 
3. Develop and validate quantitative methods, using liquid chromatography and tandem 
mass spectrometry (LC-MS/MS), for the determination of LF in mouse whole blood 
and plasma. 
4. To generate whole blood and plasma concentration-time profiles of LF dissolved in 
the Pheroid
™
 formulation, reference solution and canola oil, in a mouse model. 
5. Use NONMEM software to generate a population pharmacokinetic (PPK) model and 
PK parameter estimates, using the bioavailability data. 
6. Perform in vivo efficacy experiments using Peters‟ 4-day test, to compare Pheroid
™ 
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Computational Predictive Models: Using in silico tools to predict 
the physicochemical properties of lumefantrine 
 
2.1 Introduction 
Drug discovery and development is a time consuming and costly process, thus efficient 
experimental testing is undertaken to minimize the risk of drug failure. A flow diagram 
illustrating the physiological and physicochemical factors that may influence a drugs oral 
bioavailability and pharmacokinetics is shown in Figure 2.1.  
 
Figure 2.1: A flow diagram detailing the pharmacokinetic parameters that are influenced by poor drug 
bioavailability. The diagram is colour coded with processes involved in drug absorption being 
coloured blue, distribution: dark blue, metabolism: green and elimination: red. Abbreviations: FPM, 
first pass metabolism; PPB, plasma protein binding (Figure adapted from Eddershaw et al., 2000) 
Clinical pharmacokinetics involves all the factors that determine or influence the variability 
in systemic drug concentration. Clearance is a PK parameter that describes the volume of 
plasma that is cleared of drug per unit time. The rate of drug elimination is proportional to the 
systemic drug concentration for drugs following first order kinetics. The liver (site of drug 
metabolism) and kidneys (elimination of unchanged drug) are predominantly responsible for 
drug clearance. Volume of distribution represents the volume into which the drug appears to 
be distributed after administration. Once distributed in the blood, drugs may bind (reversibly) 
to plasma proteins and this may be of importance as only unbound drug is able to act on 















influenced by the rate of drug administration, the volume into which it distributes and its 
clearance (Makoid et al., 1999, Eddershaw et al., 2000).   
It has been estimated that 43% of drug compounds fail during phase III studies and a further 
23% fail at registration (Kola, 2008). The paradigm shift in drug discovery and development, 
to prevent late stage drug failures, involves high-throughput screening of new drug 
compounds prior to in vivo testing for early information on absorption,  distribution, 
metabolism, excretion and toxicity (ADMET) (van der Waterbeemd & Gifford, 2003). 
Computational predictive tools may be incorporated to streamline the drug development 
process by relating chemical structure to ADME/PK behaviour. „Poor pharmacokinetics‟ is 
the major underlying cause of compound failure in drug development programmes. A drug 
with poor PK may be described as having low or variable bioavailability which may result in 
inefficient activity (Eddershaw et al., 2000). The most common factors responsible for drug 
development failure are presented in Figure 2.2, the implementation of early PK drug 
screening resulted in a decrease of drug development failure due to poor PK/bioavailability 
from 40% to less than 10% over the ten year period 1991-2000 (Kola & Landis, 2004).  
 
Figure 2.2: A representative graph depicting the causative factors for, and their contribution to, drug 
compound failure. (Kola & Landis, 2004) 
In silico (computational) tools can be used to accelerate and optimize drug discovery and 
development by predicting ADMET and physicochemical data based on a compound‟s 
molecular structure. This information is valuable as the physicochemical properties of a 
compound may provide relevant insight regarding its pharmacokinetics and efficacy. For the 















its bioavailability and antimalarial efficacy, in silico predictions were used to confirm the 
poor aqueous solubility of LF and corroborate the in vivo experimental results.  
2.1.1 Physicochemical factors influencing drug bioavailability 
Lipophilicity 
The lipophilicity of a compound is defined as its intrinsic affinity for a lipidic as opposed to a 
aqueous environment and is measured by determining the compounds distribution behaviour 
in a biphasic system i.e. 1-octanol/water (Smith et al., 2001). Lipophilicity, for a neutral 
compound, is represented by the partition coefficient (LogP). For compounds that are 
ionisable, lipophilicity is pH dependant and is represented by the distribution coefficient 
(LogD). The acid-base ionization constant (pKa) of a compound indicates its ionisability at a 
particular pH. Figure 2.3 details the inter-relationship between the ionization properties of a 
drug and its lipophilicity, the ionized form of a drug compound is more soluble in the 
aqueous phase and the unionized form more readily partitions into the lipid phase (biological 
membrane). Thus, LogP may be described as the log of the partition coefficient of a 
compound, in neutral (unionized) form, in a biphasic system. LogD may be described as the 
log of the distribution coefficient of a compound (ionized and unionized) in a biphasic system 
at a specific pH (Kerns & Di, 2008).  
 
Figure 2.3: A schematic describing the relationship between pKa, LogP and LogD. 1: the equilibrium 
is a function of acid/base strength (pKa) and 2:  the equilibrium is a function of the compounds 
lipophilicity (LogP). (Smith et al., 2001) 
Lipophilicity is an important physicochemical property that influences the pharmacokinetics 
of an orally administered drug compound. As presented in Figure 2.4, a LogP value between 

















Figure 2.4: A hypothetical depiction of how lipophilicity can affect the efficient absorption of a drug 
compound (Kerns & Di, 2008). 
 
 
Solubility and Permeability 
 
Once a drug is orally administered it dissolves in the predominantly aqueous contents of the 
GI tract prior to absorption across the intestinal membrane (IM) and entry into the blood 
circulation. The dissolution of the compound in the GI tract and its ability to permeate the IM 
has a direct effect on its oral bioavailability. Figure 2.5 illustrates the processes that may 
influence the transport of a drug to the systemic blood circulation after oral administration. 
 
Figure 2.5: Solubility, permeability and metabolism may influence the systemic bioavailability of an 
orally administered drug (Kerns & Di, 2008). 
 
The speed at which the solid compound dissolves in a solvent is referred to as the dissolution 
rate (Smith et al., 2001). Solubility of a compound may be described as the degree to which it 
dissolves, and the maximum concentration attained, in a specific solvent. Permeability 
describes the ability of the dissolved drug to traverse across a biological membrane as 
illustrated in Figure 2.6. The solubility and permeability for an orally administered drug are 
variable and influenced by the physicochemical and structural properties of the drug as well 















compound also affects its absorption, as ionized compounds are more soluble than neutral 
compounds in aqueous medium. However the structural attributes of a compound that favour 
solubility in an aqueous environment often reduces permeability. Biological membranes are 
composed of phospholipid molecules, polar head groups and non-polar side chains, that self-
assemble forming a lipid bilayer as depicted in Figure 2.6. Lipophilic, neutral compounds 
permeate more readily than polar molecules as they pass easily through the lipid bilayer 
membrane.  
 
Figure 2.6: Diagram showing passive diffusion of a drug molecule through a biological membrane 
(Kerns & Di, 2008). 
 
Aim 
The aim of the investigation was to determine the physicochemical properties of LF that may 
influence its oral bioavailability. 
Objectives 
To predict the lipophilicity (LogP, LogD and pKa), solubility and permeability of 

























There is an interconnection between the molecular structure of a compound and its inherent 
physicochemical properties (lipophilicity, solubility and permeability.). The surface 
properties (electrostatic forces, hydrophobicity, potential hydrogen bonding, etc.) of a 
molecule can be used to calculate potential interaction sites around the molecule thereby 





 (available on http://ww.moldiscovery.com) apply statistical/mathematical algorithms 
using 3D MIFs to predict physicochemical as well as ADME parameters of compounds 
(Cruciani et al., 2000). The incorporated computational models were generated from 
experimental data obtained for a wide range of structurally diverse compounds, referred to as 
a training set, for ADME predictions (Bohets et al., 2001).  
The Volsurf+
®
 software was used to predict the lipophilicity (LogP and LogD) of LF and to 
qualitatively assess its aqueous solubility and permeability (Caco-2 cells). To generate partial 
least-squares projection (PLS) t-t plots, LF was projected onto in-built solubility (Soly) and 
Caco-2 models. Caco-2 cells are well-differentiated intestinal cells derived from human 
colorectal carcinoma and are used for in vitro drug absorption assays to assess permeability 
(Guangli & Yiyu, 2006). Studies have demonstrated a relation between human oral drug 
absorption and Caco-2 permeability, thus proving it a valuable model for assessing 
permeability (Stenberg et al., 2001). The Volsurf+
®
 software has been used, successfully, for 
the accurate prediction of Caco-2 permeability of new compounds (Cruciani et al., 2000). 
MoKa
®
 incorporates a quantitative structure-property relationship (QSPR) pKa prediction 
method that describes the molecular structure around an ionisable centre using topological 
distances and it consists of a model based on a training set of over 26 000 unique pKa values 
(Cruciani et al., 2000, Milletti et al., 2007). The software suite was used to predict the pKa 
values and ionization pattern (shows the relative abundant ionized species at various pH 




















The in silico analysis of LF was performed under the direction and supervision of Dr Grace 
Magumbate, Medicinal Chemistry Research group, UCT. 
Lipophilicity 
The predicted LogP, LogD and pKa values for LF are detailed in Table 2.1. LF is highly 
lipophilic as indicated by the reported LogP value for LF (with artemether) which was 8.81 
(Kassim et al., 2003), and the predicted value using Volsurf +
®
 was 9.  
Table 2.1: in silico predicted lipophilicity values for LF  
LogP 9 
LogD at:  
Blood (pH 7.4) 8.74 
Intestine (pH 6.5) 5.13 
Stomach (pH 3.5) 7.8 
pKa values  8.3 and 14.9 
 
The ionization pattern of LF as predicted using MoKa
®
 details the species (ionized or neutral) 
of LF present at any specific pH (Figure 2.7). LF is a weak base with two ionisable sites 
(shown by red circles); the most abundant i nized form present at physiological pH (7.4) is 
shown in Figure 2.7. 
 
Figure 2.7: Ionization pattern of LF as predicted using MoKa
®
. The structure of the dominant ionized 
















Solubility and Permeability 
A qualitative assessment of LF and CQ was performed using the Volsurf+
®
 software to 
predict the solubility and membrane permeability. CQ, considered to be the „gold standard‟ 
antimalarial for in vitro assays, was used as a reference drug. The generated PLS t-t score 
solubility and permeability plots are shown in Figures 2.8 and 2.9. The pink and blue regions 
indicate poor and high property regions respectively, and the solid and broken circles show 
99% and 95% confidence levels respectively. The black dots are the training set molecules. In 
both cases, CQ was predicted to have moderate solubility and good permeability. However 
the solubility of the highly lipophilic LF is very poor hence it appears in the poor solubility 
region (pink) and outside the 95% confidence level (Figure 2.8). LF was predicted to have 
good permeability; it is positioned in the blue region of the Caco-2 model generated using 
Volsurf +
®
 (Figure 2.9).  
 
Figure 2.8: Partial Least Square (PLS) t-t score plots for solubility model for LF. Black dots represent 
the library of known compounds compromising the models data set. Yellow dots represent labelled, 
















Figure 2.9: Partial Least Squares (PLS) t-t score plots for Caco-2 permeability model for LF. Black 
dots represent the library of known compounds comprising the models data set. Yellow dots represent 
projected LF and CQ molecules. The blue section indicates; good and the pink section poor 
























For the purpose of this project, the in silico tools were used to predict the physicochemical 
properties of LF that may explain its poor and variable oral absorption. Good absorption is 
dependent on the orally administered drug dissolving in the gastrointestinal tract, traversing 
the intestinal epithelium and entering the blood stream (Bohets et al., 2001). As a result drug 
compounds with low solubility and permeability may have poor absorption, variable 
bioavailability and lack of efficacy (Kerns and Di, 2008).  
The pKa values for LF (8.3 and 14.9) as predicted using MoKa
®
, is comparable to the 
reported values of 8.71 and 13.4, calculated using Advanced Chemistry Development 
Software V11.02 (Debrus et al., 2011). LF is predicted to be predominantly ionized at 
physiological pH (Figure 2.7), LF is also described as a weak base and thus ionized in acid 
environments like the GI tract and effective absorption may therefore be hindered as 
unionized drugs traverse lipid membranes more efficiently than ionized drugs.  
The qualitative assessment of LF using the in silico tools predicted that LF has relatively low 
solubility and good Caco-2 cell permeability. Kassim et al. reported the LogP value for LF 
(with artemether) as 8.81 obtained using ChemDraw Ultra 6.0 (Kassim et al., 2003). Huang 
et al. reported a LogP value of 8.67 and a LogDpH7 value of 7 for LF, calculated using 
Advanced Chemistry Development Software V11.02 (Huang et al., 2012). Debrus et al. used 
the same software as Huang et al. and also reported a LogP value of 8.67 for LF. The LogP 
value predicted for LF using Volsurf+
®
 was 9 and LogDpH7.4 was 8.74, which appears to be 
comparable to published results. According to Lipinski‟s „rule of 5‟, a LogP value of less 
than 5 is considered ideal for good oral drug absorption and permeability (Lipinski et al., 
1997). LFs high LogP value indicating poor aqueous solubility may therefore be a 
contributing factor to its poor absorption and unpredictable oral bioavailability. The predicted 
LogD values for LF at pH 7.4 (blood pH) is above five. Compounds having Log D values 
greater than five are postulated to have poor GI absorption and bioavailability due to 
insolubility (Kerns & Di, 2008). Permeability, volume of distribution and elimination half-
life is predicted to be high as these compounds partition into tissues, therefore less 
bioavailable (Kerns & Di, 2008). In a pharmacokinetic study performed in rats LF displayed 
low clearance and a large volume of distribution resulting in a long terminal elimination half-
life (Wahajuddin et al., 2011). Clinical studies have reported LF to display variable 















For correlating in vitro drug dissolution and in vivo bioavailability, compounds are 
categorized using the Biopharmaceutics Classification System (BCS). The BCS, provided by 
the United States Food and Drug Administration (FDA), classifies drugs according to their 
absorption potential in the GI tract (Amidon et al., 1995).  With reference to Figure 2.10, 
Lindenberg et al. categorised Coartem
®
 as a Class II or Class IV drug, however the 
classification was made using inconclusive solubility and permeability data (Lindenberg et 
al., 2004). 
 
Figure 2.10: Description of the Biopharmaceutics Classification System (BCS) Class categories. 
Class II compounds have low solubility and high permeability, indicating poor/slow drug 
dissolution but good absorption across the intestinal membrane. Class IV drug compounds 
have low solubility and low permeability indicating poor absorption as well as variable 
bioavailability (Amidon et al., 1995, Lindenberg et al., 2004). In a review by Kassim et al., 
the co-formulated artemether and lumefantrine was grouped in the BCS Class I category 
(Kassim et al., 2003). BCS Class I drugs have high solubility and high permeability which 
indicates good absorption. An in-situ permeability study of LF in rats demonstrated that LF 
had greater permeability than metoprolol (USFDA approved high permeability marker) 
(Wahajuddin et al., 2011). According to the BCS, Coartem
®
 (Artemether and Lumefantrine) 
could not be assigned to a specific class due to conflicting or insufficient 
solubility/permeability data. Considering the literature, categorizing a co-formulated drug 
such as Coartem
®
 would be difficult and vary from one scientific investigation to the next 
due to the different physicochemical properties of each individual drug. Considering the 
predictions generated in this investigation of LF, one may conclude that the compound has 
low solubility and good permeability and therefore comparable to the BCS Class II category 
however LF is ionized in acidic environments which may contribute to its poor absorption in 















The computational predictions of LF with respect to its lipophilicity, low aqueous solubility 
and good membrane permeability are comparable to reported experimental findings. It is well 
documented that LF is highly lipophilic and has variable oral bioavailability; which is a result 
of poor dissolution and erratic absorption in the GI tract (White et al., 1999, Ezzet et al., 
2000). Formulation strategies that may be utilised to address the poor aqueous solubility of 
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3.1. Introduction: Drug formulation and delivery systems 
Malaria is an infective disease that affects some of the poorest countries in the world, with 
the majority of malaria endemic areas located in Africa. Most of the drugs that form part of 
modern day antimalarial treatment regimens have been in circulation for decades. One such 
antimalarial is LF, which has poor aqueous solubility, variable bioavailability and is 
considered to have poor „drug like‟ properties. The efficacy of conventional antimalarial 
chemotherapy is threatened by the development of drug resistance, poor socio-economic 
conditions and patient compliance. Using drug formulation to improve and/or enhance 
existing antimalarial chemotherapy is a cost-effective and feasible strategy in eradicating 
malaria (Bagwe et al., 2001). 
The discovery and development of novel compounds is a time consuming and expensive 
process and many potential drugs are rejected due to poor oral bioavailability, toxicity or lack 
of efficacy. A drug delivery system (DDS) may be defined as a formulation or device that 
may improve a drug‟s therapeutic efficacy, safety and tolerability by facilitating its passage 
from administration to the target site (Jain, 2008). A suitable drug delivery system may serve 
as a „rescue‟ for drugs with poor „drug like‟ properties and improve the number of drug 
compounds that reach clinical trials. Drug delivery systems may also increase the longevity 
and improve the pharmacokinetics of well-established drugs like LF.  
An ideal DDS should be composed of biocompatible and/or biodegradable constituents that 
have the ability to easily entrap or adsorb a drug compound. The DDS should protect the 
entrapped drug from physical, chemical and enzymatic degradation before it reaches the 
target site; this is of particular importance for drugs administered via oral route. The DDS 
should be pliable and modifiable with regards to size, shape and functionality. It should lack 
immunogenicity and be able to traverse cell membranes. The production and manufacturing 
process of the drug and carrier (DDS) formulation should be cost-effective, consistent and 
reproducible (Jain, 2008). Pheroid
™
 technology is a patented novel colloidal drug delivery 
















3.2 Colloidal drug delivery systems 
Colloidal drug delivery systems include liposomes, emulsions and lipid or polymer based 
nanoparticles. A colloidal system refers to chemical systems that consist of a continuous 
phase or medium (e.g. water) in which small particles (colloids), typically sized 1-1000 nm, 
and are dispersed forming an emulsion or suspension. The advantages of using colloidal 
carriers as DDSs include; optimising oral drug administration, decreasing toxicity, protecting 
the drug from extracellular degradation, assisting selective transport across cell membranes, 
drug targeting and improving drug pharmacokinetics as well as efficacy (Bagwa et al., 2001, 
Grobler et al., 2008). Liposomes, emulsions and nano-particulate drug delivery systems as 
well as examples of their application in the treatment of malaria will be subsequently 
discussed.  
3.2.1. Liposomes 
Liposomes as carriers may be used to entrap hydrophilic and hydrophobic drugs. These lipid 
molecules arrange into vesicles, in an aqueous solution and range in size from 25 nm to 50 
nm (Grobler et al., 2008, Jain 2008). As presented in Figure 3.1, they are composed of 
phospholipids, other amphipathic lipids and cholesterol arranged in one or more lipid bi-
layers separated by aqueous compartments (Grobler et al., 2008). Liposomes may be 
modified with respect to lipid composition, size, surface charge and method of preparation 
(Jain 2008).  
 
Figure 3.1:  A representative example of a surface modified liposome encapsulating hydrophilic drugs 
in the aqueous interior and hydrophobic drugs in the lipid bi-layer (picture sourced form Fahmy et al., 
2007). 
Studies performed using a murine model, demonstrated that liposome encapsulated β-















malaria (Chimanuka et al., 2002, Date et al., 2007). Liposomes also allow for surface 
modification and attachments of ligands (Grobler et al., 2008, Date et al., 2007). In a study 
done by Postma et al., liposome bound recombinant human tumour necrosis factor (rhTNFα), 
administered intravenously, was found to suppress parasitemia and protect against induced 
experimental cerebral malaria in mice (Postma et al., 1999, Date et al., 2007). However 
liposomes are not stable in the GI tract and require optimization of liposome composition and 
surface modification to effectively deliver drugs via oral administration (Woodley, 1985).  
3.2.2. Emulsions and Microemulsions 
Emulsions consist of two or more immiscible, typically, liquid phases (oil and water) and a 
surfactant and are used to solubilize hydrophobic drugs (Grobler et al., 2008). As shown in 
Figure 3.2, the droplets that assemble spontaneously may form water-in-oil or oil-in-water 
emulsions and are generally ≥1 µm in size. Emulsions are optically turbid dispersions and 
may separate, over time, to form a two-phase system however microemulsions are optically 
isotropic and thermodynamically stable (Bagwe et al., 2001, Lawrence & Rees, 2000). The 
droplet sizes of a microemulsion range from 20 to 200 nm. Microemulsions require 
surfactants (lecithin, sodium palmitate, Tween80, cremophore EL) as well as co-surfactants 
(ethanol, glycerol and PEG) to stabilize the interfacial area and maintain droplet formation 
(Gelderblom et al., 2001). Self-microemulsifying drug delivery system (SMEDDS) is a type 
of emulsion, consisting of an oil component and surfactant, used to improve the oral 
bioavailability of hydrophobic drugs. The SMEDDS formulation is transformed into an oil-
in-water microemulsion in GI fluids after in vivo oral administration (Mandawgade et al., 
2008, Gursoy & Benita, 2001). Large amounts of hydrophobic and hydrophilic drugs may be 
solubilized using microemulsions allowing for improved drug absorption after oral 
administration, improved efficacy and minimized toxicity (Bagwe et al., 2001).  
 
Figure 3.2:  A representation of a (micro)emulsion; a system of oil, water and surfactant (picture 















Primaquine (PQ) is the only antimalarial used to eradicate asexual hepatic stages and latent 
tissue forms (in liver) of P. vivax and P. ovale. A study done by Dierling et al., prepared an 
artificial chylomicron emulsion incorporating PQ to enhance the uptake and accumulation of 
PQ in mouse liver for treatment of resurgent P. vivax malaria. The incorporation of PQ into 
the emulsion significantly enhanced its accumulation in the mouse liver and prevented 
enzymatic degradation in vivo (Dierling & Cui, 2005). 
3.2.3. Nanoparticles 
Nanoparticulate delivery systems encompass solid lipid nanoparticles (SLN), lipid drug 
conjugates (LDCs), nanosuspensions, dendrimers, nanocapsules, inorganic and polymeric 
nanocapsules (Date et al., 2007). Nanoparticles are composed of biodegradable polymers 
such as polylactides (PLAs) as well as natural polymers such as albumin and chitosan. These 
carrier particles range in size from 1 to 1000 nm, an active pharmaceutical ingredient (API) 
may be entrapped, adsorbed or covalently attached to the particle, as shown in Figure 3.3. 
The miniscule size of these drug carriers allow for efficient transport across biological 
membranes and delivery to target sites. Nanoparticles are biologically stable and suitable for 
drug delivery using oral administration (Date et al., 2007). 
 
Figure 3.3:  A representation of a nanoparticle, drugs compounds may be encapsulated in a 
nanocapsule or attached to the surface to the nanoparticle creating a nanosphere. 
Mosqueira et al. prepared PLA nanocapsules (NCs) containing the antimalarial halofantrine 
(HF) and assessed the improved efficacy in mice infected with Plasmodium berghei. PLA 
nanocapsules containing HF with surface attached polyethylene glycol (PEG) was also 
prepared. PEG may enhance the circulation life span of the NCs, and other drug carriers, as it 
functions to prevent interactions with plasma proteins and hinder enzymatic degradation 
(Mosqueira et al., 2004). The NCs loaded with HF reduced the parasite development more 















had a more sustained effect in vivo. The study concluded that using the NCs as a carrier also 






 technology originated from Emzaloid
™
 technology which was a product initially 
used for the treatment of psoriasis, formulated by MeyerZall Laboratories. It was discovered 
that the Emzaloid
™
 formulation contained micro and nano-sized vesicles that could entrap the 
active component (coal tar for psoriasis). Further research proved that the vesicles could be 
used to entrap active drug compounds as well as assist its delivery to the target site. The 
intellectual property of Emzaloid
™
 technology was purchased by the North West University, 
South Africa from MeyerZall (Pty) (ltd) in 2003 where, after further development, the term 
Pheroid
™
 was coined. The Pheroid
™
 formulation differs from Emzaloid
™
 with respect to the 




 technology can be described as a colloidal drug delivery system that contains stable 




 vesicles range in size from 
200-400 nm and have porous membranes. Like liposomes, Pheroids
™
 contain a lipid bi-layer 
but do not contain phospholipid or cholesterol. Pheroid
™
 vesicles form by a self-assembly 
process and are dispersed within a dispersion medium, similar to microemulsions. The 
morphology, structure, size and function of the Pheroid
™
 vesicles may be modified 
specifically for the active drug compound of interest as well as the intended route of 
administration (Grobler et al., 2008).  
3.3.1 Pheroid
™
 composition and molecular organisation 
Pheroid
™
 formulations consist of ethylated and PEGylated polyunsaturated fatty acids in the 
cis-configuration including Omega 3 and 6 fatty acids but excluding arachidonic, oleic, 
linoleic and linolenic fatty acids. Like other drug colloidal carriers, Pheroids
™
 are composed 
of biocompatible constituents. Pheroids
™ 
also contain vitamin E (tocopherol) which serves as 
an anti-oxidant and PEG which has been shown to contribute to extending the circulating life 
of the drug formulation (Grobler et al., 2008). 
The Pheroid
™
 consists of an oil, water and gas phase. Nitrous oxide (N2O) gas is water and 
fat soluble and is dispersed within the oil and water phases, adding another dimension to the 
basic Pheroid
™















shown to contribute to the self-assembly process and the physical stability of the Pheroids
™
 
as well as to facilitate the formation of a homogeneous solution. Due to its unique inter-
dispersed phases the Pheroid
™
 delivery system is able to entrap and transport hydrophobic 




Different types of Pheroid
™




 may be prepared by varying the composition or ratio of the 
fatty acids and manufacturing method. Pro-Pheroid
™ 
formulation differs from a Pheroid
™
 
formulation as it contains no water phase as shown in Figure 3.4. 
 
Figure 3.4:  An illustration of the constituent components of a) Pro-Pheroid
™
 and b) Pheroid
™
 (figure 
sourced from Grobler et al., 2008) 
The Pro-Pheroid
™
 consists of an oil based liquid phase with an interdispersed gas phase. The 
APIs suspended in a Pro-Pheroid
™
 formulation may be included into Pheroid
™
 vesicles upon 
the addition of water or aqueous medium. A Pro-Pheroid
™
 formulation may be likened to a 
SMEDDS formulation as it is hypothesized that the Pheroid
™
 vesicles spontaneously form in 
aqueous GI fluids after in vivo oral administration (Grobler et al., 2008).  
Confocal laser scanning microscopy (CLSM) is used to visualize the Pheroids
™
 and 
determine the structural characteristics and morphology of the particles. Confocal microscopy 
is a technique used for high-resolution three dimensional imaging of fluorescently labelled 
biological samples, as shown in Figure 3.5; the Pheroid
™
 is labelled with the fluorophore Nile 
red, allowing for the visualisation of the Pro-Pheroid
™ 





















Figure 3.5:  A representative confocal laser scanning micrograph of Pheroid
™
 vesicles (red) of 
submicron size with entrapped drug  (dark spots). Image obtained from a spectrophotometric method 
report for lumefantrine, courtesy of Dr.Lissinda du Plesiss, North-West University. 
CLSM is used for the qualitative control monitoring of manufactured Pheroid
™
 formulations. 
CLSM is also used to determine the entrapment efficacy of drug in Pheroid
™
 formulations. 
The size, charge, solubility and concentration of the drug or API influences the amount of 




formulations are reproducible and have 
an entrapment efficacy of 85-100% with all compounds tested (Grobler et al., 2008). 





 technology has been used for various applications to enhance or improve existing 
and novel drug therapy. The application of Pheroid
™
 technology to enhance the oral 
absorption of novel artemisinin derivatives, for the treatment of malaria, was investigated by 
Steyn et al. and the concentration of artemisone in blood was reported to be 4.57 times higher 
when the drug was entrapped in the Pheroid
™
 vesicles as compared to artemisone in reference 
(aqueous) formulation (Steyn et al., 2011). Pheroid
™
 technology has also been successfully 
used for nasal peptide delivery, transdermal drug delivery and cosmetic applications 






















One scientific publication was found, detailing the use of drug formulation to enhance the 
antimalarial efficacy of LF. Gahoi et al. prepared a LF nanopowder using a wet milling 
DYNO MILL technique to improve drug dissolution rate and therapeutic efficacy. Wet 
milling is a nanonization technique used to mechanically reduce drug particle size thereby 
generating nano-sized drug crystals. LF was first dispersed uniformly in an aqueous medium 
containing dispersing agents (HPMC E3, PVP and Tween 80), these components are used to 
facilitate reduction in particle size, before being milled for 6 hours with 0.4-0.6 mm yttrium-
stabilized zirconium beads. Unmilled LF was found to have a particle size of 75.24 µm and 
the mean particle size of the LF nanopowder was 0.251 µm. It was reported that the nano-
sized LF had an enhanced dissolution rate compared to unmilled LF. In vitro antimalarial 
activity was assayed using a chloroquine (CQ) sensitive P. falciparum 3D7 strain, the IC50 
value of nano-sized LF was 0.1 ng/ml which was considerably lower than the IC50 for 
unmilled LF and CQ which was 17.5 ng/ml and 4.2 ng/ml respectively. The in vivo 
antimalarial experiment was performed in mice inoculated with P. Yeolii nigeriensis (rodent 
malaria parasite). The drug was tested at three different dose concentrations; 60, 30 and 15 
mg/kg and the mice were monitored for 28 days. The test groups that received the LF 
nanopowder had a mean survival time (MST) of ≥28 days at all examined dose strengths and 
the groups that received the unmilled LF had a MST of ≥28 days at the 60 and 30 mg/kg dose 
and a MST of 23.8 days at the 15 mg/kg dose (Gahoi et al., 2012). The results of the study 
demonstrated the efficiency of wet milling using DYNO MILL to produce stable LF 
nanopowder. The LF nanopowder enhanced in vitro antimalarial efficacy however 
bioavailability studies need to be performed to gain greater insight into the pharmacokinetics 
of this drug formulation (Gahoi et al., 2012). 
Aim and Objective 
For this „proof of concept‟ study LF was entrapped in a Pro-Pheroid
™
 formulation, to 
evaluate an improvement in in vitro efficacy and in vivo bioavailability and efficacy, 
compared to a reference formulation. The LF in Pro-Pheroid
™
 used in this study was a 
preliminary formulation that may be optimized for further investigation. The in vitro and in 
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In vitro antimalarial activity against P. falciparum 
4.1 Introduction 
A typical screening program, as detailed in Figure 4.1, consisting of pre-clinical in vitro and 
in vivo assays, was followed for the purpose of comparing the antimalarial activity of the 
Pheroid
™
 formulated LF with LF suspended in reference solution (LF in reference 
formulation). This chapter will elaborate on the antimalarial activity of LF in the two 
different formulations against a chloroquine sensitive (CQ-S) P.  falciparum strain using an 








Figure 4.1: An experimental flow diagram for the screening of antimalarial compounds 
The activity or effect of the test drug is quantified as inhibition of parasite growth; an IC50 is 
the concentration of the test drug that inhibits parasite growth by 50%.  When screening 
novel compounds for in vitro antimalarial activity, compounds exhibiting an IC50 < 1 µM 
with equivalent activity against CQ-S and CQ-R strains warrants further development and in 
vivo activity testing (Fidock et al., 2004). Routine in vitro antimalarial assays are also 
performed, using fresh parasite isolates from malaria infected individuals, to monitor the 
activity of drugs in clinical use and predict the emergence of drug resistant parasites. 
Several in vitro assays have been developed to measure antimalarial activity against malaria 
parasites and these may be categorised as isotopic (using radioactive material) or non-
isotopic. [
3
H]-hypoxanthine is an isotopic in vitro assay which uses radioactive tritium 
labelled hypoxanthine that may be incorporated into parasite DNA as the parasite propagates. 
This assay measures how much an antimalarial drug inhibits parasite growth (drug activity) 
by quantitating the uptake of [
3
H]-hypoxanthine using a liquid scintillation spectrometer.  
In vitro screening (pLDH assay) 
 
 
In vivo screening: 
Bioavailability study in mice 
 
 
4-day Plasmodium suppression 
test in mice 















A fluorimetric test is a non-radioactive DNA based assay which uses a fluorescent nucleic 
acid stain (PicoGreen
®
 or Sybr Green) to measure parasite growth and drug activity. 
Immunoenzymatic assays are also non-isotopic and may utilise monoclonal antibodies 
specific for parasite lactate dehydrogenase enzyme (pLDH activity is correlated to parasite 
growth) to quantify drug activity by measuring the inhibition of enzyme activity (Co et al. 
2010). Another example of an immunoenzymatic antimalarial assay is the highly sensitive 
enzyme-linked immunosorbant (ELISA) test kits, it allows for the measurement of histidine 
rich protein 2 (HRP2) which is produced by the parasite as it grows. The Giemsa stained slide 
method is low cost but not suitable for high throughput in vitro antimalarial drug screening. 
The parasites are incubated with the test compounds and the parasitemia is determined by 
preparing blood films and counting Giemsa stained parasites using light microscopy (Kalra et 
al., 2006, Co et al., 2010). The WHO in vitro micro test kit consists of plates pre-dosed with 
antimalarial drug compounds, parasites are added to the plates followed by an incubation 
period of 24 hours. Thereafter thick blood films are prepared and parasite drug susceptibility 
is determined microscopically by counting the amount of Giemsa stained parasites that have 
developed into shizonts (WHO, Mark III test kit instructions, 2001).  
The colorimetric pLDH assay was used for quantifying the antimalarial activity of the test 
formulations in this study. This in vitro assay described by Makler et al. was developed to 
detect P. falciparum by measuring the enzymatic activity of pLDH in clinical samples. pLDH 
is differentiated from human red blood cell LDH as it rapidly uses 3-acetyl pyridine NAD 
(APAD) as a coenzyme in the reaction leading to the formation of pyruvate from lactate. This 
reaction produces a reduced APAD which in turn reduces tetrazolium (colour changing 
substrate) forming a blue formazan product that can be measured using a spectrophotometric 
plate reader (Makler and Hinrichs, 1993). 
There are many factors such as initial haematocrit and parasitemia which may influence the 
in vitro drug sensitivity of the parasite and lead to variable results. Using synchronous 
parasite cultures for the in vitro assays ensures more consistent results (Kalra et al., 2006, Co 
et al., 2010). As detailed in Table 4.1, the IC50 values reported for LF ranges from 1.91 to 
90.1 nM. This high variability may be due to the lipophilicity of LF, the type of in vitro assay 



















Table 4.1: Reported in vitro activity (IC50 values) for lumefantrine/benflumetol tested using isolates of 
P. falciparum  
 
 
Abbreviations: CQ-S; chloroquine sensitive, CQ-R; cloroquine resistant, PI; primary infection, RI; recrudescent 
infection, ATR; adequate treatment results, LTF; late treatment failure. 
 
Aim and Objective 
To determine and compare the in vitro activity (IC50 value) of LF in Pheroid
™
 formulation 












Author Year P.falciparum Origin LF IC50 (nM) In vitro  assay system Details
Basco et al. 1998 fresh isolates (CQ-S) Yaounde, Cameroon 12.4 isotopic microtest No significant difference in activity
fresh isolates (CQ-R) 10.2 [
3
H]hypoxanthine in CQ-S and CQ-R strains
van Vugt et al. 1998 fresh isolates (PI) Thailand 54 isotopic microtest Isolates from a primary infection
fresh isolates (RI) 42 [
3
H]hypoxanthine Isolates from recrudescent infection
Wernsdorfer et al. 1998 fresh isolates (CQ-R) Tanzania 12.4 WHO microtest No significant difference in activity between LF 
and respective enantiomers
Hassan-Alin et al. 1999 T-996, multiresistant strain Thailand 2.3 Giemsa stained thin blood films Laboratory adapted strains
LS-21, CQ-R India 1.91
Pradines et al. 1999 fresh isolates Senegal 55 isotopic microtest,[3H]hypoxanthine
Brockman et al. 2000 fresh isolates (PI) Thailand 61.1 isotopic microtest Isolates from a primary infection
fresh isolates (RI) Thailand 78.5 [
3
H]hypoxanthine Isolates from recrudescent infection
Tanariya et al. 2000 fresh isolates (PI) Thailand 18.1 Giemsa stained thin blood films Isolates from a primary infection
fresh isolates (RI) Thailand 14.9 Isolates from recrudescent infection
Denis et al. 2006 fresh isolates (ATR) NW Cambodia 18.8 isotopic microtest Tested using isolates from patients with adequate
fresh isolates (LTF) NW Cambodia 28.9 [
3
H]hypoxanthine  treatment response and treatment failure
Nkhoma et al. 2007 fresh isolates Blantyre, Malawi 90.1 WHO microtest
Starzengruber et al. 2007 fresh isolates Thailand 27.3 WHO microtest
Kaddouri et al. 2008 fresh isolates Bamako,Mali 11.2 (pLDH) ELISA
Mwai et al. 2009 fresh isolates Kenya 50 isotopic microtest,[3H]hypoxanthine
Wong et al. 2011 3D7 (CQ-S) Laboratory adapted 65.2 isotopic microtest Laboratory adapted strains

















4.2 Materials and Methods 
Chemicals & Reagents 
 
Acetonitrile, methanol and water of HPLC grade, LiChrosolv
®
 was purchased from Merck 
(Darmstadt, Germany). Formic acid and Dimethyl sulfoxide (DMSO) was purchased from 
Merck (Darmstadt, Germany). Acetic acid purchased from Sigma-Aldrich (Germany). N2O 
water was supplied by Dr. Lissinda Du Plessis, University of North West (Potchefstroom). 
Lumefantrine (LF) was donated by Novartis (Basel, Switzerland). Chloroquine diphosphate 
(CQ) was purchased from Sigma. 
 
Sample preparation for antimalarial assay 
 
LF in 10% DMSO sample (reference) 
 
The reference stock sample of LF was prepared at a concentration of 2 µg/ml in a 
DMSO:water (1:9 v/v) solution. The sample was mixed using a vortex mixer (Scientific 
Industries, Vortex Genie 2) and then sonicated for 10 minutes at 100% power and 18°C 
(Labcon, ultra-sonic). LF dissolved poorly in the reference solution and was tested as a 
suspension. The 2 µg/ml reference sample was diluted 10-fold using culture medium (CM) to 








 stock sample of LF was prepared by Dr L. du Plessis (University of North 
West, Potchefstroom) at a concentration of 5 mg/ml. Due to the high lipid content of the Pro-
Pheroid
™
 formulation, the samples have a milky appearance which may cause interference 
with absorption reading and variability in the results. The Pro-Pheroid
™
 formulation was 
diluted, using a drug free Pro-Pheroid
™
 solution, for the pLDH assay to ensure accurate 
results. The diluent; a blank Pro-Pheroid
™
 and N2O water solution was used for dilutions. 
The test sample was prepared at a concentration of 2 µg/ml. The 2 µg/ml (2000 ng/ml) test 
sample was then serially diluted 2-fold using diluent, producing ten concentrations ranging 
from 2000-4 ng/ml. The ten test samples were then further diluted 10-fold, using aseptic 


















Antimalarial in vitro assay 
 
The assay was performed by Mrs Sumaya Salie and Ms Ntokozo Dambuza, at the Division of 
Pharmacology, UCT. Continuous in vitro cultures of asexual blood stages of P. falciparum 
were maintained using a modified method described by Trager and Jensen (Trager and 
Jensen, 1976). Using a modified pLDH assay, the antiplasmodial activity of LF in a reference 
and Pheroid
™
 formulation was quantitatively determined as inhibition of parasite growth.  
 
The drug samples were evaluated in triplicate, on two different occasions, against a 
chloroquine (CQ) sensitive strain of P. falciparum (D10). Chloroquine diphosphate was used 
as the reference control drug in the pLDH assay. The diluent was used as a negative control 
for the test sample and DMSO:water (1:9 v/v) solution was used as a negative control for the 
reference sample.. As shown in Figure 4.2, negative (non-infected RBC at 1% hematocrit) 
and positive (drug-free RBC at 1% parasitemia) assay controls were added in column one and 
two respectively. 
 
Figure 4.2:  A representative 96-well plate detailing the in vitro assay sample locations and the final 
drug concentration range after the addition of RBCs. 
 
As detailed in Figure 4.2, 100µl of the test samples at each concentration was added directly 
to the wells in columns 3 to 12 in rows A, B and C followed by the addition of 100 µl of 















transferred to the well in column 3 in rows D, E and F at a starting concentration of 200 
ng/ml and thereafter serially diluted 2-fold using CM producing ten concentrations ranging 
from 200-0.4 ng/ml. The reference samples were then further diluted 2-fold with the addition 
of 100 µl parasitized red blood cells yielding a final concentration range of 100-0.2 ng/ml. 
The same dilution technique was used for the control samples with a total volume of 200 µl 
in each well of the 96-well assay plate. All drug samples were tested for their antimalarial 
activity at ten different concentrations; ranging from 100-0.2 ng/ml to determine the 
concentration inhibiting 50% of parasite growth.  
 
The assay plates were incubated (Prolab incubator) at 37ºC in a gas chamber with a 
controlled environment of 3% O2, 4% CO2 and 93% N2 for 48 hours. The plates were then 
removed from the incubator and stored at -20°C until analysis. The plates were thawed, the 
contents of each well was re-suspended using a pipette and then 15 µl of the cell suspension 
was transferred to a corresponding well in a separate plate containing 100 µl of Malstat 
reagent (Sigma-Aldrich). The cell suspension and Malstat reagent were mixed thoroughly and 
air bubbles were removed. Subsequently 25 µl of nitro blue tetrazolium salt (NBT) (Sigma-
Aldrich) was added to each well and the plate was placed in a dark cupboard to develop, the 
result can be seen in Figure 4.3. Thereafter the absorbance was measured using a Midas 
microplate reader at 600 nm; the growth in drug-exposed cultures was determined relative to 




Figure 4.3: A representative 96 well plate after development, the darker the colour in the wells the 






















The in vitro antimalarial assays were performed on two separate occasions and the average 
calculated IC50 values (average of six replicates) are reported in Table 4.2 below. Using the 
average IC50 values, LF in the Pheroid
™
 formulation was 1.87 times more active against the 
CQ-S P. falciparum, D10 strain than LF in the reference formulation.  
 
Table 4.2: Results of in vitro drug susceptibility assay against P. falciparum D10 strain detailing the 
average IC50 values for LF in Pheroid
™
, LF in reference formulation and CQ. Reported IC50 values are 





With respect to the calculated CV (%), which is an indication of the precision of the assay, 
there is less variability in the results when LF is formulated with the Pheroid
™
 than when 
dissolved in the reference solution. This may be as result of LF‟s aqueous insolubility, the 
reference solution is a mostly aqueous solution and LF did not dissolve appropriately 




The dose-response curves generated using GraphPad Prism 4.0, for the test formulations and 
CQ are illustrated in Figures 4.4 to 4.6. These graphs are plotted using the Log concentration 
values of the test compounds and the corresponding % parasite survival for the purpose of 
determining IC50 values. In Figure 4.5, the test formulations exhibit variable results which 












Assay Pheroid™ Reference CQ
Experiment 1 33.1 73.4 18.5
Experiment 2 21.1 28.4 9.45
Ave. 27.1 50.9 14.0
STDEV 8.5 31.8 6.4
















a.                                                                           b. 
P. falciparum D10 strain
LF in Pheroid formulation
























LF in Pheroid formulation























Figure 4.4: Dose response curves of LF in Pheroid
™
 formulation against P. falciparum D10 strain 
(CQ-S), a. and b. corresponds to experiment 1 and 2 respectively. 
 
a.                                                                            b.                







IC50 = 38.8ng/ml (73.4nM)
P. falciparum D10 strain
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Figure 4.5: Dose response curves of LF in reference formulation against P. falciparum D10 strain (CQ 
-S), a. and b. corresponds to experiment 1 and 2 respectively. 
 
a.                                                                         b. 
P.falciparum D10 strain
CQ
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CQ

























Figure 4.6: Dose response curves of CQ, standard control, against P. falciparum D10 strain (CQ-S), a. 

















This in vitro antimalarial assay was performed to determine if the improved solubility of LF 
in the Pheroid
™
 formulation would result in lower IC50 values when compared to LF in an 
aqueous reference solution. The results indicate that the LF in Pheroid
™
 formulation has 
improved antimalarial activity in vitro by 47%, when compared to the reference formulation, 
however the large variation in the data may render this conclusion unreliable.  
The reported IC50 values for LF against P. falciparum, determined using in vitro assays are 
detailed in Table 4.1 (refer to page 47). LF in reference and Pheroid™ formulation had an 
IC50 value of 50.9 and 27.1 nM respectively. These values fall within the reported range of 
1.91 to 90.1 nM, determined from the studies presented in Table 4.1.   
 
There are various reasons for the wide range of reported IC50 values for LF. Most of the in 
vitro assays, as shown in Table 4.1, were performed using fresh P. falciparum isolates from 
malaria infected individuals and parasite drug susceptibility may vary from one geographical 
area to another. Also the different in vitro assays are not standardized or comparable with 
respect to the calculated IC50 values. The study performed by Wong et al. was the only one to 
use laboratory adapted parasite strains, and they reported an IC50 value of 65.2 nM for LF 
against a CQ-S strain which is comparable to the reported value of 50.9 nM in this study 
(Wong et al., 2011). The in vitro antimalarial assay, using fresh parasite isolates, allows for 
the determination of the intrinsic drug-susceptibility of the parasite however no deductions 
can be made regarding the effect of pharmacokinetic or immunological variations (Kalra et 
al., 2005, Nkhoma et al., 2007). As a result, in vitro drug susceptibility assays are performed 
using clinical isolates from a primary infection and then performed again using isolates from 
subjects with recrudescent infections or experiencing late treatment failure to confirm the 
presence of drug resistant parasites (van Vugt et al., 1998, Brockman et al., 2000, Tanariya et 
al., 2000, Denis et al., 2006).  
Despite the limitations, in vitro drug susceptibility assays are fast, efficient and allow for high 
through-put screening of antimalarial compounds. For this study the in vitro results were used 
to corroborate the in vivo efficacy results when comparing LF in Pheroid
™
formulation to LF 
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Quantitative bioanalysis of lumefantrine 
5.1 Introduction 
Developing sensitive and selective analytical methods for analyte and/or metabolite 
quantification is imperative for any pharmacokinetic study. When developing a bioanalytical 
method there are many techniques which can be employed in order to produce an efficient, 
accurate and reliable method. For this study high pressure liquid chromatography and tandem 
mass spectrometry (LC-MS/MS) was chosen for sample analysis. A LC-MS/MS 
bioanalytical method consists of four procedures, namely sample extraction, chromatography, 
detection and quantification. High performance liquid chromatography (HPLC) is a technique 
used for the chromatographical separation of the analyte(s) of interest, based on 
physicochemical properties or size, prior to detection and quantification using mass 
spectrometry (MS). Mass spectrometry may be coupled to other separation techniques 
including gas chromatography (GC) or capillary electrophoresis (CE) (de Hoffmann & 
Stoobant, 2007). Samples may also be introduced directly into the ion source of the mass 
spectrometer, bypassing elution chromatography, and analysed by flow-injection-MS/MS 
(Niessan, 2006).  
A mass spectrometer is an analytical tool, for quantitative and qualitative analysis, with 
increasing scientific application including high throughput bioanalysis, structure elucidation 
of unknown compounds, metabolite identification, to name a few examples. A mass 
spectrometer is a computerized system and consists of essentially five parts: a sample inlet, 
an ion source interface, mass analyser, ion detector and data processor as shown in Figure 5.1 
below. 
 
Figure 5.1: A schematic of the constituent components of a mass spectrometer (Gross, 2011) 
The liquid chromatography coupled to tandem mass spectrometry process involves the 















solution to an ion source for the production of molecular ions, for example via electrospray 
ionization (ESI), atmospheric pressure chemical ionization (APCI) or atmospheric pressure 
photo ionisation (APPI). The ions then pass through a Curtain Gas
™
 interface between 
atmospheric pressure and high vacuum. Ion separation occurs in the mass analyser; according 
to specific mass-to-charge (m/z) ratio values (Q1), fragmentation in a collision cell (Q2) and 
selection of product ion (Q3) as shown in Figure 5.2. The charged ions are detected using an 
electron multiplier and signals are then transferred to a computer and data analysis is 
performed using analytical software. 
 
 
Figure 5.2: MRM scan mode in a triple quadrupole mass spectrometer (Picture sourced from AB 
Sciex) 
When a sample is introduced, depending on the specific ion source utilized, molecular ions 
may be produced by electron ejection, electron capture, protonation, deprotonation or adduct 
formation. Sample ionization is necessary as a mass spectrometer only detects charged 
species and separates ions according to their mass-to-charge (m/z) ratio (de Hoffmann & 
Stroobant, 2007, Gross, 2011). Multiple reaction monitoring (MRM) or selective reaction 
monitoring (SRM) has become the mode of choice in quantitative mass spectrometric 
bioanalysis (Niessan, 2006). As illustrated in Figure 5.2, SRM allows for the selection of a 
specific precursor or molecular ion (e.g. m/z 216) in the first quadrupole (Q1) then controlled 
fragmentation of the selected precursor ion in the collision cell (Q2) and selection of a 
specific product or fragment ion (e.g. m/z 174), for detection, in the third quadrupole (Q3) 
(Gross, 2011). Ions exiting the quadrupoles are detected, transformed into a digital signal and 
relayed to the computer for data processing and interpretation using Analyst
®
 software.  
LC-MS/MS is an analytical technique utilized in the drug development process, allowing fast 















LC-MS/MS method validation   
The purpose of validating bioanalytical methods for analyte quantification in a specific 
biological matrix (blood, plasma, urine, etc.), is to ensure that the method is robust and 
reproducible for analysing samples of unknown concentrations. A LC-MS/MS method 
validation, involving specific laboratory investigations, was performed according to the 
guidelines for bioanalytical method validation, developed by the USFDA (FDA; Guidelines 
for Industry, 2001). These procedures are undertaken to ensure a complete system of quality 
control and assurance. A LC-MS/MS method validation is performed to objectively 
demonstrate and document the accuracy, precision, selectivity, sensitivity and reproducibility 
of the developed method. The stability of the analyte is also investigated to ensure that the 
analyte concentration is not affected by the assay procedure or associated storage conditions.   
Literature Review 
Published LC-MS/MS methods for the quantification of LF in biological matrix are detailed 
in Table 5.1. One method was developed for the determination of LF in rat plasma while the 
other five were developed for human plasma. All the methods were developed and validated 
according to FDA or the AIDS Clinical Trial Group (ACTG) guidelines. There are no 
published LC-MS/MS methods for the determination of LF in mouse whole blood (WB) 
and/or plasma (refer to Table 5.1). 
Table 5.1: Summary of published LC-MS/MS methods for LF 
 
Liquid chromatography coupled to tandem mass spectrometry allows for the development of 
sensitive and selective quantitative methods, using low sample volumes and run time, which 
may be utilised for high throughput sample analysis (Jemal 2000). The methods for the 
detection of LF developed by Sethi et al.,  Hodel et al., Cesar et al. and Huang et al., each 
have long sample run times (≥ 5 min) which may not be feasible for high throughput sample 
analysis  (i.e. process ≥100 samples/day)  (Lee1999).  Sethi et al. used a solid phase 
extraction method which is time consuming and expensive. Wahajuddin et al. and Huang et 
Reference Year Extraction Conc. range Sample Injection LC Analytical Flow rate Sample run time Biological 
Method (ng/ml)  vol (ul) vol (µl) Column (ml/min)  (min) Matrix
Wahajuddin et al. 2009 Liquid-Liquid 2-500 100 10 C18 0.5 5 rat plasma
Hodel et al. 2009 Protein prec. 4-4000 200 10 C18 0.3 17 human plasma
Munjal et al. 2010 Protein prec. 210-25050 100 5 C8 0.6 2.9 human plasma
Cesar et al. 2011 Protein prec. 10-18000 250 50 Zorbax SB-Cyano 1 9 human plasma
Sethi et al. 2011 SPE 2-2000 100 10 Xterra RP18 0.5 15 human plasma
Huang et al. 2012 Liquid-Liquid 50-20000 25 10 Zorbax C18 0.4 8 human plasma
















al. used a liquid-liquid sample extraction method which is more labour intensive and time 
consuming than protein precipitation sample extraction. A plasma volume of ≥100 µl would 
be considered a large volume, using the mouse as an experimental animal but the sensitivity 
of mass spectrometry allows for the reduction of the biological sample volume required. 
Huang et al. developed the only LC-MS/MS method for the quantitation of LF using a stable 
isotope labelled analyte as internal standard (ISTD) to eliminate matrix effects and ionization 
saturation. All the published methods have shortcomings regarding their use for pre-clinical 
high throughput analysis in mouse blood or plasma.  
Aim and Objective 
To develop and validate a LC-MS/MS method for the quantification of LF in mouse plasma 




























5.2 Materials and Methods 
Solvents and chemicals 
Analytical grade, LiChrosolv
®
 water, acetonitrile and methanol were purchased from Merck 
(Darmstadt, Germany).  Formic acid was purchased from Merck (Darmstadt, Germany). 
Acetic acid was purchased from Sigma-Aldrich (Germany). LF (Figure 5.3) was donated by 
Novartis (Basel, Switzerland) and the deuterated internal standard, D9-LF (Figure 5.4) was 
purchased from Toronto Research Chemicals Inc. (Ontario, Canada).  
 
               
Figure 5.3: Chemical structure of the analyte lumefantrine (LF)  
                                                  
Figure 5.4: Chemical structure of the internal standard; deuterated lumefantrine (D9-LF)  
 
Biological matrix 
Blood from C57/BL6 mice was collected by cardiac puncture in Lithium Heparin (anti-
coagulant) vacuum tubes. The mice, sacrificed for blood collection, were obtained from the 
Animal Unit, University of Cape Town. The pooled mouse blood was used for the 
Molecular  formula: C30H23D9Cl3NO 
Molecular weight: 538g/mol 
 
Molecular formula: C30H32Cl3NO 















preparation of the calibration standards and quality control standards. The fresh mouse blood 
was centrifuged at 2300 G for 10 minutes (Eppendorf 5415D) to obtain mouse plasma.  
Instrumentation 
The LC-MS/MS method was developed and validated on an Agilent 1200 series HPLC 
system coupled with an AB Sciex API 3200 triple quadrupole mass spectrometer (AB Sciex). 
The mass spectrometer is equipped with a Turbo V
™
 ion source and patented LINAC
® 
collision cell. Bioanalysis was performed using ESI in the positive ion mode. For the 
quantitation of LF the LC-MS/MS system was operated at unit resolution in MRM mode, 
monitoring the transition of the precursor ion m/z 530.1 to the product ion m/z 347.9 for LF 
and the transition of precursor ion m/z 539.1 for D-LF (ISTD), to product ion m/z 347.9 as 





XP computer running Analyst
®
 software version 1.5.1. Analyst
®
 
software was used for LF chromatographic data acquisition, peak integration and 
quantification. 
 
Figure 5.5: Product ion spectrum (Q3) of the analyte, showing the [M+H]
+ 
 ion at m/z 530.0  
 +MS2 (530.06) CE (50): 26 MCA scans from Sample 1 (TuneSampleName) of lumefantrine_2_InitProduct_Pos.wiff (Turbo Spray) Max. 1.7e6 cps.
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Figure 5.6: Product ion spectrum (Q3) of the ISTD, showing the [M+H]
+ 
 ion at m/z 539.0  
Chromatography and Mass Spectrometry  
Chromatography was performed on a Phenomenex Luna, PFP 2 (50 x 2.0 mm, 5 µm) 
analytical column (Separations, South Africa). The sample injection volume was 2 µl and the 
mobile phase consisting of acetonitrile and 0.1% formic acid (formic acid: water, 1:1000 v/v) 
at a ratio of 3:7 (v/v) was delivered at a constant flow rate of 0.5 ml/min. The analyte eluted 
at 1.3 min for WB samples and 1.12 min for plasma samples. Detection was performed on an 
AB Sciex 3200 mass spectrometer and the optimised settings are summarised in Tables 5.2 
and 5.3. The total LC-MS/MS run time was 3 minutes per sample analysed. 
Table 5.2: ESI settings                                                    
Curtain gas (CUR) 20 
Collision gas (CAD) 5 
Ion spray voltage (V) 4500 
Source temperature (°C) 500 
Gas 1 (psi) 50 
Gas 2 (psi) 60 
 
 
 +MS2 (539.15) CE (50): 26 MCA scans from Sample 1 (TuneSampleName) of deuterated-lumefantrine_InitProduct_Pos.wiff (Turbo Spr... Max. 1.1e6 cps.







































































Sample Extraction Procedure  
A protein precipitation extraction procedure was developed using 20 µl of mouse WB or 
plasma sample (Figure 5.7). The extraction procedure was performed in 1.5 ml polypropylene 
Eppendorf tubes. The precipitation solution (PPT) consisted of 0.1% formic acid and 
acetonitrile (1:3, v/v). 5 µl of a 1 mg/ml ISTD stock solution (methanol:acetic acid (99.8:0.2, 
v/v)) was spiked into 30 ml of PPT to yield an final ISTD concentration of 166 ng/ml 
(PPT+ISTD). The extraction procedures are detailed in Figure 5.7, 200 µl of the PPT+ISTD 
solution was added to 20 µl of sample and mixed using a vortex mixer (Scientific Industries, 
Vortex Genie 2), sonicated ( Labcon, ultra-sonic) and then centrifuged (Eppendorf 5415D ) to 
yield the analyte containing supernatant. 100 µl of the supernatant was transferred to a 










  LF D-LF 
Q1 mass [M+H]
+
 530.1 539.1 
Q3 mass 347.9 347.9 
Declustering potential (V) 66 71 
Entrance potential (V) 4.5 8.5 
Collision energy (V) 59 59 
Collision cell exit potential (V) 6 6 
Scan type MRM MRM 
Polarity positive positive 


























Figure 5.7:  Sample extraction procedures for LF whole blood (WB) and plasma samples. 
Preparation of ISTD solution 
For quantitation accuracy and precision a deuterated internal standard (ISTD) with near 
identical physicochemical properties was used, namely D9-LF. One milligram of D9-LF was 
weighed accurately using a microbalance scale (Satorius) and subsequently dissolved in 1 ml 
of stock solution (SS), namely; methanol:acetic acid (99.8:0.2, v/v). Five microliters of 1 
mg/ml ISTD stock solution (ISS1) was spiked into 30 ml of the precipitation solution (PPT) 
resulting in a final concentration of 166.67 ng/ml. ISS1 was stored at -80°C. 
Preparation of LF stock solutions  
Stock solutions of LF (SS1) were prepared at a concentration of 1 mg/ml. A mass of 1 mg of 
LF was accurately weighed, using a microbalance scale (Satorius) and dissolved in 1 ml of 
stock solute (SS), methanol:acetic acid (99.8:0.2 v/v). As stated in an earlier scientific 
publication, LF dissolves optimally at a lower pH and acetic acid was therefore added to the 
organic solvent, methanol and found to be efficient (Zeng et al 1996). These stock solutions 
were used to prepare working solutions to spike blank mouse plasma and whole blood as 

















Preparation of calibration standards and quality control standards 
A set of calibration standards (STDs) and quality control standards (QCs) were prepared 
volumetrically in mouse whole blood and plasma, applying the same dilution technique and 
using the same stock solutions. A working stock solution was prepared at a concentration of 
100 µg/ml (SS2) by diluting 100 µl of SS1 with 900 µl SS. 40 µl of SS2 was spiked into 960 
µl of blank plasma/WB which was then serially diluted with blank plasma/WB to attain the 
desired STD concentration range of 15.6 – 4000 ng/ml as presented in Table 5.4. STD 9 at 
4000 ng/ml is the upper limit of quantification (ULOQ) and STD 1 at 15.6 ng/ml is the lower 
limit of quantification (LLOQ).  
For the quality control standards, 64 µl of SS2 was spiked into 1936 ml of plasma/WB which 
was then serially diluted with blank plasma/WB to attain the desired QC concentration range 
of 25-3200 ng/ml as presented in Table 5.5. 
 
Table 5.4:  Preparation of calibration standards for LF 
 
 





Standard Blank plasma/wb Volume SS2 Dilution source Dilution source Total volume of Concentration
volume (µl) spiked  (µl) volume  (µl) dilution  (µl) (ng/ml)
ULOQ - STD 9 960 40 1000 4000
STD 8 500 STD 9 500 1000 2000
STD 7 500 STD 8 500 1000 1000
STD 6 500 STD 7 500 1000 500
STD 5 500 STD 6 500 1000 250
STD 4 500 STD 5 500 1000 125
STD 3 500 STD 4 500 1000 62.5
STD 2 500 STD 3 500 1000 31.3
LLOQ - STD 1 500 STD 2 500 1000 15.6
QC standard Blank plasma/wb Volume SS2 Dilution source Dilution source Total volume of Concentration
volume (µl) spiked  (µl) volume  (µl) dilution  (µl) (ng/ml)
QC 1 (High) 1936 64 2000 3200
QC 2 (Medium) 1000 QC 1 1000 2000 1600
QC 3 1000 QC 2 1000 2000 800
QC 4 1000 QC 3 1000 2000 400
QC 5 1000 QC 4 1000 2000 200
QC 6 1000 QC 5 1000 2000 100
QC 7 (Low 1) 1000 QC 6 1000 2000 50















Calibration standard curve 
Aliquots of the full sets of calibration STDs and QCs were made and stored frozen at -80°C. 
On the day of analysis, the required aliquots were thawed, extracted and analysed for each 
validation run. Using Analyst
®
 software standard curve fitting was determined by applying 
the simplest model that adequately describes the concentration vs response relationship using 
appropriate weighting. The calibration curve is comprised of eight different STDs at 
concentrations ranging from 15.6 ng/ml (LLOQ) to 4000 ng/ml (ULOQ). For LF quantitation 
the eight-point calibration standard curves were calculated based on peak area ratios of 
analyte to ISTD and fitted using 1/x (1/concentration) weighted quadratic regression. 1/x 
weighted quadratic regression was found to be the simplest regression model for LF 























LC/MS/MS method validation 
A complete method validation consists of three validation batches, analysed on three different 
occasions as well as a stability assessment of the analyte to ascertain that the method is 
accurate, precise and reproducible. An example of a typical validation sample batch list is 
shown in Table 5.6, calibration standards are analysed in duplicate and QC samples in six 
fold. The QC samples are monitored over the three validation batches performed on three 
different occasions to demonstrate intra-batch and inter-batch accuracy and precision. 
Table 5.6: A representation of a validation run sample batch list. Abbreviations: DB (double blank); 






Sample no. Sample ID Sample no. Sample ID
1 SYS 25 STD 5
2 Blank 26 QC L2
3 DB 27 QC L1
4 STD 1 28 QC M
5 STD 1 29 QC H
6 STD 2 30 STD 6
7 STD 2 31 STD 6
8 QC L2 32 QC L2
9 QC L1 33 QC L1
10 QC M 34 QC M
11 QC H 35 QC H
12 STD3 36 STD 7
13 STD3 37 STD7
14 QC L2 38 QC L2
15 QC L1 39 QC L1
16 QC M 40 QC M
17 QC H 41 QC H
18 STD 4 42 STD 8
19 STD 4 43 STD 8
20 QC L2 44 STD 9
21 QC L1 45 STD 9
22 QC M 46 Blank
23 QC H 47 DB















Intra-batch accuracy and precision 
As detailed in Table 5.6, a typical validation batch is comprised primarily of a set of 
calibration standards, analysed in duplicate and the QC standards, analysed in six fold. The 
system performance verification sample (SYS) is a QC standard that is extracted and injected 
in triplicate at the beginning and end of every analytical run to monitor the consistency of 
instrument performance throughout the analytical run.  A validation batch also includes a 
Blank (blank matrix) sample which is an extracted sample containing no analyte as well as a 
DB (double blank) sample which is an extracted sample containing no analyte and no ISTD. 
Inter-batch accuracy and precision 
The QC samples are monitored over three successive validation batches performed on 
different occasions to ascertain between-batch accuracy and precision.  
Stability Assessment 
For method validation one needs to demonstrate that the analyte is stable (does not degrade) 
throughout the sample preparation, extraction and analytical procedure including associated 
conditions such as temperature variations. 
Stock solution stability 
Stock solutions of LF were prepared in methanol:acetic acid (9.98:0.2 v/v) solution at a 
concentration of 1 mg/ml and aliquoted. A test sample was left at room temperature for 6 
hours and a control sample was kept at -80°C for the same length of time.  A fresh reference 
stock solution was prepared after the storage period of the test and control samples. The 
reference, test and control samples were subsequently diluted with mobile phase to a 
concentration of 62.5 ng/ml (low), 800 ng/ml  (medium) and 3200 ng/ml  (high) then 
analysed according to the method procedure. Peak areas of the test and control samples were 
compared to the reference samples. The stability of the ISTD stock solution was not 
investigated as fresh solutions were prepared for each batch of sample analysis.  
Freeze and thaw stability in matrix 
To determine the freeze and thaw stability of LF, sample aliquots of quality control standards 
at low (62.5 ng/ml), medium (800 ng/ml) and high concentrations (3200 ng/ml) were stored 
frozen at -80°C and put through three freeze and thaw cycles. Each cycle consisted of a thaw 















time. These samples were analysed against a valid calibration curve and compared to controls 
from the batch, analysed at the same concentration. A precision of more than 15% and an 
accuracy deviating more than 15% of the observed mean QC concentration could indicate 
freeze and thaw instability of LF in matrix. 
On-bench stability 
To determine on-bench stability, sample aliquots at three different concentrations were stored 
frozen at -80°C then thawed and left on the bench (at room temperature) for six hours. These 
samples were analysed against a valid calibration curve and compared to QC samples from 
the batch, analysed at the same concentration. 
On-Instrument stability 
The on-instrument (sample inlet) stability experiment is performed to ensure analyte 
reinjection reproducibility and analyte stability, if an analytical run has to be reanalysed in 
case of instrument failure.  Six aliquots of a QC standard at a mid-concentration of 800 ng/ml 
were extracted and pooled. The samples were analysed as part of a validation batch. These 
samples were injected six fold over two consecutive days to evaluate the stability of the 
analyte in extracted samples when kept in the sample inlet compartment at 5°C, throughout 
the specified 24 hour period. The analyte/ISTD peak area ratios of the „24hr‟ injections were 
compared to the ratios of the initial set of injections. 
Specificity 
A method should be selective for a specific analyte and not be affected by interfering or co-
eluting components in the biological matrix. Any interference would be most apparent at low 
analyte concentration levels. The selection of a specific precursor ion followed by the 
formation and detection of a specific product ion renders quantitative mass spectrometry 
highly specific.  
Carry-over 
Carry-over occurs when traces of analyte are transferred forward to the next chromatographic 
injection affecting peak intensity (Morin et al., 2012).  Carry-over may occur due to analyte 
adsorption on the chromatographic column or sample residue on the sampling needle. After 
the sample is taken up, the autosampler needle is washed with needle rinsing solution 















A blank and a double blank were positioned in the injection sequence directly after the 
highest calibration standard (ULOQ) to assess possible carry-over effects. A peak that is 
observed as a result of carry-over should not be ≥20% of the area or height of the peak 
obtained at LLOQ and is calculated using Equation 5.1 (Morin et al., 2012). 
  
 
Equation 5.1: Calculation of percentage analyte carry-over 
Sensitivity 
The sensitivity of the mass spectrometer and the robustness of the LS-MS/MS quantification 
method at low analyte concentration levels may be evaluated by determining the analyte 
signal/noise ratio at LLOQ. The analyte signal/noise ratio calculated from the LLOQ 
chromatogram should be larger than 5:1 and better than 15% variability.  
Matrix effects (ME) 
The basis of matrix effect is the modification of the ionization of the drug analyte by 
endogenous biological matrix background components. The evaluation of ME was performed 
based on strategies proposed by Matuszewski et al. (Matuszewski et al., 2003, Matuszewski, 
2006). To evaluate ME, 20 µl aliquots of blank mouse matrix (WB/plasma) from six different 
sources were processed using the protein precipitation method detailed previously, to yield 
post-extraction supernatant. Pooled aliquots of post-extraction supernatant from each of the 
six different lots of matrix were then spiked, using LF stock solutions, to yield post-extraction 
ME samples containing LF at low, medium or high concentrations. The post-extraction ME 
samples were added to a 96-well plate and analysed as part of a validation batch.  
The average ratio of LF/ISTD peak areas at low, medium and high concentration of the ME 
samples was used to plot a line graph for each lot of matrix tested. The variability of the 
slopes of the lines fitted through low, medium and high concentrations of LF samples from 
the six different lots of matrix (WB/plasma) may be used as a good indicator of relative ME. 
The precision (CV) of the slopes should not exceed 5%. 
 
 
% carry-over  =    peak area of analyte in blank after ULOQ     x 100 

















The analyte recovery of the extraction procedure was determined by comparing the responses 
measured for pre-extraction spiked quality control samples with responses measured for post-
extraction spiked samples of LF at specified concentrations. To evaluate absolute recovery 
two sets of samples were prepared. The pre-extraction spiked quality control samples (test 
samples) were prepared and extracted as detailed previously. For the post-extraction spiked 
samples (reference samples), 20 µl aliquots of blank mouse matrix (WB/plasma) were 
processed using the protein precipitation method detailed previously, to yield post-extraction 
supernatant. Pooled aliquots of post-extraction supernatant was then spiked, using LF stock 
solutions, to yield post-extraction samples containing LF at low, medium or high 
concentrations. All samples were analysed in six fold and analyte RE was determined at low, 
medium and high concentration levels. The ratio of the analyte peak areas of the test and 
reference samples is expressed as a percentage recovery, calculated using Equation 5.2. 
% RE = (Peak area of test sample/Peak area of reference sample) x 100 
Equation 5.2: Calculation to determine percentage analyte recovery 
The mean RE of the quantitative drug assay method should be consistent and the precision of 
the measured RE (CV) should not exceed 15% for any particular concentration of the analyte 


























A validation batch consists of all the STDs analysed in duplicate to produce one calibration 
curve and six replicates of each QC standard. In order to demonstrate acceptable within- and 
between day accuracy and precision of the method, the STDs and QCs were extracted and 
analysed in three consecutive runs. 
Accuracy (%) of an analytical method refers to the calculated mean test results relative to the 
nominal or true concentration of the analyte. The precision of an analytical method describes 
the closeness of individual measures of an analyte, at a specific concentration, when a 
procedure is applied repeatedly and is expressed as the coefficient of variation (CV).  The 
acceptance criteria for a valid method require the within- and between-batch accuracy to be 
within 15% of the nominal concentration for the entire calibration range except for the LLOQ 
where accuracy within 20% of the nominal concentration is allowed. 
5.3.1 Validation of the LC-MS/MS method for the quantitation of LF in mouse WB   
Intra-batch accuracy and precision 
From the data shown in Tables 5.7 and 5.8 below, it is evident that all the STDs and QCs for 
the first validation run have demonstrated acceptable accuracy and precision. This indicates 
that the method is accurate, precise and sensitive for the duration of one validation run. 
Table 5.7: Accuracy and precision of LF calibration standards for WB validation 1 
 
Table 5.8: Summary of LF inter-validation quality control standards for WB validation 1 
 
 
Sample ID Nominal Conc. Mean observed Standard Deviation Accuracy (%) CV (%) n 
(ng/ml)  conc. (ng/ml)
S1 15.6 17.3 0.544 110.7 3.2 2
S2 31.3 30.8 1.47 98.5 4.8 2
S3 62.5 59.0 0.859 94.4 1.5 2
S4 125 126.0 5.95 100.8 4.7 2
S5 250 243.9 5.57 97.5 2.3 2
S6 500 473.0 22.2 94.6 4.7 2
S7 1000 1022.1 8.54 102.2 0.8 2
S8 2000 2026.1 72.6 101.3 3.6 2
S9 4000 3985.8 108.8 99.6 2.7 2
Sample ID Nominal Conc. Mean observed Standard Deviation Accuracy (%) CV (%) n 
(ng/ml)  conc. (ng/ml)
QC L2 25 27.9 2.04 111.7 7.3 6
QC L1 50 47.8 2.82 95.6 5.9 6
QC M 1600 1621.1 106.4 101.3 2.3 6
QC H 3200 3378.4 70.7 105.6 6.6 6















Inter-batch accuracy and precision 
From the results presented in Tables 5.9 to 5.12, it may be concluded that the method has 
performed adequately over three validation runs; all the STDs and QCs have a calculated % 
CV of less than 15%. The calculated accuracy, for all STDs and QCs are within 15% of the 
nominal concentration values. The bioanalytical method has demonstrated reproducible 
precision, accuracy and sensitivity.   
Table 5.9: Accuracy and precision of LF calibration standards for WB validation 2 
 
Table 5.10: Summary of LF inter-validation quality control standards for WB validation 2 
 
Table 5.11: Accuracy and precision of LF calibration standards for WB validation 3 
 
Table 5.12: Summary of LF inter-validation quality control standards for WB validation 3 
 
Sample ID Nominal Conc. Mean observed Standard Deviation Accuracy (%) CV (%) n 
(ng/ml)  conc. (ng/ml)
S1 15.6 18 0.011 115.4 0.1 2
S2 31.3 32.79 0.017 104.8 0.1 2
S3 62.5 60.71 1.68 97.1 2.8 2
S4 125 115.8 5.29 92.6 4.6 2
S5 250 228.8 1.49 91.5 0.7 2
S6 500 462.3 16.1 92.5 3.5 2
S7 1000 1018.9 25.7 101.9 2.5 2
S8 2000 2135.3 47.6 106.8 2.2 2
S9 4000 3876.5 16.4 96.9 0.4 2
Sample ID Nominal Conc. Mean observed Standard Deviation Accuracy (%) CV(%) n 
(ng/ml)  conc. (ng/ml)
QC L2 25 27.2 0.924 108.6 3.4 6
QC L1 50 49.4 1.11 98.8 2.2 6
QC M 1600 1595.9 123.2 99.7 7.7 6
QC H 3200 3236.6 225.5 101.1 7.0 6
SYS 200 176.4 3.63 88.2 2.1 6
Sample ID Nominal Conc. Mean observed Standard Deviation Accuracy (%) CV (%) n 
(ng/ml)  conc. (ng/ml)
S1 15.6 18.3 1.50 117.5 8.2 2
S2 31.3 33.3 3.30 106.4 9.9 2
S3 62.5 56.8 0.078 90.9 0.1 2
S4 125 117.5 2.60 94.0 2.2 2
S5 250 230.6 6.87 92.2 3.0 2
S6 500 480.8 5.73 96.2 1.2 2
S7 1000 964.7 21.0 96.5 2.2 2
S8 2000 2205.8 11.3 110.3 0.5 2
S9 4000 3814.4 211.6 95.4 5.5 2
Sample ID Nominal Conc. Mean observed Standard Deviation Accuracy (%) CV (%) n 
(ng/ml)  conc. (ng/ml)
QC L2 25 27.4 0.974 109.5 3.6 6
QC L1 50 44.6 1.68 89.2 3.8 6
QC M 1600 1471.6 51.2 92.0 3.5 6
QC H 3200 3166.8 103.0 99.0 3.3 6















Summary of combined calibration standard quality control results  
A summarised analysis of the QC standards for the three validation runs are presented in 
Table 5.13.  
Table 5.13: Overall accuracy and precision estimation for the quality control standards of LF in 
mouse WB 
 
*no value due to sample aliquot error 
Results from the validation assays indicate that the method is accurate and precise for LF 









Validation Nominal QC L2 (25ng/ml) QC L1 (50ng/ml) QC M (1600ng/ml) QC H (3200ng/ml)
Batch Replicates
Validation 1 1 26 50.4 1530 3410
2 28.5 50.5 1560 3330
3 31 48.5 1610 3420
4 27.6 48.6 1620 3400
5 29 45.2 1580 3260
6 25.5 43.5 1830 3460
Validation 2 1 27.3 49.9 1540 3590
2 28.3 50.5 1580 3310
3 26.9 50.6 1550 3290
4 27.6 48.9 1480 3160
5 * 48.4 1580 3170
6 25.8 48 1840 2900
Validation 3 1 27.9 47.2 1500 3260
2 27.8 43.1 1540 3230
3 26.3 44.3 1500 2970
4 28.8 45.6 1440 3210
5 27.1 44.7 1390 3140
6 26.5 42.6 1460 3200
Average 27.6 47.3 1562.8 3261.7
STDEV 1.36 2.76 118.9 168.6
 CV (%) 4.9 5.8 7.6 5.2
















Stock solution stability  
Stock solution stability was assessed at low, medium and high concentrations namely 62.5, 
800 and 3200 ng/ml respectively. The peak areas of the test and control samples were 
compared to the reference samples, results are presented in Table 5.14. 
The % CV calculated for the control samples at low, medium and high concentration were 
less that 15% which indicates good analyte stability. The % CV calculated for the test 
samples at medium and high concentration were less that 15% which indicates good analyte 
stability, when left at ambient temperature for 6 hours. However the accuracy calculated for 
the analyte at the low concentration under test conditions was 119% which was more than 
15% greater than the reference sample peak area. The analyte is more likely to degrade at 
room temperature and as a result a decrease in accuracy would be expected, thus the 
discrepancy may be due to matrix effects or a dilution error instead. This discrepancy was not 
observed during the LF in plasma validation (where a matrix effect evaluation was 
performed) therefore it more likely occurred as a result of human error than analyte 
instability. This should not affect the validity of the method as stock solutions are only used 
for spiking calibration STDs and QCs, during which the stocks are kept on ice and returned to 
-80°C storage promptly. 
Table 5.14:  Stock solution stability at ambient temperature (16°C) and -20°C compared to fresh 
reference solution at three different concentrations 
 
Reference Test (16°C) Controls (-20°C)
Low conc. Peak area 1 26500 32200 25200
Peak area 2 26700 31100 24700
Average 26600 31650 24950
STDEV 141.4 777.8 353.6
CV (%) 0.5 2.5 1.4
Accuracy (%) 119.0 93.8
Medium conc. Peak area 1 367000 369000 363000
Peak area 2 360000 361000 371000
Average 363500 365000 367000
STDEV 4949.7 5656.9 5656.9
CV (%) 1.4 1.5 1.5
Accuracy (%) 100.4 101.0
High conc. Peak area 1 1020000 1070000 957000
Peak area 2 1020000 1040000 949000
Average 1020000 1055000 953000
STDEV 0.000 21213.2 5656.9
CV (%) 0 2.0 0.6















Freeze and thaw stability in matrix 
Freeze and thaw stability of the analyte in WB was assessed at low, medium and high 
concentrations, namely 62.5, 800 and 3200 ng/ml respectively. The measured concentrations 
and calculated accuracy for the test samples, after three freeze and thaw cycles, are presented 
in Table 5.15. The precision and accuracy for LF tested at the three different concentrations 
are acceptable, which indicates that LF is stable for at least three freeze and thaw cycles. 
 
















Low concentration (62.5ng/ml) Medium concentration (800ng/ml) High concentration (3200ng/ml) 
 
Observed mean QC Observed F/T  Observed mean QC Observed F/T  Observed mean QC Observed F/T  
 
conc. (ng/ml) conc. (ng/ml) conc. (ng/ml) conc. (ng/ml) conc. (ng/ml) conc. (ng/ml) 
 49.4   800   3236.6   
Sample 1   52.5   729   3230 
Sample 2   50.4   744   3280 
Sample 3   48.4   803   3300 
Sample 4   49.2   779   3380 
Sample 5   49.3   765   2950 
  Average 50 Average 764.2 Average 3181.7 
  STDEV 1.43 STDEV 26.0 STDEV 185.8 
  CV (%) 2.9 CV (%) 3.4 CV (%) 5.8 
 
















The measured concentrations and calculated accuracies for the test samples are presented in 
Table 5.16. A % CV of more than 15% and an accuracy deviating more than 15% of the 
observed mean QC concentration could indicate on-bench instability of LF in mouse WB. 
The analyte in mouse WB at low, medium and high concentrations was found to be stable at 
room temperature for six hours. 
Table 5.16: On bench (at room temperature) stability of LF in mouse WB 
 
Low (62.5ng/ml) Medium (800ng/ml) High (3200ng/ml) 
  Observed 
mean QC 
conc. (ng/ml) 










Observed B/T  
conc. (ng/ml)   
  62.09   800   3228.16   
Sample 1   59   817   3220 
Sample 2   59.3   814   3160 
Sample 3   59.9   827   3160 
Sample 4   62   808   3160 
Sample 5   66.1   824   3150 
 
Average 61.3 Average 818 Average 3170 
 
STDEV 2.95 STDEV 7.65 STDEV 28.3 
 
CV (%) 4.8 CV (%) 0.9 CV (%) 0.9 
 





























A % CV and accuracy deviation higher than 15% of the measured ratio values could indicate 
on-instrument instability. As seen in Table 5.17, extracted WB samples containing the analyte is 
stable on instrument for 24 hours, with acceptable precision and a calculated 5.2% difference to 
initial measured concentrations.  




area Ratio   Peak area 
ISTD peak 
area Ratio         
Sample 1 52700 284000 0.186 Sample 1 40200 211000 0.191 
Sample 2 50900 285000 0.179 Sample 2 39900 215000 0.186 
Sample 3 50800 285000 0.178 Sample 3 39500 207000 0.191 
Sample 4 51600 285000 0.181 Sample 4 40100 209000 0.192 
Sample 5 49300 281000 0.175 Sample 5 38800 208000 0.187 
Average 51060 284000 0.180 Average 39700 210000 0.189 
STDEV 1242.2 1732.1 0.004 STDEV 570.1 3162.3 0.003 
CV (%) 2.4 0.6 2.1 CV (%) 1.4 1.5 1.5 
        Accuracy after 24 hrs (%) 105.2 
    
Difference (%) 5.2 
  
Specificity 
A representative chromatogram of STD 1 (LLOQ) is presented in Figure 5.9, indicating no 
interfering peaks. The method is specific for the quantitation of LF from mouse WB samples. 
 


















As shown in Table 5.18, a 9.3% carryover was calculated using equation 5.1 (refer to page 
70) and is within the acceptable limit (≤ 20%). As presented in Figure 5.10 and 5.11, no 
significant carryover or contamination was observed in the extracted double blank (no analyte 
and no ISTD) or blank (no analyte) WB samples.  




Figure 5.10: A representative chromatogram of a blank extracted WB sample situated after the ULOQ 























Figure 5.11: Chromatogram of a double blank (no analyte and no ISTD) WB extract 
Sensitivity 
As presented in Figure 5.12, the calculated analyte signal/noise ratio for LF at LLOQ is 23.7, 
which indicates that the method is sensitive for LF quantification and not affected by 
interference at low analyte concentrations. 
 

















The analyte RE was calculated and expressed as a percentage using Equation 5.2 (refer to 
page 71). As presented in Table 5.19, the mean recovery of LF from mouse WB over the 
calibration range, 15.6-4000 ng/ml is 95% with a % CV of 12%. The extraction method has 
demonstrated acceptable recovery.   
Table 5.19: Recovery calculation results for LF extraction from mouse WB 
 

















 Sample 1 6575 5880 79875 85800 243750 204000 
Sample 2 6275 6240 79125 86000 241250 190000 
Sample 3 6375 6590 82375 87900 246250 203000 
Sample 4 6350 5610 78875 81800 243750 203000 
Sample 5 6225 6010 81500 86300 236250 207000 
Sample 6 6325 5870 81500 86900 232500 200000 
Average 6354.2 6033.3 80541.7 85783.3 240625 201166.7 
STDEV 120.8 341.3 1444.1 2093.2 5229.1 5913.3 
CV (%) 1.9 5.7 1.8 2.4 2.2 2.9 
Recovery (%) 95.0 106.5 83.6 




     
STDEV 11.5 
     
CV (%) 12.1 
 
Matrix effects 
The analysis was performed using Microsoft Excel 2010, the results are presented in Table 
5.20 and the overall % CV of the slopes is calculated and presented graphically in Figure 
5.13. The quantity r is known as the correlation coefficient and the value range is -1≤ r ≤1. In 
this case r describes the strength of the linear association between the nominal LF 
concentration and the calculated LF/ISTD ratios. As shown in Table 5.20, the r values for the 
six different lots of matrix is equal to or close to 1, indicating a strong positive linear 
relationship between the two variables and it may be deduced that any variance in the 
LF/ISTD ratio values may be related to analyte concentration and not ME. The calculated 
precision of the slopes for six different WB (matrix) sources is expressed as a % CV of 3.9%, 
which indicates that LF quantification from different sources is precise and reproducible with 















Table 5.20: Mean LF / ISTD peak area ratios and the precision (expressed as % CV) of slopes of lines 
fitted through low, medium and high samples of LF in six different lots of WB. 
 
Concentration (ng/ml)   
 
 
62.5 800 3200 Slope r 
Matrix 1  0.129 1.98 9.07 0.0029 0.9996 
Matrix 2 0.132 2.12 8.70 0.0027 1.0000 
Matrix 3 0.132 2.07 8.27 0.0026 1.0000 
Matrix 4 0.127 2.00 8.31 0.0026 1.0000 
Matrix 5 0.130 2.04 8.40 0.0026 1.0000 
Matrix 6 0.131 1.98 8.45 0.0027 0.9999 
Average 0.13 2.03 8.53 0.0027   
STDEV 0.00 0.057 0.301 0.0001   
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5.3.2 Validation of the LC-MS/MS method for the quantitation of LF in mouse plasma   
Intra-batch accuracy and precision 
As seen in Table 5.21 and Table 5.22, all the STDs and QCs for the first validation run have 
acceptable precision and accuracy measures.  This indicates that the method is accurate, 
precise and sensitive for the duration of one validation run. 
Table 5.21: Accuracy and precision of LF calibration standards for plasma validation 1 
 
Table 5.22: Summary of LF intra-validation quality control standards for plasma validation 1 
 
Inter-batch accuracy and precision 
As seen in Tables 5.23 to 5.26, the method has performed adequately as all the STDs and 
QCs have a calculated % CV of less than 15%. The calculated accuracy, for all STDs and 
QCs including the LLOQ, is within 15% of the nominal concentration values. The 
bioanalytical method has demonstrated reproducible precision, accuracy and sensitivity.   
Table 5.23: Accuracy and precision of LF calibration standards for plasma validation 2 
 
 
Sample ID Nominal Conc. Mean observed Standard Deviation Accuracy (%) CV (%) n 
(ng/ml)  conc. (ng/ml)
S1 15.6 13.9 0.855 89.2 6.1 2
S2 31.3 30.4 0.763 97.3 2.5 2
S3 62.5 67.0 1.74 107.2 2.6 2
S4 125 129.6 0.767 103.7 0.6 2
S5 250 257.7 1.04 103.1 0.4 2
S6 500 508.2 2.65 101.6 0.5 2
S7 1000 988.8 35.3 98.9 3.6 2
S8 2000 1974.4 88.8 98.7 4.5 2
S9 4000 4014.5 44.8 100.4 1.1 2
Sample ID Nominal Conc. Mean observed Standard Deviation Accuracy (%) CV (%) n 
(ng/ml)  conc. (ng/ml)
QC L2 25 22.0 1.32 88.0 6.0 6
QC L1 50 46.1 1.85 92.2 4.0 6
QC M 1600 1548.8 20.0 96.8 1.3 6
QC H 3200 3126.3 81.7 97.7 2.6 6
SYS 200 181.4 6.23 90.7 3.4 6
Sample ID Nominal Conc. Mean observed Standard Deviation Accuracy (%) CV (%) n 
(ng/ml)  conc. (ng/ml)
S1 15.6 14.2 1.28 91.0 9.0 2
S2 31.3 32.5 0.539 103.8 1.7 2
S3 62.5 63.4 4.49 101.4 7.1 2
S4 125 134.5 11.9 107.6 8.8 2
S5 250 243.9 6.31 97.6 2.6 2
S6 500 504.7 18.8 100.9 3.7 2
S7 1000 949 5.67 94.9 0.6 2
S8 2000 2059.8 52.0 103.0 2.5 2















Table 5.24: Summary of LF inter-validation quality control standards for plasma validation 2 
 
Table 5.25: Accuracy and precision of LF calibration standards for plasma validation 3 
 














Sample ID Nominal Conc. Mean observed Standard Deviation Accuracy (%) CV (%) n 
(ng/ml)  conc. (ng/ml)
QC L2 25 23.4 2.32 93.8 9.9 6
QC L1 50 47.2 3.84 94.3 8.1 6
QC M 1600 1459.5 46.1 91.2 3.2 6
QC H 3200 3047.1 97.2 95.2 3.2 6
SYS 200 186.2 6.32 93.1 3.4 6
Sample ID Nominal Conc. Mean observed Standard Deviation Accuracy (%) CV (%) n 
(ng/ml)  conc. (ng/ml)
S1 15.6 16.1 0.432 103.3 2.7 2
S2 31.3 30.1 3.80 96.3 12.6 2
S3 62.5 64.0 2.49 102.3 3.9 2
S4 125 125.8 4.36 100.6 3.5 2
S5 250 250.5 8.03 100.2 3.2 2
S6 500 486.6 19.8 97.3 4.1 2
S7 1000 976.9 78.5 97.7 8.0 2
S8 2000 2054.4 77.2 102.7 3.8 2
S9 4000 3980.1 178.0 99.5 4.5 2
Sample ID Nominal Conc. Mean observed Standard Deviation Accuracy (%) CV (%) n 
(ng/ml)  conc. (ng/ml)
QC L2 25 23.3 1.17 93.1 5.0 6
QC L1 50 48.0 3.38 96.0 7.0 6
QC M 1600 1477.3 78.4 92.3 5.3 6
QC H 3200 3042.6 91.7 95.1 3.0 6















Summary of combined quality control results  
A summarised analysis of the QC standards for the three validation runs is presented in Table 
5.27. Results from the validation assays indicate that the method is accurate and precise for 
LF quantification with a valid calibration range of 15.6 – 4000 ng/ml. 











Validation Nominal QC L2 (25ng/ml) QC L1 (50ng/ml) QC M (1600ng/ml) QC H (3200ng/ml)
Batch Replicates
Validation 1 1 21.7 45.8 1590 3220
2 21.6 47.4 1550 3120
3 22.1 47.7 1530 2990
4 20.4 47.9 1540 3190
5 24.4 43.6 1530 3150
6 21.8 44.2 1550 3090
Validation 2 1 21.3 44.9 1500 3120
2 23.1 44.1 1520 3000
3 22.7 45.9 1420 2910
4 22.7 44 1410 3190
5 22.9 51.2 1480 3040
6 28 52.8 1430 3020
Validation 3 1 22.9 52.6 1480 2880
2 24 46.8 1370 3110
3 21.5 42.9 1550 3050
4 24.2 46.4 1570 3140
5 22.4 50.2 1410 3020
6 24.5 49 1480 3050
Average 23.0 47.1 1495.0 3071.7
STDEV 1.74 3.14 61.2 88.7
CV (%) 7.6 6.7 4.1 2.9
















Stock solution stability 
The stability of the analyte in solution was tested at a concentration of 500 ng/ml at ambient 
temperature (16°C) and control (-20°C) conditions and compared to freshly prepared stock 
solutions. The peak areas of the test and control samples compared to the reference samples 
are presented in Table 5.28. Under test (ambient temperature) conditions, the % CV and 
accuracy for the analyte was 3.25% and 99.6% respectively. Under control conditions; 
analyte stock solution stored at -20°C, the % CV and accuracy was 3.82% and 99.6%, 
respectively. These results indicate that the analyte is stable in stock solution when stored at 
room temperature and -20°C for 6 hours. 
Table 5.28: Stock solution stability assessment at 500 ng/ml 
 
  Reference Test (16°C) Controls (-20°C) 
Medium 
conc. Peak area 1 199000 190000 201000 
  Peak area 2 196000 184000 180000 
  Peak area 3 189000 180000 191000 
  Peak area 4 196000 194000 185000 
  Peak area 5 166000 186000 185000 
  Peak area 6 189000 196000 188000 
 
Average 189166.7 188333.3 188333.3 
 
STDEV 12056.8 6121.0 7201.9 
 
CV (%) 6.4 3.3 3.8 
 

























The test results are presented in Table 5.29. The precision and accuracy for LF tested at the 
three different concentrations are acceptable, which indicates the analyte is stable in plasma 
for at least three freeze and thaw cycles. 
Table 5.29: Freeze and thaw stability of LF  
 



















Observed F/T  
conc. (ng/ml) 
   47.2   760.0   3047.1   
Sample 1   46.6   683   3000 
Sample 2   47.8   664   2880 
Sample 3   54.7   746   3010 
Sample 4   45.9   710   3020 
Sample 5   51.2   709   3060 
Sample 6   45.4   751   2720 
  Average 48.6 Average 710.5 Average 2948.3 
  STDEV 3.64 STDEV 34.1 STDEV 127.2 
  CV (%) 7.5 CV (%) 4.8 CV (%) 4.3 



























The test results are presented in Table 5.30. The analyte in mouse plasma at low, medium and 
high concentrations was found to be stable at ambient temperature (16°C) for 6 hours. 
Table 5.30: On bench (at ambient temperature) stability of LF 
 








mean QC Observed B/T  
Observed 
mean QC Observed B/T  
Observed 
mean QC Observed B/T  
  conc. (ng/ml) conc. (ng/ml) conc. (ng/ml) conc. (ng/ml) conc. (ng/ml) conc. (ng/ml) 
  47.2   782.7   3047.1   
Sample 1   48.4   838   3080 
Sample 2   49.7   746   2910 
Sample 3   46.5   714   2910 
Sample 4   45.2   738   2830 
Sample 5   44.6   753   2980 
Sample 6   46.8   694   2720 
 
Average 46.9 Average 747.2 Average 2905 
 
STDEV 1.92 STDEV 49.6 STDEV 123.4 
 
CV (%) 4.1 CV (%) 6.6 CV (%) 4.2 
 




























A % CV and difference higher than 15% of the measured ratio values could indicate on-
instrument instability. The results are presented in Table 5.31. The reported peak area values 
for both the analyte and ISTD were reduced by approximately 50% over the 24 hour test 
period. This occurrence was not observed for LF in WB and was therefore most likely due to 
a drop in instrument sensitivity rather than analyte instability. The extracted plasma samples 
containing the analyte LF at a medium concentration of 800 ng/ml, are stable on instrument 
(in the sample inlet compartment) for 24 hours, the % CV is 3.61% and there is a 1.74% 
difference to the analyte concentrations measured initially.  





area Ratio   Peak area 
ISTD peak 
area Ratio 
Sample 1 77300 611000 0.127 Sample 1 36100 289000 0.125 
Sample 2 74200 610000 0.122 Sample 2 35600 284000 0.125 
Sample 3 75100 610000 0.123 Sample 3 36000 302000 0.119 
Sample 4 74700 597000 0.125 Sample 4 41100 312000 0.132 
Sample 5 74700 599000 0.125 Sample 5 41100 315000 0.130 
Sample 6 74900 593000 0.126 Sample 6 42600 331000 0.129 
Average 75150 603333.3 0.125 Average 38750 305500 0.127 
STDEV 1095 7916.2 0.002 STDEV 3174.1 17490 0.005 
CV (%) 1.5 1.3 1.5 CV (%) 8.2 5.7 3.6 
 
    
 
Accuracy after 24 hrs (%) 101.7 
   

























A representative chromatogram of STD 1 (LLOQ) is presented in Figure 5.14, indicating no 
interfering peaks. The method is specific for the quantitation of LF. 
 
Figure 5.14: Representative chromatogram of LF at LLOQ (STD1) 
Carry over 
As shown in Table 5.32, the calculated carryover, using equation 5.1 (refer to page 70), is 
6.4%. As presented in Figure 5.15 and 5.16, no significant carryover or contamination was 
observed in the double blank (no analyte and no ISTD) or blank (no analyte) samples.  























Figure 5.15: A representative chromatogram of a blank extracted plasma sample situated after the 
standard with the highest analyte concentration (STD 9), in the analytical batch list. The analyte peak 
was manually integrated to calculate percentage carryover. 
 
Figure 5.16: Representative chromatogram of a double blank extracted plasma sample, with no LF 



















The method is sensitive for the quantitation of LF, with no interference at the lowest level of 
quantitation; 15.6 ng/ml. The analyte signal/noise ratio calculated from the LLOQ 
chromatogram should be larger than 5:1. The calculated analyte signal/noise ratio for LF at 
LLOQ is 29.5:1 as presented in Figure 5.17. 
 
























The analyte RE was calculated and expressed as a percentage using Equation 5.2 (refer to 
page 71). Presented in Table 5.33 are the peak area values for the reference and test samples 
at low, medium and high analyte concentrations. The extraction method has demonstrated 
acceptable precision and analyte recovery from mouse plasma with a calculated mean 
recovery of 108.2% and % CV of 6.5%.   
Table 5.33: Recovery data for LF in plasma at low, medium and high concentrations  
 















Peak Area (50ng/ml) Peak Area (800ng/ml) Peak Area (3200ng/ml) 
 
2060 1920 28700 29400 96600 110000 
 
1970 1960 28600 31600 98200 116000 
 
2030 2080 28700 33300 96900 109000 
 
1670 1700 29900 33700 97200 107000 
 
1800 1920 30300 32500 97100 113000 
Average 1906.0 1916.0 29240.0 32100 97200 111000 
STDEV 165.9 137.4 798.7 1710.3 604.2 3535.5 
CV (%)  8.71 7.17 2.73 5.33 0.622 3.19 
Recovery (%) 100.5 109.8 114.2 
     
Mean 
Recovery (%) 108.2 
     
STDEV 6.98 
    
 CV (%) 6.5 
 
Matrix effects (ME) 
The analysis was performed using Microsoft Excel 2010. The results are presented in Table 
5.34 and the overall CV (%) of the slopes is calculated and presented in Figure 5.18, the 
variability or coefficient of variation (CV) of the slopes should not exceed 5%. The 
calculated variability of the slopes for six different plasma sources is 3.75%, which indicates 
that LF quantification from different mouse plasma sources is reproducible. As shown in 
Table 4.33, the correlation coefficient ( r
 
) values for the six different lots of matrix is equal to 
or close to 1, indicating a strong linear relationship between the two variables and it may be 
deduced that any variance in the LF/ISTD ratio values may be related to analyte 

















Table 5.34: Mean LF / ISTD peak area ratios and the precision (expressed as % CV) of slopes of lines 
fitted through low, medium and high samples of LF in six different lots of mouse plasma. 
 
Concentration (ng/ml)     
  50 800 3200 Slope r 
Matrix 1  0.177 3.07 10.7 0.0033 0.999 
Matrix 2 0.196 2.95 10.3 0.0032 0.999 
Matrix 3 0.173 2.73 10.8 0.0034 1.00 
Matrix 4 0.191 2.73 11.3 0.0035 1.00 
Matrix 5 0.171 2.87 10.7 0.0033 1.00 
Matrix 6 0.177 2.79 10.5 0.0033 1.00 
Average 0.181 2.86 10.7 0.0033   
STDEV 0.010 0.134 0.345 0.0001   
CV (%) 5.8 4.7 3.2 3.8   
 
 















































The accuracy and precision of the developed LC-MS/MS method for quantitating LF in 
mouse WB and plasma was assessed over three consecutive, independent validation runs and 
the method was found to be acceptable and reproducible, according to FDA guidelines. A 
concentration range of 15.6 - 4000 ng/ml was validated for the quantitation of LF in mouse 
WB and plasma. Stable isotope labelled LF was used as the ISTD and the calibration curve 
was constructed based on the calculated ratio of the signal intensities of the analyte, LF and 
the ISTD, D9-LF. The stable isotope-labelled ISTD compensates for variations that occur 
during analysis, such as variations in sample injection volume and fluctuations in detector 
sensitivity (de Hoffmann and Stroobant, 2007). This was amply demonstrated in the present 
work as variations in LF and D9-LF concentrations were comparable throughout the analysis. 
No substantial matrix effects influencing LF quantitation was found, however the detection 
signal did vary from day to day as demonstrated with the on-instrument analysis. This may be 
due to matrix components, thus the use of a stable isotope labelled ISTD may prove 
invaluable to overcome ion suppression and ensure the reproducibility of this quantitative 
method. The use of a stable isotope labelled LF as the ISTD was shown to eliminate the 
influence of matrix effects and ionization saturation when quantitating LF in human plasma 
(Huang et al., 2012).  
The mean recovery for LF was 95 and 108.2% for WB and plasma, respectively which is 
encouraging considering the simple protein precipitation extraction method used. Cesar et al. 
used a protein precipitation extraction method and reported recovery values for LF ranging 
from 81.4 to 83.2% (Cesar et al., 2011). Munjal et al. also used a protein precipitation 
extraction method and reported a mean LF recovery of 58.8% (Munjal et al., 2010). The 
longer sample mixing and sonication times incorporated in the developed extraction method 
may be responsible for the higher analyte recoveries achieved when compared to the 
extraction method used by Munjal et al..  
The developed LC-MS/MS methods, using a stable isotope labelled LF as ISTD, are sensitive 
and selective for the quantitation of LF. The analyte, LF was shown to be stable in mouse 
WB and plasma and the quantitation of LF was proven to be reproducible throughout the 
validation process as well as the stability assessments.  
Long term stability of frozen stored WB/plasma samples was not assessed in this validation, 















analysis was not a feasible option. Also the samples were only stored at -80°C for a short 
period of time before analysis. The long term stability of LF has however been assessed and 
published in other scientific articles. Wahajuddin et al. reported that LF was stable in rat 
plasma, when stored in a freezer at -80°C ±10°C for 15 days (Wahajuddin et al., 2009). 
Lindergardh et a.l reported no significant loss of LF after storage in plasma at -80°C and -
20°C for 4 months (Lindergardh et al., 2005). 
There are currently no published LC-MS/MS methods for the quantitation of LF in mouse 
WB or plasma. As presented in Table 5.35, the developed and validated methods, reported 
here, are accurate and precise for the quantitation of LF using lower sample volumes, simpler 
and more cost effective sample extraction procedures, and a minimal run time of 3 minutes 
when compared to the published LC-MS/MS methods. 
Table 5.35: A comparison between published and currently presented (in blue) LC-MS/MS methods 


























al. 2009 Liquid-Liquid 2-500 100 10 C18 0.5 5 rat plasma 
Hodel et al. 2009 Protein prec. 4-4000 200 10 C18 0.3 17 
human 
plasma 
Munjal et al. 2010 Protein prec. 210-25050 100 5 C8 0.6 2.9 
human 
plasma 
Cesar et al. 2011 Protein prec. 10-18000 250 50 
Zorbax 
SB-Cyano 1 9 
human 
plasma 
Sethi et al. 2011 SPE 2-2000 100 10 
Xterra 
RP18 0.5 15 
human 
plasma 
Huang et al. 2012 Liquid-Liquid 50-20000 25 10 
Zorbax 
C18 0.4 8 
human 
plasma 
Present study 2012 Protein prec. 15.6-4000 20 2 PFP (2) 0.5 3 
mouse 
plasma  
                  and WB 
  
Most methods for the quantification of drugs are developed and validated in plasma; however 
drug levels may differ with different biological matrices and anticoagulants. Drug analysis 
should thus be performed using methods that have been validated in the same biological 
matrix as the test samples. In the following chapter the developed LC-MS/MS methods have 
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As detailed previously, pharmacokinetics (PK) is the study of the concentration vs. time 
course of a drug, in the body, following drug administration. PK studies (pre-clinical and 
clinical) are essential for drug development and pharmaceutical research as elucidating the in 
vivo disposition of a drug after administration is necessary for optimum therapeutic drug use 
(Benedetti et al., 2009). 
Many factors affect the bioavailability of a drug. Variability in bioavailability may be 
attributed to the physicochemical properties of the drug compound or dosage form or it may 
be patient related. The myriad of physiological factors that influence drug bioavailability 
includes variation in absorption rate across the GI tract, variation of the pH of gastric fluids 
and gastric emptying rate, all of which may be affected by food (Makoid et al., 1999). 
Lumefantrine is a hydrophobic and highly lipophilic drug compound displaying variable 
bioavailability and is associated with a positive food effect (White et al., 1999, Ezzet et.al., 
1998, Ashley et al., 2007). As stated in a review by Wernsdorfer, the erratic and potentially 
inadequate absorption of LF during a fasting state is detrimental for effective antimalarial 
treatment in acutely ill malaria patients. This would necessitate the need for appropriate dose 
adjustment of AL as acutely ill malaria patients have a diminished appetite and are often 
anorexic (Wernsdorfer, 2004). Using formulation technology to address the poor water 
solubility and variable bioavailability of LF, after oral administration, may eliminate the need 
for any dose adjustment. The primary objective of this study was to improve the in vivo 
bioavailability of LF by using Pheroid
™
 formulation to address its aqueous insolubility. 
Improving the solubility of LF was achieved using the patented Pheroid
™
 formulation 
technology. LF was also found to dissolve sufficiently in canola oil. The improvement in 
bioavailability was determined by comparing groups of mice dosed with LF dissolved in a 
reference (aqueous) solution to the groups dosed with Pheroid
™
 formulated LF and LF 















It has been clinically reported that the bioavailability of LF is increased when administered 
after a meal; this is referred to as the „food effect‟. The second objective of this study was to 
determine if the improvement of LF‟s solubility could eliminate the food effect. Groups of 
mice in each of the three treatment arms of the experiment were divided into two groups; one 
group receiving food throughout the experiment (fed) and the other group had the food 
removed twelve hours before dose administration and then replaced one hour after dose 
administration (starved). The mice were fed a standard rodent maintenance feed which 
contained sufficient fats to render a positive food effect. 
LF was quantitated in mouse WB and plasma to investigate any disparities in drug 
concentration levels between red blood cells and plasma. Determining the blood to plasma 
ratio may prove valuable when evaluating novel antimalarial compounds. Malaria  parasites 
infect red blood cells specifically therefore a drug that has a higher concentration in WB than 
plasma, due to the drug distributing to the erythrocyte, may be more effective as an 
antimalarial (Yu et al., 2005).   
LF is absorbed and eliminated slowly, with a terminal elimination half-life of 2-3 days in 
healthy volunteers and 4-6 days in malaria infected patients (Ezzet et al. 1998, White et al., 
1999, Ezzet et al., 2000). LF is highly protein bound (>99%) and is predominantly 
metabolized by cytochrome P450 3A4 (CYP 3A4) (Coloussi et al., 1999, White et al., 1999). 
Table 6.1: Reported pre-clinical pharmacokinetic parameters for LF in a rat model after oral dose 




























20 72 ns 
rat 
plasma NCA 6579.8 590.6 3 16.8 
Wahajuddin 







NCA 22025.3 1488 8 36.1 Wahajuddin 




18281.1 939.8 3.5 25.7 
40     39958.7 2280 5 38.2 
20 120 Starved* 
rat 
plasma NCA 18281.1 938.8 4.25 ns 
Wahajuddin 
et al., 2012 
Abbreviations: ns; not specified, NCA; non-compartmental analysis was performed using WinNonlin 
version 5.1 
Previous preclinical studies of LF have been performed in rats, as shown in Table 6.1. 
Wahajuddin et al. preformed PK studies in male rats, weighing 200-220 g. The animals were 















dose administration. In this study LF was dissolved in a 25% carboxy methyl cellulose 
(CMC) suspension and evaluated at three different concentrations; 10, 20 and 40 mg/kg. 
Blood samples were collected over a time period of 72-120 hours and the concentration of LF 
in rat plasma was determined using LC-MS/MS. The study reported a Tmax range of 2-8 hours 
for LF after oral administration and the Cmax and AUC0-inf values did not increase 
proportionally with the increase of dose. The calculated percentage bioavailability for LF was 
11.6, 4.8 and 5.3 for the 10, 20 and 40 mg/kg treatment groups respectively, indicating a non-
linear relationship between dose and bioavailability (Wahajuddin et al., 2011). 
In this study, the bioavailability of LF was only evaluated at a 10 mg/kg dose over a 24 hour 
sampling time period. During the bioavailability experiment whole blood and plasma samples 
were collected and analysed using LC-MS/MS to obtain concentration-time data. The 
bioavailability data was then modelled, by Dr Paolo Denti (Pharmacometrics, Division of 
Pharmacology, UCT) using population pharmacokinetic (PPK) compartmental analysis. PPK 
allows for the identification and quantification of stochastic between-subject variability in PK 
parameters and deterministic factors that cause changes in a drugs dose-concentration 
relationship and the extent of the variability of those changes in a representative study 
population. This analytical approach uses concentration-time data to estimate the PK 
parameters and explain their variability in the study population using non-linear mixed-
effects (NONMEM) modelling (Guidance for industry: population pharmacokinetics, 1999). 
The PPK analytical approach was thus appropriate for this study as the aim was to improve 
LF bioavailability with the application of Pheroid
™
 formulation technology and assess the 
elimination of the associated food effect and between-subject variability in bioavailability.  
Aim 
To determine if the bioavailability of LF is improved when formulated using Pheroid
™
 
technology or canola oil as compared to LF in reference solution. 
Objectives 
Bioavailability experiments will be performed in mice, to test and compare three different 
formulations of LF namely: reference, canola oil and Pro-Pheroid
™
 formulations. The 
concentration-time data from the experiments will be used to generate PK profiles for each 
formulation to determine any improvement in the bioavailability of LF, when compared to 

















technology improves the bioavailability of LF and eliminates the clinically associated „food 
effect‟ using PPK. 
6.2 Materials and Methods  
Solvents and solutions 
Analytical grade LiChrosolv
®
 water and dimethyl sulfoxide (DMSO) was purchased from 
Merck (Darmstadt, Germany). The retail brand of canola oil used in this project was B-Well, 
produced by Southern Oil Ltd. (South Africa).   
Contents of Mice Food 
The rodent feed was supplied by the Faculty of Health Sciences, Animal Unit (UCT). The list 
of contents of the food is detailed in Figure 6.1, as underlined in red; most of the components 
contain fat. Soya oil (fat) comprises 5% of the total nutritional composition of the rodent 
feed. The amount of food each experimental mouse consumed was not monitored or 
recorded. Food stock per cage, as seen in Figure 6.2, was replenished every 5 days. 
 
 















                      





For this study LF was entrapped in a Pro-Pheroid
™
 formulation, prepared by Dr Lissinda Du 
Plessis (Pheroid
™
 formulation facility, North-West University). Pro-Pheroids
™
 are prepared 
by mixing vitamin F ethyl ester, cremaphor EL and PEG400 (60:30:5) together with 
preservatives and heating it to 70°C. The dl-α- Tocopherol (1%) is added and the mixture is 
gassed for four days with N2O (Steyn et al., 2011). LF was incorporated in the oil phase 
during manufacturing. The LF in Pro-Pheroid
™
 formulation was diluted using a drug free 
Pro-Pheroid
™
 in N2O water solution (diluent) to prepare the 10 mg/kg dose for oral 
administration.  
Experimental mice 
C57/BL6 male mice, 8-10 weeks old, were used for the bioavailability studies. The mice 
were sourced from the Animal Unit, University of Cape Town (UCT) Medical School, Chris 
Barnard building. The mice were housed at the Animal Laboratory Unit, Old main building, 
Groote Schuur hospital,  in open cages with food and water available ad libitum. The mice 
were weighed and randomly grouped (forty mice per experimental group) prior to the 
bioavailability experiment. As shown in Figure 6.3, the forty mice were then divided into two 
groups, fed and starved each consisting of twenty mice. The fed and starved groups were 
further divided into two groups of ten mice each. The bioavailability study was approved by 
the Research Animal Committee of UCT, ethical clearance number: 010/027. All animals 
were treated humanely and the in vivo experiments were planned based on the guidelines for 



































Figure 6.3: Diagram showing experimental design of the bioavailability study. *Each treatment arm of 
the experiment had the same experimental design. 
 
LF dosage formulations 
The reference treatment group received LF dissolved in a DMSO:water (1:9 v/v) solution and 
the canola group received LF dissolved in canola oil. For the reference and canola oil groups, 
LF was weighed and dissolved in each respective solution to a concentration calculated 
according to the average weight of the mice in the treatment group. The 10 mg/kg dosing 
concentrations were calculated as shown in Figure 6.4; for an average mouse mass of 30 g, 
200 µl dose volume per mouse and a total volume of 6ml requires 9 mg of LF to be dissolved 




Figure 6.4:  Calculation for 10 mg/kg LF dosing solutions.  
10 mg/33.3 1000 g / 33.3
0.3 mg/0.2 ml 30 g (ave. mouse mass)
1.5 mg/ml
For 6 ml of dosing solution at 10 mg/kg:
1.5 mg/ml x 6 ml = 9 mg of LF









(Total 40 mice/treatment group) 
1. *Reference 
2. *Canola oil 
3. *Pheroid 
Group A (10 mice): Blood sampling 
at 0.5, 1.5, 5, 10 and 24hrs 
Group B (10 mice): Blood sampling 
at 1, 3, 7, 12hrs 
Group C (10 mice): Blood sampling 
at 0.5, 1.5, 5, 10 and 24hrs 
Group D (10 mice): Blood sampling 

















 treatment group received LF in Pro-Pheroid
™
 formulation prepared by Dr L Du 
Plessis (University of North West, Potchefstroom). As detailed in Table 6.2, the LF in Pro-
Pheroid
™





 and N2O water) to obtain the exact dosage 
concentrations. The dosage concentrations were calculated based on the average weight of 
the mice in the treatment group.  
Table 6.2 Dose calculation for LF in Pheroid
™
 formulation. *Calculated for a mouse of average 
weight 30 g. 
 
Dose administration and blood sample collection 
Mr Trevor Finch (scientific officer) performed the dose administration and blood sample 
collections. The mice were dosed via oral gavage. The 10 mg/kg dose was calculated and 
prepared according to the average weight of each experimental group of mice. All the mice 
received a 10 mg/kg dose of LF dissolved in reference solution, canola oil or Pro-Pheroid
™
. 
For the mice in the starved group, food was removed 12 hours before dose administration and 
returned one hour after. The fed and starved groups were further divided into two subgroups 
for the purpose of alternating blood sample collection (refer to Figure 6.3). Thus reducing 
blood sample collections to a maximum of five per mouse and allowing sufficient recovery 
time. Blood was sampled via tail bleeding at 0.5, 1, 1.5, 3, 5, 7, 10, 12 and 24 hours post 
dosage. Fifty to sixty microliters of blood was collected per sampling time point in 0.8 ml 
Lithium Heparin (LiHep) tubes (MiniCollect, greiner bio-one). WB samples (20 µl) were 
immediately aliquoted into 1.5 ml polypropylene Eppendorf tubes and stored at -80°C. The 
remaining blood in the LiHep tubes was centrifuged at 2300 G for ten minutes to obtain the 
plasma samples. The plasma samples were then aliquoted into 1.5 ml polypropylene 
Eppendorf tubes and stored at -80°C. 
Sample Analysis 
The WB and plasma samples were analysed using the validated LC-MS/MS methods detailed 
in Chapter 5.  
 
Dose *Final Concentration Pheroid
™
 Diluent 5 mg/ml Stock Total volume of
(mg/kg) (mg/ml) volume (µl) spiked volume (µl) dosing solution (µl)
















A nonlinear mixed-effects model (Beal & Sheiner, 1982) has been developed for 
lumefantrine PK. The software NONMEM version 7.2 (Beal et al., 2009) was used for the 
implementation of the model, while Perl Speaks NONMEM (Lindbom et al., 2004), Xpose 
(Jonsson & Karlsson, 1999) and Pirana (Keizer et al., 2010) were employed for model 
diagnostic and to facilitate the modeling process. Model development was guided by the 
NONMEM objective function value (assumed to be χ
2
-distributed), goodness of fit plots and 
visual predictive checks (Holford, 2005). 
First-order and transit compartment absorption and one- and two-compartment disposition 
models were tested. Allometric scaling, based on the mouse weight, was used to adjust 
clearance and volume parameters for the (albeit small) difference in size between mice 
(Anderson and Holford, 2008). Between-subject variability was tested on the PK parameters 
using a log-normal distribution, with the exception of bioavailability for which a logit 
transformation was used, similarly to what was done in Bouzom et al. (Bouzom et al., 2000). 
The effect of fed/starved status and formulation on the PK parameters was investigated, in 

























The developed and validated LC-MS/MS method for the quantitation of LF in mouse WB 
and plasma was used for the analysis of the bioavailability study samples. The accuracy and 
precision of the calibration standards and quality control samples of all the analytical runs 
will be subsequently detailed. The experimental analysis of the fed group was comprised of 
group A and B samples and the starved group was comprised of group C and D samples. 
6.3.1 Quantitation of reference formulated lumefantrine in mouse WB and plasma 
A summary of the calibration STDs and QCs used for the WB test sample analysis is shown 
in Tables 6.3 and 6.4. A summary of the calibration STDs and QCs used for the plasma test 
sample analysis is shown in Tables 6.5 and 6.6. Each analytical run included all the test 
samples from a specific group, namely A, B, C or D. The test samples in groups A and B 
comprised the fed group and the mice in groups C and D comprised the starved group. 
All the analytical runs performed well, the precision and accuracy for the calibration STDs 
and QCs were acceptable and the LF concentrations of the WB and plasma test samples may 
be deemed accurate. 
Animal test samples 
LF in reference formulation was administered to the experimental mice in groups of 10. The 
formulation was evaluated in the fed and starved states. The concentration-time data 
including the average concentration of LF at each sampling time point is detailed in Tables 
6.7 and 6.8 for WB and plasma respectively. The average concentration-time data for LF is 
illustrated in Figures 6.5 and 6.6 for WB and plasma respectively.  




















Calibration STD and QC data for reference formulated LF in mouse whole blood 
 
6.3: Summary of calibration standard concentrations for the analytical runs of reference formulated LF in WB 
Group  
Fed/Starved 










 (125 ng/ml) 
n=8 
S5 












 (4000 µg/ml) 
n=8 
A-Fed 16.5 30.8 61.9 123.0 253.4 473.7 1022.6 2009.4 3993.0 
B-Fed 16.9 29.8 56.3 130.3 257.0 498.1 1001.1 1990.3 4004.8 
C-Starved 16.1 30.0 54.2 133.0 273.2 508.4 972.6 1984.4 4021.6 
D-Starved 16.5 29.3 55.0 135.4 256.2 494.1 999.5 1993.9 4003.6 
Ave 16.5 30.0 56.8 130.4 259.9 493.6 998.9 1994.5 4005.8 
STDEV 0.322 0.651 3.46 5.40 8.97 14.6 20.5 10.7 11.8 
CV (%) 2.0 2.2 6.1 4.1 3.5 2.9 2.1 0.5 0.3 
Accuracy (%) 105.7 95.8 90.9 104.4 104.0 98.7 99.9 99.7 100.1 
  
Table 6.4:  Summary of quality control standard concentrations for the analytical runs of reference formulated LF in WB 
Group 
Fed/Starved 
QC L2 (25 ng/ml) 
n=8 
QC L1 (50 ng/ml) 
n=8 
QC M (1600 ng/ml) 
n=7 
QC H (3200 ng/ml) 
n=7 
SYS (160 ng/ml) 
n=24 
A-Fed 27.1 51.1 1398.1 2730.5 178.0 
B-Fed 25.6 47.4 1377.6 2771.2 165.4 
C-Starved 22.3 45.7 1370.0 2730.0 155.0 
D-Starved 21.8 43.1 1387.8 2770.0 150.3 
Ave 24.2 46.8 1383.4 2750.4 162.2 
STDEV 2.56 3.34 12.2 23.3 12.3 
CV (%) 10.6 7.1 0.9 0.8 7.6 















Calibration STD and QC data for reference formulated LF in mouse plasma 





















n=8 n=8 n=8 n=8 n=8 n=8 n=8 n=8 n=8 
A-Fed 14.6 32.0 64.5 127.7 254.1 489.4 981.0 2032.6 3989.2 
B-Fed 15.3 30.8 60.8 129.5 261.2 491.6 1007.3 1976.9 4012.8 
C-Starved 15.2 32.4 61.2 127.8 252.2 496.6 967.2 2051.0 3980.2 
D-Starved 13.5 33.1 65.6 133.9 250.0 495.8 976.5 2023.8 3994.5 
Ave 14.7 32.0 63.0 129.8 254.4 493.4 983.0 2021.1 3994.2 
STDEV 0.814 0.982 2.38 2.91 4.87 3.41 17.2 31.6 13.8 
CV (%) 5.6 3.1 3.8 2.2 1.9 0.7 1.8 1.6 0.3 
Accuracy (%) 94.0 102.4 100.8 103.8 101.8 98.7 98.3 101.1 99.9 
  
Table 6.6: Summary of the quality control standard concentrations for reference formulated LF in mouse plasma. 
Group QC L2 (25 ng/ml) QC L1 (50 ng/ml) QC M (1600 ng/ml) QC H (3200 ng/ml) SYS (200 ng/ml) 
Fed/Starved n=8 n=8 n=8 n=8 n=24 
A-Fed 28.6 57.5 1738.9 3375.8 222.7 
B-Fed 28.5 56.7 1733.3 3416.4 222.2 
C-Starved 30.0 53.4 1763.1 3521.8 219.9 
D-Starved 28.6 56.9 1687.8 3632.9 219.9 
Ave 28.9 56.2 1730.8 3486.7 221.2 
STDEV 0.720 1.87 31.4 115.2 1.51 
CV (%) 2.5 3.3 1.8 3.3 0.7 















Reference formulated LF in WB: Bioavailability Data 
Table 6.7: Concentrations of reference formulated LF in WB, tested in the fed (Groups A and B) and 
starved (Groups C and D) state.  
 
 
Figure 6.5: Average concentration vs. time graph for reference formulated LF in WB, evaluated in the 
fed (A&B) and starved (C&D) state. 
 
Time Ave STDEV
(hour) A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 (ng/ml)
0.5 45.8 92 142 28 192 234 328 509 199 118 188.8 144.1
1.5 1080 1200 1310 1226 1060 1568 1600 1010 1260 1250 1256.4 197.9
5 1140 1070 1210 1070 623 687 1190 688 965 834 947.7 223.2
10 383 578 610 610 342 332 737 278 474 377 472.1 153.0
24 96.5 91.2 106 178 69.7 83.8 132 64.9 90.4 80.6 99.3 33.5
Time Ave STDEV
(hour) B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 (ng/ml)
1 371 789 301 438 548 71.6 93.3 106 70.1 40.2 282.8 252.7
3 1070 1820 1020 987 1590 149 199 145 143 112 723.5 656.7
7 549 968 644 489 812 90.9 177 166 75.9 68.9 404.1 332.8
12 240 434 314 293 381 53.5 104 166 44 40.9 207.0 146.0
Time Ave STDEV
(hour) C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 (ng/ml)
0.5 104 23.8 24.5 105 0 85.2 139 63.1 311 23.5 87.9 90.4
1.5 476 642 584 991 146 1010 496 514 1090 290 623.9 315.0
5 326 458 278 634 97.9 408 381 373 637 226 381.9 168.0
10 176 247 189 407 55.8 246 252 271 432 175 245.1 110.8
24 62.3 37.2 68.2 126 65.2 79.3 220 69.2 400 71.2 119.9 111.0
Time Ave STDEV
(hour) D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 (ng/ml)
1 88.8 91.3 50 48 545 23.1 39.8 38.6 43 57.9 102.6 156.9
3 302 534 168 575 111 106 149 125 124 127 232.1 179.3
7 206 109 219 130 342 86.4 183 90.7 123 98.6 158.8 80.3
12 83.4 48.8 145 77.9 219 83.7 98.5 35.1 58.4 56.6 90.6 54.6
Mice in Group C (ng/ml)
Mice in Group D (ng/ml)
Mice in Group A (ng/ml)















































Reference formulated LF in plasma: Bioavailability Data 
Table 6.8: Concentrations of reference formulated LF in plasma, tested in the fed (Groups A and B) 





Figure 6.6: Average concentration vs. time graph for reference formulated LF in mouse plasma, 
evaluated in the fed (A&B) and starved (C&D) state. 
Time Ave STDEV
(hour) A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 (ng/ml)
0.5 50.6 112 173 25.4 208 290 375 184 229 135 178.2 105.7
1.5 1200 1230 2470 1266 1130 1550 1500 859 1240 1550 1399.5 431.8
5 1050 1090 939 1130 699 768 1010 767 846 819 911.8 152.3
10 405 498 605 625 287 316 702 327 411 292 446.8 152.2
24 102 96 89.1 168 62.6 65.2 91.2 58.1 59.5 60.5 85.2 33.7
Time Ave STDEV
(hour) B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 (ng/ml)
1 435 1020 330 541 672 59.9 106 93.2 88.1 43.5 338.9 327.9
3 511 828 607 451 879 94.2 167 187 75.8 57.7 385.77 313.4
7 263 438 262 226 351 46.7 98.3 120 41.1 34.3 188.0 141.2
Time Ave STDEV
(hour) C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 (ng/ml)
0.5 28.4 26.6 23 84.7 0 107 147 64.9 255 21.5 75.8 77.8
1.5 414 617 584 985 124 821 367 482 876 297 556.7 274.1
5 299 405 215 492 58.2 406 272 289 428 185 304.9 131.3
12 155 201 143 280 37.5 188 170 222 292 136 182.5 73.9
24 50.2 34.9 52.2 71.7 49.5 61.4 185 48.9 280 58.5 89.2 79.3
Time Ave STDEV
(hour) D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 (ng/ml)
1 82.5 78.9 50 47.4 381 0 39 35.5 39 60.4 81.4 107.8
3 277 239 144 460 118 120 126 105 129 105 182.3 113.9
7 176 95 159 114 303 55.4 158 51 108 79.1 129.9 74.6
10 70.8 43 102 68.2 169 41 81.7 33.7 40.7 45.7 69.6 41.2
Mice in Group D (ng/ml)
Mice in Group A (ng/ml)
Mice in Group B (ng/ml)

















































Based on the concentration-time data for the reference formulated LF, there is no clearly 
visible difference in blood and plasma LF concentrations. There is a marked difference in LF 
concentrations between the fed and starved states, with measured LF concentrations more 
than 2 times higher in the fed state. The highest measured LF concentration occurred at 1.5 hr 
sampling time point irrespective of biological matrix or fed state.  
 
6.3.2 Quantitation of canola oil formulated LF in mouse WB and plasma 
 
A summary of the calibration STDs and QCs used for the WB test sample analysis is shown 
in Tables 6.9 and 6.10. A summary of the calibration STDs and QCs used for the plasma test 
sample analysis is shown in Tables 6.11 and 6.12. Each analytical run included all the test 
samples from a specific group, namely A, B, C and D. All the analytical runs performed well, 
the precision and accuracy for the calibration STDs and QCs were acceptable and the LF 
concentrations of the WB and plasma test samples may be deemed accurate. 
 
Animal test samples 
LF in canola oil was administered to the experimental mice in groups of 10. The formulation 
was evaluated in the fed and starved states. The concentration-time data including the average 
concentration of LF at each sampling time point is detailed in Tables 6.13 and 6.14 for WB 
and plasma respectively. In Table 6.14, there are zero reported values for mouse A10 for time 
points 5, 10 and 24 hours, as not enough plasma was available for analysis. The average 
concentration-time data for LF is illustrated in Figures 6.7 and 6.8 for WB and plasma 
respectively.  















Calibration STD and QC data for canola oil formulated LF in mouse WB 
 
 
Table 6.9: Summary of calibration standard concentrations for the analytical runs of canola oil formulated LF in WB 
Group  
S1 




 (62.5 ng/ml) 
S4 











Fed/Starved n=8 n=8 n=6 n=8 n=8 n=8 n=8 n=8 n=8 
A-Fed 13.8 30.3 65.9 132.7 257.7 511.1 1009.0 1929.2 4036.8 
B-Fed 13.8 29.6 63.9 147.4 255.2 478.1 989.0 2004.9 4003.0 
C-Starved 13.9 33.2 no value 127.6 268.9 485.0 972.2 2028.0 3993.8 
D-Starved 15.1 30.8 66.0 133.2 224.3 508.1 1011.0 1996.9 3999.1 
Ave 14.1 31.0 65.3 135.2 251.5 495.6 995.3 1989.7 4008.2 
STDEV 0.665 1.58 1.15 8.50 19.1 16.5 18.3 42.5 19.5 
CV (%) 4.7 5.1 1.8 6.3 7.6 3.3 1.8 2.1 0.5 
Accuracy (%) 90.7 98.9 104.4 108.2 100.6 99.1 99.5 99.5 100.2 
 
Table 6.10:  Summary of quality control standard concentrations for the analytical runs of canola oil formulated LF in WB 
Group QC L2 (25 ng/ml) QC L1 (50 ng/ml) QC M (1600 ng/ml) QC H (3200 ng/ml) SYS (200 ng/ml) 
Fed/Starved n=8 n=8 n=8 n=8 n=24 
A-Fed 23.6 53.0 1706.8 3253.3 219.4 
B-Fed 28.8 54.6 1839.4 3313.9 220.7 
C-Starved 25.0 55.0 1758.2 3308.6 230.7 
D-Starved 26.2 62.5 1607.6 2836.9 197.4 
Ave 25.9 56.3 1728.0 3178.2 217.1 
STDEV 2.19 4.23 97.1 229.1 14.0 
CV (%) 8.5 7.5 5.6 7.2 6.5 















Calibration STD and QC data for canola oil formulated LF in mouse plasma 
 



















 (4000 ng/ml) 
Fed/Starved n=8 n=8 n=8 n=8 n=8 n=8 n=8 n=8 n=8 
A-Fed 14.8 28.1 67.2 133.2 256.8 507.7 971.8 2000.3 4004.6 
B-Fed 14.7 30.5 68.0 127.1 251.2 484.8 993.2 2021.8 3992.9 
C-Starved 17.7 31.0 62.6 123.5 243.4 483.9 987.3 2073.8 3957.8 
D-Starved 16.2 31.2 63.2 123.7 243.2 491.5 993.6 2045.7 3975.6 
Ave 15.8 30.2 65.3 126.9 248.6 492.0 986.5 2035.4 3982.7 
STDEV 1.43 1.45 2.74 4.56 6.58 11.0 10.2 31.6 20.4 
CV (%) 9.0 4.8 4.2 3.6 2.6 2.2 1.0 1.6 0.5 
Accuracy (%) 101.6 96.5 104.4 101.5 99.5 98.4 98.6 101.8 99.6 
 
Table 6.12:  Summary of quality control standards concentrations for the analytical runs of canola oil formulated LF in plasma 
Group QC L2 (25 ng/ml) QC L1 (50 ng/ml) QC M (1600 ng/ml) QC H (3200 ng/ml) SYS (200 ng/ml) 
Fed/Starved n=8 n=8 n=8 n=8 n=24 
A-Fed 24.0 52.8 1673.7 3283.6 191.5 
B-Fed 27.9 52.8 1608.3 3249.5 197.4 
C-Starved 24.3 49.2 1612.6 3533.0 184.3 
D-Starved 23.9 49.0 1709.3 3555.7 199.6 
Ave 25.0 51.0 1651.0 3405.4 193.2 
STDEV 1.94 2.16 49.0 161.3 6.86 
CV (%) 7.8 4.2 3.0 4.7 3.5 
















Canola oil formulated LF in WB: Bioavailability Data 
Table 6.13: Concentrations of canola oil formulated LF in WB, tested in the fed (Groups A and B) 





Figure 6.7: Average concentration vs. time graphs of canola oil formulated LF in WB, administered to 
groups of mice under fed (A&B) and starved (C&D) conditions. 
Time Ave STDEV
(hour) A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 (ng/ml)
1.5 163 353 189 381 326 137 224 370 387 271 280.1 95.9
5 535 909 627 705 622 356 831 670 622 685 656.2 151.2
10 679 987 509 1120 474 471 682 712 517 NS 683.4 232.0
24 134 254 108 181 162 247 218 191 191 NS 187.3 48.5
Time Ave STDEV
(hour) B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 (ng/ml)
3 735 839 549 525 632 496 830 319 480 953 635.8 198.2
7 728 961 651 1010 631 851 831 1000 725 810 819.8 138.0
12 740 464 557 785 561 789 967 930 541 326 666.0 208.2
48 27.9 17.3 31.1 38.2 33.4 31.8 46 72.7 36.8 42.4 37.8 14.6
Time Ave STDEV
(hour) C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 (ng/ml)
0.5 BLQ BLQ BLQ BLQ BLQ BLQ BLQ BLQ BLQ 21.8 2.18 6.89
1.5 364 68 333 240 68.5 957 341 281 253 624 353.0 264.4
5 788 641 645 329 1330 859 780 832 562 823 758.9 257.6
10 408 402 254 153 707 538 397 540 363 562 432.4 160.7
24 198 135 93.6 51.3 217 195 159 206 74.1 180 150.9 59.5
Time Ave STDEV
(hour) D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 (ng/ml)
1 BLQ 166 79.9 80.8 BLQ 85.4 139 140 96.7 201 98.9 65.5
3 BLQ 967 613 615 422 633 1380 1060 390 1020 710.0 401.0
7 1230 567 397 560 627 825 852 666 236 847 680.7 276.6
12 NS 394 302 377 409 483 425 479 141 436 382.9 105.9
Mice in Group D (ng/ml)
Mice in Group A (ng/ml)
Mice in Group B (ng/ml)
















































Canola oil formulated LF in plasma: Bioavailability Data 
 
Table 6.14: Plasma concentrations of canola oil formulated LF, tested in the fed (Groups A and B) 





Figure 6.8: Average concentration vs. time graphs of canola oil formulated in plasma, administered to 
groups of mice under fed (A&B) and starved (C&D) conditions 
 
Time Ave STDEV
(hour) A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 (ng/ml)
1.5 267 401 314 444 407 235 308 657 560 453 404.6 132.1
5 773 1290 994 1040 966 557 1110 987 975 0 869.2 361.6
10 916 763 671 1510 616 621 912 950 668 0 762.7 377.1
24 184 338 155 252 241 318 286 242 247 0 226.3 96.7
Time Ave STDEV
(hour) B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 (ng/ml)
3 1210 1340 907 836 1110 784 1280 570 756 1440 1023.3 291.5
7 1080 1450 1050 1570 1300 1280 1140 1560 1130 1280 1284 190.5
12 935 563 833 1140 852 1110 1350 1400 753 754 969 273.1
48 49.5 28.4 54.1 54.6 53.9 58.3 76.8 112 77 85.6 65.02 23.3
Time Ave STDEV
(hour) C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 (ng/ml)
0.5 BLQ BLQ BLQ BLQ BLQ BLQ BLQ 20.2 BLQ 34.3 5.45 12.0
1.5 346 94.1 391 291 84.6 889 447 301 287 795 392.6 264.0
5 1260 844 928 384 1480 989 888 1130 832 1050 978.5 291.1
10 584 731 214 237 995 615 442 642 462 653 557.5 232.1
24 201 180 118 60.3 210 226 197 250 92 215 174.9 62.8
Time Ave STDEV
(hour) D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 (ng/ml)
1 BLQ 212 118 74.3 29.2 157 183 152 98 162 118.6 68.1
3 NS 1230 788 814 470 847 1580 1320 484 1240 877.3 477.1
7 344 639 543 615 606 1060 899 893 302 869 677 249.3
12 NS 441 390 456 420 268 467 501 555 181 367.9 169.7
Mice in Group D (ng/ml)
Mice in Group A (ng/ml)
Mice in Group B (ng/ml)















































LF dissolved adequately in canola oil and the evident positive food effect seen with LF in 
reference solution has been resolved by improving the solubility of LF. When formulated 
with canola oil, the measured LF concentrations seem to be higher in plasma than WB. In 
plasma, the measured peak concentrations of LF in the fed and starved state are 1284 ng/ml 
and 978 ng/ml, respectively. The concentrations of LF are still higher in the fed state. Also in 
the fed state the maximum measured LF concentration occurred at the 7 hour time point 
whereas in the starved state the maximum measured LF concentration occurred at the 5 hour 
time point. The presence of food as well as the formulation may have played a role in 
delaying the absorption of LF. 
 
6.3.3 Quantitation of Pheroid
™
 formulated LF in mouse WB and plasma 
 
A summary of the calibration STDs and QCs used for the WB test sample analysis is shown 
in Tables 6.15 and 6.16. A summary of the calibration STDs and QCs used for the plasma test 
sample analysis is shown in Tables 6.17 and 6.18. Each analytical run included all the test 
samples from a specific group, namely A, B, C and D. All the analytical runs performed well, 
the precision and accuracy for the calibration STDs and QCs were acceptable and the LF 
concentrations of the WB and plasma test samples may be deemed accurate. 
Animal test samples 
LF in Pro-Pheroid
™
 formulation was administered to the experimental mice in groups of 10. 
The formulation was evaluated in the fed and starved states. The concentration-time data 
including the average concentration of LF at each sampling time point is detailed in Tables 
6.19 and 6.20 for WB and plasma respectively. The average concentration-time data for LF is 
















Calibration STD and QC data for Pheroid
™
 formulated LF in mouse WB 
Table 6.15: Summary of calibration standard concentrations for the analytical runs of Pheroid
™
 formulated LF in WB 
Group  
S1 

















Fed/Starved n=8 n=8 n=8 n=8 n=8 n=8 n=8 n=8 n=8 
A-Fed 13.5 30.7 69.2 129.6 260.1 528.6 1001.5 1914.9 4040.4 
B-Fed 14.5 32.5 61.5 134.9 241.0 502.2 981.8 2022.4 3993.1 
C-Starved 13.5 27.6 69.1 128.6 261.5 498.1 1056.5 1877.1 4054.2 
D-Starved 15.5 31.8 57.8 126.2 267.6 501.2 983.9 1995.2 4005.2 
Ave 14.2 30.6 64.4 129.8 257.5 507.5 1005.9 1952.4 4023.2 
STDEV 0.963 2.15 5.68 3.66 11.5 14.2 34.9 67.9 28.8 
CV (%) 6.8 7.0 8.8 2.8 4.5 2.8 3.5 3.5 0.7 
Accuracy (%) 91.3 97.9 103.1 103.8 103.0 101.5 100.6 97.6 100.6 
 
Table 6.16:  Summary of quality control standard concentrations for the analytical runs of Pheroid
™
 formulated LF in WB 
Group QC L2 (25 ng/ml) QC L1 (50 ng/ml) QC M (1600 ng/ml) QC H (3200 ng/ml) SYS (200 ng/ml) 
Fed/Starved n=8 n=8 n=8 n=8 n=24 
A-Fed 21.8 53.9 1817.7 3584.9 226.2 
B-Fed 21.8 43.8 1391.9 2758.3  * 
C-Starved 22.6 48.6 1789.3 3673.3  * 
D-Starved 24.3 55.7 1697.4 3562.3 222.1 
Ave 22.6 50.5 1674.1 3394.7 224.2 
STDEV 1.19 5.40 195.0 427.0 2.90 
CV (%) 5.3 10.7 11.6 12.6 1.3 
Accuracy (%) 90.5 101.0 104.6 106.1 112.1 















Calibration STD and QC data for Pheroid
™
 formulated LF in mouse plasma 
Table 6.17: Summary of calibration standard concentrations for the analytical runs of Pheroid
™
 formulated LF in plasma 
Group  
S1 




 (62.5 ng/ml) 
S4 
 (125 ng/ml) 
S5 




 (1000 ng/ml) 
S8 
 (2000 ng/ml) 
S9  
(4000 ng/ml) 
Fed/Starved n=8 n=8 n=8 n=8 n=8 n=8 n=8 n=8 n=8 
A-Fed 16.3 27.0 65.4 123.2 255.0 517.4 1047.6 1893.5 4039.2 
B-Fed 13.4 28.4 67.8 147.5 247.6 505.4 969.8 1996.5 4008.1 
C-Starved 14.5 29.8 67.6 127.7 256.4 512.7 943.3 2040.4 3991.9 
D-Starved 13.5 29.9 70.4 131.1 254.8 501.9 983.6 1992.2 4007.0 
Ave 14.4 28.8 67.8 132.4 253.4 509.4 986.1 1980.6 4011.6 
STDEV 1.38 1.38 2.04 10.6 3.97 7.00 44.3 62.0 19.9 
CV (%) 9.5 4.8 3.0 8.0 1.6 1.4 4.5 3.1 0.5 
Accuracy (%) 92.5 92.0 108.5 105.9 101.4 101.9 98.6 99.0 100.3 
 
Table 6.18:  Summary of quality control standard concentrations for the analytical runs of Pheroid
™
 formulated LF in plasma 
Group QC L2 (25 ng/ml) QC L1 (50 ng/ml) QC M (1600 ng/ml) QC H (3200 ng/ml) SYS (200 ng/ml) 
Fed/Starved n=8 n=8 n=8 n=8 n=27 
A-Fed 25.4 47.8 1589.7 3389.4 190.0 
B-Fed 24.1 48.4 1586.7 3414.6 206.5 
C-Starved 27.1 55.6 1640.2 3375.5 204.8 
D-Starved 25.3 51.6 1687.0 3350.4 191.2 
Ave 25.5 50.9 1625.9 3382.5 198.1 
STDEV 1.23 3.62 47.6 26.8 8.73 
CV (%) 4.8 7.1 2.9 0.8 4.4 

















 formulated LF in WB: Bioavailability Data 
Table 6.19: Concentrations of Pheroid
™
 formulated LF in WB, tested in the fed (Groups A and B) and 




Figure 6.9: Average concentration vs. time graphs of Pheroid
™
 formulated LF in WB, administered to 
groups of mice under fed (A&B) and starved (C&D) conditions 
Time Ave STDEV
(hour) A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 (ng/ml)
0.5 26.7 BLQ BLQ BLQ 52.2 BLQ BLQ BLQ 360 BLQ 43.9 112.4
1.5 137 173 156 167 167 166 367 94.2 1040 122 258.9 284.0
5 984 684 1180 1040 926 1190 954 709 426 928 902.1 236.0
10 1640 741 1550 1370 1070 1420 829 796 0 1270 1187.3 340.1
24 384 232 385 458 398 293 142 573 0 877.0 415.8 213.7
Time Ave STDEV
(hour) B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 (ng/ml)
1 13.9 13.3 43.6 41.6 25.9 26.4 45.1 31.2 57.6 47.5 34.6 14.8
3 296 375 452 301 308 336 503 384 626 443 402.4 105.5
7 911 697 855 822 788 539 670 479 1090 830 768.1 179.3
12 765 538 613 713 811 472 855 700 936 672 707.5 142.4
Time Ave STDEV
(hour) C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 (ng/ml)
0.5 20.7 8 19.4 12 12 15.9 39.9 40 33.3 7.87 20.9 12.5
1.5 263 143 357 218 192 368 257 348 293 128 256.7 86.5
5 1070 857 1460 923 1420 1660 855 767 926 542 1048 353.1
10 1020 687 1290 715 1120 1120 1140 886 1150 909 1003.7 198.8
24 243 102 179 317 416 119 133 406 496 233 264.4 138.6
Time Ave STDEV
(hour) D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 (ng/ml)
1 68.2 30 40 NS 52 69.6 102 43.5 114 56.6 64.0 28.2
3 550 588 293 NS 561 697 912 534 1120 659 657.1 238.2
7 436 486 404 NS 478 672 920 569 737 531 581.4 166.6
12 654 620 453 NS 530 762 768 657 561 481 609.6 113.1
Mice in Group C (ng/ml)
Mice in Group D (ng/ml)
Mice in Group A (ng/ml)

















































 formulated LF in plasma: Bioavailability Data 
Table 6.20: Concentrations of Pheroid
™ 
formulated LF in plasma, tested in the fed (Groups A and B) 




Figure 6.10: Average concentration vs. time graphs of Pheroid
™
 formulated LF in plasma, 
administered to groups of mice under fed (A&B) and starved (C&D) conditions 
Time Ave STDEV
(hour) A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 (ng/ml)
0.5 31.8 BLQ BLQ BLQ 78.5 BLQ BLQ BLQ 444 BLQ 55.4 138.9
1.5 126 182 165 203 172 164 316 193 1310 137 296.8 359.8
5 873 636 872 879 746 1030 798 652 NS 672 715.8 280.3
10 1250 642 1110 1120 955 1260 738 734 NS 911 872 375.7
24 231 182 271 442 350 319 126 432 NS 623 297.6 177.8
Time Ave STDEV
(hour) B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 (ng/ml)
1 16.9 28.9 60.8 123 54.3 52.1 81.8 42.5 96 82.3 63.9 32.2
3 360 453 559 534 421 412 619 520 763 667 530.8 125.9
7 913 839 920 1040 883 546 745 619 1150 887 854.2 180.8
12 627 655 700 835 829 452 857 773 1000 700 742.8 151.1
Time Ave STDEV
(hour) C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 (ng/ml)
0.5 32.6 19.6 43.5 34.1 41.4 57.9 57.8 54.2 57.2 30.4 42.9 13.6
1.5 249 152 307 199 224 355 260 306 250 106 240.8 74.7
5 857 692 1210 771 1240 1400 716 632 732 501 875.1 300.1
10 726 551 1060 562 857 893 892 673 840 703 775.7 161.0
24 212 97 132 220 307 123 107 282 392 216 208.8 97.1
Time Ave STDEV
(hour) D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 (ng/ml)
1 124 50.4 57.6 386 100 118 170 81.1 189 112 138.8 97.3
3 683 800 390 NS 664 852 1210 774 1680 909 796.2 447.0
7 586 689 565 NS 661 851 1170 738 1020 780 706 312.1
12 404 733 565 NS 532 845 922 688 680 676 604.5 259.4
Mice in Group D (ng/ml)
Mice in Group A (ng/ml)
Mice in Group B (ng/ml)















































The shape of the concentration-time profile for LF in Pheroid
™ 
formulation differs from the 
profiles for LF in reference solution or canola oil. The difference in LF concentration-time 
profile between the fed and starved state seems negligible. The highest measured WB LF 
concentrations in the fed and starved state were 1187.3 ng/ml and 1048 ng/ml respectively. 
The highest measured plasma LF concentrations in the fed and starved states were 872 ng/ml 
and 875 ng/ml respectively. Similar to LF in canola oil, the highest measured LF 
concentration occurred later in the fed state than the starved state. The presence of food in the 
GI tract at the time of dose administration may delay LF absorption. As seen with the canola 
oil formulation, the Pheroid
™
 formulation may also contribute to delaying the absorption of 
LF in the GI tract. 
 
The pooled concentration-time data for LF in WB and plasma, in the fed and starved state are 
graphically presented in Figure 6.11. For LF in the reference solution, in plasma, the 
concentration-time profile seems to be more erratic in the starved state compared to the fed 
state. For LF in the Pheroid
™
 formulation the measured level of LF peaks at 5 hours, then 
drops at the 7 hour time point before peaking again at the 10hr time point. This occurred for 
Pheroid
™
 formulated LF in the WB profile only. LF concentration levels at the 24 hour time 
point was higher for LF in the Pheroid
™































Figure 6.11: Graphs of pooled average concentration vs. time for LF in the three different formulations, a. and b. represents the WB data in starved 
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6.3.4 Population Pharmacokinetics (PPK) 
 
A PPK model was constructed using the collective concentration-time data for all the 
formulations for each biological matrix; 1113 observations from 123 concentration-time 
profiles were included.  
Lumefantrine PK is best described by a 1-compartment model, with first-order elimination 
and transit compartment absorption (Savic et al., 2007). A structural representation of the 
PPK model for LF is shown in Figure 6.12. The final model parameter estimates are reported 
in Table 6.21, and a VPC is displayed in Figure 6.13.  
 
 




The final PPK model for LF was evaluated using a visual predictive check (VPC). VPC was 
performed to assess the ability of the final model to correctly describe the variability in the 
data. In the VPC graphs in Figure 6.13, the shaded areas are what the model predicts the 5th, 
50th and 95th percentile to be (based on a 1000 simulations), while the solid and dashed lines 
represent the same percentiles that are observed in this experiment. There is good agreement 
between the experimental data and model prediction as the percentiles of the observations are 
consistent with the respective predicted regions. The final model is robust and adequately 

















Figure 6.13: Visual predictive check diagrams for the LF PPK model in plasma and WB. The open 





 percentiles of the observed data, respectively. The middle solid line 
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Diagnostic plots used to assess the model also included goodness-of-fit plots including 




Figure 6.14: Goodness of fit plots of LF for the final model. The upper left and right panels show 
population and individual predicted concentration versus observed concentration. The solid lines are 
lines of identity. The lower panels are the conditional weighted residual plots for the final model. 
 
For Figures 6.15 to 6.20, where the open circles represent the observed concentrations, the 
dotted and solid lines represent the population and individual prediction-time profiles, 
respectively. The population prediction is the behaviour of the typical subject, i.e. the model 
prediction obtained considering the deterministic dose and covariate effects, but not the 
random individual effects specific to that particular subject. From the charts it can be seen 
that the individual predictions fit the data well, while the discrepancy between population and 
individual predictions shows the large extent of between-subjects variability not explainable 




















Lumefantrine in WB  
 
 
Figure 6.15: Observed and predicted WB LF concentration vs. time profiles for 8 randomly selected 
experimental mice administered LF in reference solution. 
 
       
Figure 6.16: Observed and predicted WB LF concentration vs. time profiles for 8 randomly selected 

















Figure 6.17: Observed and predicted WB LF concentration vs. time profiles for 8 randomly selected 
experimental mice administered LF in Pheroid™ formulation. 
 
 
Lumefantrine in plasma 
 
 
Figure 6.18: Observed and predicted plasma LF concentration vs. time profiles for 8 randomly 






















Figure 6.19: Observed and predicted plasma LF concentration vs. time profiles for 8 randomly 




Figure 6.20: Observed and predicted plasma LF concentration vs. time profiles for 8 randomly 




The plasma and WB data were modelled jointly by introducing a scaling factor, refer to table 
6.21. The model based WB/plasma scaling factor or ratio was 0.913 (which is close to 1) and 
a calculated between-subject variability of 16.7%, which indicates that there is no clinically 















data for LF, the estimation of the absolute bioavailability of LF was not possible. As a result 
of the logit transformation, used for bioavailability, NONMEM proposes the most likely 
bioavailability value for each combination of formulation and fed/starved state, but those 
values are an approximation. Only the ratios between the estimated bioavailability values are 
reliable and can be used for comparison. The final PPK parameter estimates are detailed in 
Table 6.21. A simulation using the final PPK model was used to estimate the NCA-equivalent 
parameters, shown in Table 6.22. 
 
Table 6.21: The final parameter estimates for the LF pharmacokinetic model. CL and V are reported 
for a 27g mouse and allometrically scaled according to Anderson and Holford, 2008. 
  
 
Abbreviations: RSE; residual standard error, BSV; between-subject variability, CL; Clearance, V; volume of 
central compartment, MTT; mean transit time (for absorption) and NN; number of transit compartments. 
 
Table 6.22: Simulation based NCA-equivalent PK parameter estimates for LF in the three different 




The presence of food increased the absorption mean transit time (MTT), calculated for all 
formulations, by 17.3%. LF in Pheroid
™
 formulation had the highest MTT of 3.51 hours, 
which was 75% longer than the MTT for LF in reference solution. The typical value for LF 
bioavailability was 3.2 times higher when formulated with the Pheroid
™
 (or canola oil) as 
compared to LF in the reference solution in the starved state. The bioavailability of LF in 
reference formulation heavily depended on food intake resulting in a 2.7 times higher 
Parameter Formulation (Fed/Starved) Typical value (RSE[%]) %BSV  (RSE[%])
CL (mL/h) 15.5 (20.1) 26.4 (10.3)
V (mL) 138 (19.5) 28.5 (12.3)
MTT (h) Reference 0.881 (5.2)
Canola oil 2.06 (3.7) 21.4 (8.9)
Pheroid™ 3.51 (6.6)
Effect of food on MTT (h) 17.3% (32.7)
NN Reference & Canola oil 6.33 (5.1)
Pheroid™ 1.74 (4.8)
Bioavailability Reference (Starved) 0.219 (24.2) 44
Reference (Fed) 0.584 (22.8) 21
Pheroid™ or Canola oil 0.705 (19.9) 15
Scaling WB/Plasma 0.913 (2.4) 16.7 (19.1)
Additive residual error (mg/L) 16.8 (6.6)
Proportional residual error (%) 19.7 (2.7)
LF Formulation:
Starved/Fed Starved Fed Starved Fed Starved Fed
Cmax (ng/mL) 382 (163-846) 994 (532-1680) 1118 (652-1798) 1088 (635-1742) 916 (545-1422) 866 (528-1331)
Tmax (h) 1.7 (1.2-3.1) 2.0 (1.4-3.4) 3.7 (2.7-5.2) 4.2 (3.1-6.0) 6.2 (4.6-8.5) 7.2 (5.4-9.6)
AUCinf (ng.h/mL) 5066 (2219-11106) 13229 (7248-22782) 16151 (9177-26427) 15975 (9160-26065) 16050 (9451-26758) 16013 (9457-25992)
T1/2 (h) 8.3 (4.3-15.7) 8.2 (4.4-15.2) 8.2 (4.4-15.8) 8.3 (4.3-15.7) 8.3 (4.5-15.8) 8.2 (4.4-15.4)
Bioavailability 0.22 (0.1-0.4) 0.57 (0.36-0.76) 0.69 (0.48-0.84) 0.69 (0.47-0.84) 0.69 (0.48-0.85) 0.69 (0.48-0.84)
















bioavailability in the fed state. The between-subject variability in bioavailability was less for 
the Pheroid
™
 formulation making the achievement of similar exposure in different subjects 
more feasible as compared to LF in reference solution, especially in the starved state.  
 
Non compartmental analysis (NCA) was not performed during this study and the NCA PK 
parameter estimates, detailed in Table 6.22, were generated using model simulation. For the 
purpose of this study the pharmacokinetic parameters AUC, Cmax and Tmax can be used to 
qualitatively compare the different formulations of LF. AUC is defined as the area under the 
plasma/WB concentration-time curve; it is directly proportional to the amount of drug that is 
in systemic circulation and thus proportional to bioavailability and inversely proportional to 
CL. Cmax is the highest systemic drug concentration predicted by the model and may serve as 
an indication of the rate and extent of drug absorption. Tmax is the time at which Cmax occurs 










































 formulation to improve the solubility and bioavailability of LF, 
eliminates the food effect associated with LF as well as significantly reducing the between 
subject variability in bioavailability. A similar effect can be obtained after the oral 
administration of LF in canola oil. The bioavailability of LF, calculated using the PPK model 
was 3.2 higher when formulated using the Pheroid
™
 technology as compared to LF in the 
reference solution (fasting state). Food may continue to affect the bioavailability of LF even 
when formulated using Pheroid
™
 technology, however the effect detected using the PPK 
model, was not significant. Food was found to slow down absorption, possibly as result of 
slower gastric emptying. For LF in Pheroid
™
 formulation, the between subject variability 
(BSV) for bioavailability was ~15% compared to ~44% for LF in reference solution, under 
fasting conditions. The BSV for LF in reference solution in the fed state is approximately half 
of the BSV in the fasted state.  
It has been clinically established that LF exposure (normally quantified using AUC) is 
associated with its antimalarial efficacy and that the function of LF when co-administered 
with artemether is to remove residual parasites and prevent recrudescence (Ezzet et al., 
1998). A higher LF AUC was also found to significantly increase the antimalarial treatment 
efficacy or cure rate of AL (Ezzet et al., 1998). The AUC of LF when administered in 
Pheroid
™
 formulation (16 013 ng.h/ml) was higher than LF in reference solution (13 229 
ng.h/ml) in the fed state. Based on the model predictions, there was no significant difference 
in bioavailability between LF in Pheroid
™
 formulation and LF in canola oil. Using the 
Pheroid
™
 formulation did improve the solubility, absorption and bioavailability of LF 
following oral administration. This may indicate that Pheroid
™
 formulation technology can 
be applied as a versatile drug delivery system for lipophilic drugs.  
The Pheroid
™
 delivery system has been used in other studies to improve drug 
pharmacokinetics. A study done by Steyn et al., performed in a mouse model, involved 
evaluating the potential application of Pheroid
™
 technology in enhancing the absorption of 
novel artemisinin derivatives. Steyn et al. reported a 4.57 fold increase in AUC of Pheroid
™
 
formulated artemisone, when orally administered compared to the reference formulation 
(Steyn et al., 2011). In a study done by du Plessis et al., Pheroid
™
 technology used as a drug 
delivery system, significantly improved the nasal and intestinal absorption of calcitonin, a 















Despite the enhancement of LF bioavailability when formulated with Pheroid
™
 formulation, 
the Cmax values are comparable to LF in reference solution in the fed state, with LF in canola 
oil reaching slightly higher concentrations. The LF in Pheroid
™
 formulation used for this 
study was a preliminary formulation and optimization of drug inclusion into the Pheroid
™
 
vesicles was not performed. Other studies using an optimized drug in Pheroid
™
 formulation 
reported enhanced Cmax as well as higher AUC values (Steyn et al., 2011, du Plessis et al., 
2010).  
When formulated with the Pheroid
™
, LF had a much longer MTT and took longer to reach 
Cmax than the other formulations. The increase in MTT indicates a delay in absorption rate, 
due to the composition of the Pheroid
™
 formulation it may form a protective lipid barrier 
around the drug and this could have delayed the release and metabolism of the entrapped LF 
(Chigutsa et al., 2011, Velcov et al., 2005, Steyn et al., 2011). The increase in Tmax of a 
Pheroid
™
 formulated drug has been previously reported in a study done by Steyn et al. 
Artemisone in the Pheroid
™
 vesicle formulation took longer to reach its Cmax in comparison 
to artemisone in the reference formulation (Steyn et al., 2011).  
The other preclinical studies investigating the pharmacokinetics of LF were performed in a 
rat model and using NCA analysis, reported LF to have variable oral absorption, low 
clearance, a large volume of distribution and long elimination half-life which concurs with 
clinical findings (Wahajuddin et al., 2011). The sensitive LC-MS/MS quantification method 
developed in this study allowed for the PK investigation of LF in a mouse model, sampling 
significantly lower blood volumes than previous preclinical studies. PPK can be performed 
using sparse sampling data therefore the combined use of LC-MS/MS and PPK may reduce 
the number of experimental animals sacrificed for the pharmacokinetic investigation of drugs 
with long elimination half lives, saving time and cost.  
This study was intended as a „proof of concept‟ study for the determination of enhanced LF 
bioavailability, LF was only evaluated over a 24 hour time period which is not sufficient to 
conclusively describe the elimination phase of LF and effectively measure clearance, volume 
of distribution and elimination half-life. It is thus difficult to compare this study to previous 
studies however it can be concluded that the application of Pheroid
™
 formulation technology 
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The pre-clinical evaluation of test compounds culminates in determining the efficacy of the 
drug in treating an active infection in a suitable animal model. Aotus and Saimiri monkeys 
may be infected with P. falciparum and may be the best animal model for predicting 
antimalarial efficacy in humans however it‟s not a cost effective animal model and the mouse 
malaria model is more suited for preliminary studies. As human malaria parasites are unable 
to infect non-primate animals, antimalarial efficacy is routinely evaluated using a mouse 
malaria model. Rodent malaria parasites serve as good experimental models, in vivo, for the 
study of human malaria. Plasmodium vinckei, Plasmodium chabaudi, Plasmodium yoelli and 
Plasmodium berghei are the four malaria parasites that infect rodents and are used for the 
investigative study of the developmental biology of the malaria parasite, drug resistance, 
parasite–host interactions and drug efficacy (Fidock et al., 2004, Pink et al., 2005). Rodent 
malaria parasites exhibit analogous structure, physiology and life cycle when compared to 
human malaria parasites and are therefore reliable models for predicting treatment efficacy. 
The rodent parasites also have comparable genetics to human parasites, thus a viable model 
for genetic modification studies. In previous pre-clinical studies, rodent malaria models have 
been used to demonstrate the antimalarial efficacy of mefloquine, halofantrine and the 
artemisinin derivatives (Peters et al., 1977, Peters et al., 1987, Posner et al., 2003 and Fidock 
et al., 2004). There are, however differences between human and rodent plasmodia and 
careful assessments need to be considered when making predictions of human treatment 
outcomes based on efficacy studies in mice.  
 
The rodent plasmodia differ in virulence, pathology, synchronicity and some may be more 
sensitive to specific antimalarials. P. chaubadi and P. vinckei generate high parasitemia‟s and 
produce synchronous infections; all the parasites exist at the same stage of intracellular 
development. The P. yeolli 17X strain is intrinsically partially resistant to CQ and P. 
chaubadi and P. vinckei are sensitive to ion chelators and lipid biosynthesis inhibitors (Carter 
and Diggs 1977, Fidock et al., 2004). P. berghei produces rapidly fulminating, asynchronous 















berghei is primarily used in drug screening assays (Carter and Diggs, 1977, Kalra et al., 
2006) 
There are few publications detailing pre-clinical efficacy studies on LF, Kiboi et al. used the 
P. berghei ANKA strain to select for resistance to LF and Piperaquine (PQ) by continuous 
drug pressure in vivo. The effective dose of drug which reduces parasitemia by 50% (ED50) 
and 90% (ED90) for LF and PQ were measured in a quantitative standard 4-day suppressive 
test, in which the parasites are exposed to four, daily, drug doses. The reported ED90 for LF 
using the parent P. berghei strain was 3.93 mg/kg, however when using the resistant strain 
the ED90 increased more than 50 times (Kiboi et al., 2009). The drug resistant parasite strains 
may be used in future to study and understand the mechanisms of LF and PQ resistance, 
provided the mechanism of resistance in P. berghei is similar to P. falciparum. For the 
purpose of this study, the P. berghei ANKA strain was chosen for infection of the 
experimental mice. It is a CQ sensitive parasite strain and ideal for a preliminary antimalarial 
efficacy study. A modified Peters‟ 4-day suppressive test was performed to compare the 
efficacy of the test formulations, administered in four daily doses, to the standard drug CQ in 




This efficacy study was performed to test the hypothesis that an improved oral bioavailability 
of LF when formulated using Pheroid
™
 technology, would result in improved antimalarial 
efficacy. The specific aim was to determine if LF in Pheroid
™
 formulation, administered 
orally, was more effective than LF in reference formulation, in increasing the survival time of 




Perform Peters‟ 4-day test to compare the efficacy (suppression of parasitemia) of LF in the 
reference and Pheroid
™
 formulations to the standard drug CQ. 
Test each formulation at three different concentrations to estimate an effective dose range. 
Compare the survival times and chemosuppression of the treatment groups for each 
formulation, at each dose concentration to CQ. 
Determine, using survival analysis, which of the formulations is more effective or 















7.2 Materials and Methods 
Solvents and chemicals 
Analytical grade LiChrosolv
®
 water and methanol was purchased from Merck (Darmstadt, 
Germany). Dimethyl sulfoxide (DMSO) was purchased from Merck (Darmstadt, Germany). 
Chloroquine diphosphate (CQ) was purchased from Sigma.  
 
LF dose formulations 
 
The reference treatment group received LF dissolved in a DMSO:water (1:9 v/v) solution. 
The 10, 5 and 1 mg/kg dosing concentrations were calculated as shown in Chapter 6, Figure 
6.4 (refer to page 104), for an average mouse mass of 25 g and 200 µl dose volume per 
mouse per day (for four day treatment: 800 µl/mouse). As shown in Table 7.1, LF was 
weighed out and dissolved in solution to obtain a final concentration calculated according to 
the average weight of the mice in the treatment group.  
Table 7.1: Dose calculation for LF in reference formulation. *Calculated for an average mouse weight 




The positive control group received CQ dissolved in water at a dose concentration of 10 
mg/kg. The negative control group was administered the diluent or solution that the 
compound is dissolved in. For the reference formulation the negative control group received 
DMSO:water (1:9 v/v) solution, and for the Pheroid
™
 formulation they received a Pro-
Pheroid
™ solution, containing no active drug. 
The Pheroid
™
 treatment group received LF in Pro-Pheroid
™
 formulation prepared by Dr L Du 
Plessis (University of North West, Potchefstroom). As detailed in Table 7.2, the Pro-
Pheroid
™
 formulated LF was prepared at a 5 mg/ml stock solution and was diluted using a 
drug free pro-pheroid solution to obtain exact dosage concentrations based on the average 
weight of the mice in the treatment group.  
Dose *Final concentration Mass of LF Total volume of
(mg/kg) (mg/ml) (mg) dosing solution (ml)
10 1.25 7.5 6
5 0.625 3.75 6















Table 7.2: Dose calculation for LF in Pheroid
™




P. berghei rodent malaria 4-day suppressive test 
The experimental animals used for this study, 8-10 week old, male C57/BL6 mice, were 
obtained from the University of Cape Town‟s Medical School, Animal Unit. The mice were 
housed at the Animal Laboratory Unit, Groote Schuur Hospital, OMB (K floor) and kept in 
ventilated cages with food and water available ad libitum. All animals were treated humanely 
and the in vivo experiments were planned based on the guidelines for the ethical use of 
animals in research (Austin et al., 2004). 
To evaluate the blood schizontocidal activity of the formulations, the modified Peters‟ 4-day 
suppressive test was performed in mice infected with P. berghei, ANKA strain (CQ sensitive) 
parasites as per protocol, approved by UCT Animal Ethics Committee, ethics clearance no. 
010/027 (Peters, 1975). The weight of the mice was used as an indication of health and 
monitored continuously throughout the experimental period. As per protocol, the mice were 
euthanized if a 20% loss in initial body weight was observed. Chloroquine (CQ) was used as 
the standard drug and the positive control group was dosed at 10 mg/kg (non-curative dose) 
via oral gavage. To generate statistically reliable results each treatment and control group 
consisted of 5 mice.  
The experiment was performed on two separate occasions as it would have been difficult to 
efficiently dose the required amount of test mice. The first test compared the reference 
formulation to CQ and the second compared the Pheroid
™ 
formulation to CQ. The procedure 




Dose *Final concentration Pheroid™ Diluent 5µg/ml stock Total volume of
(mg/kg) (mg/ml) volume (µl) spiked volume (µl) dosing solution (ml)
10 1.25 4500 1500 6
5 0.625 5250 750 6



























Figure 7.1: Schematic detailing the experimental procedure for the in vivo 4-day suppressive test. 
 
Test Procedure 
This efficacy study required „donor‟ mice, to maintain parasitemia passage as the 
experimental mice had to be inoculated with parasitized red blood cells. The P. berghei 
parasite stock was stored in liquid nitrogen, thawed and used to infect the donor mouse. Once 
the donor mouse had developed the P. berghei infection, at approximately 30% parasitemia, 
blood samples were collected and the parasitized RBCs were diluted using sterile phosphate 
buffered saline (PBS). A 0.2 ml aliquot of this solution, containing 1 x 10
6
 parasitized 
erythrocytes, was used to inoculate the experimental mice via intraperitoneal (IP) injection. 
The first treatment dose was administered 2 hours after inoculation. The test formulations 
were administered, by oral gavage, to the P. berghei infected mice as described by Peters et 
al., and were evaluated according to the reduction in parasitemia and survival time of the 
experimental mice compared to the positive control group (Peters, 1975, Tona et al., 2001). 
Each formulation was tested at three different concentrations; 10, 5, and 1 mg/kg, to obtain a 
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was administered daily for 4 consecutive days after the mice were infected. Similarly, the 
positive control group received CQ and the negative control groups the diluent or DMSO 
solution.  
The level of parasitemia was determined, for all experimental mice, at specified time points. 
For the LF in reference formulation experiment, parasitemia was determined on days 1, 3, 8, 
11 and 15. For the LF in Pheroid
™
 formulation experiment, parasitemia was determined on 
days 2, 4, 8, 12, 16 and 23. 
For the determination of parasitemia: The tail is nicked and a small drop of blood is smeared 
on a glass slide, the smear is fixed onto the slide using 100% methanol and rinsed off using 
tap water. The slide is then stained using a Giemsa stain solution prepared using distilled 
water (1:9, v/v), the stained blood slide is then rinsed and dried. As depicted in Figure 7.2, the 
stained slide is viewed using a light microscope, under oil immersion with a 100 x 1.4 
objective. The parasitemia was determined by counting four fields of approximately 100 
RBCs per field, making note of the total number of infected and uninfected RBCs (Fidock et 
al., 2004). The parasitemia is calculated using the following formula: 
Parasitemia = No. of Infected RBC / Total RBC 
Where total RBC is equal to the number of infected + uninfected RBCs. 
 
Figure 7.2:  Images depicting the morphology of P. berghei using light microscopy, the different 
stages of parasite development shown here are: a. ring-form, b. trophozoite and c. shizont. 
For this experiment, the parasitemia values were calculated without distinguishing between 
the different stages of parasite development. 
Survival Analysis 
Survival analysis was performed on the data using Stata
®
 11.0 statistical software package. 
Cox proportional hazards regression model was used for the analysis and Kaplan-Meier 

















7.3.1 LF in reference formulation 
Throughout the duration of the Peters‟ 4-day suppressive test, the level of parasitemia was 
determined for all treatment and control groups. Each group consisted of 5 mice and the 
average parasitemia values are presented in Table 7.3. For LF in reference formulation the 
treatment groups survived as long as the CQ group and almost twice as long as the negative 
control group. As shown in Figure 7.3, all the mice in the 1 mg/kg succumbed to infection by 
day 11 while the 5 and 10 mg/kg groups faired comparably to the CQ group, surviving to day 
15. The mice in the negative control group survived for an average of eight days after 
infection. 
Table 7.3:  Average parasitemia (%) values for the LF in reference formulation group at each 




D1 D3 D8 D11 D15
10 mg/kg Average 1 1 1 4.2 29
STDEV 0 0 0 4.44 0
5 mg/kg Average 1 1 1 1 37.5
STDEV 0 0 0 0 17.7
1 mg/kg Average 1 1 27 45
STDEV 0 0 3.08 11.2
CQ Average 1 1 1 3 25
positive control STDEV 0 0 0 0 0
DMSO Average 1 30.7 50


















Figure 7.3: Average % parasitemia vs. time graph for the LF in Reference formulation treatment 
groups at concentrations of 10, 5 and 1 mg/kg  as well as the control groups; CQ (positive control) 
and DMSO (negative control). The error bars represent the standard deviation in the data. 
The percentage chemosuppression was calculated using the following formula:  [(A-B)/A] x 
100, where A is the average parasitemia for the negative control group and B is the average 
parasitemia for the test group. Chemosuppression is usually determined using the parasitemia 
values calculated on day 5 but due to the low parasitemia values observed, it was decided to 
determine activity on day 8 for the reference group and day 12 for the Pheroid
™
 group. The 
infection rate was slower when testing the Pheroid
™
 group compared to the reference group 
therefore activity was calculated on different days. 
The level of chemosuppression was determined for all treatment dose concentrations for the 
reference group on day 8 after infection and the results are detailed in Table 7.4. The 5 and 10 
mg/kg group had a 98% chemosuppression on day 8 after infection, comparable to CQ, but 
the CQ group had lower parasitemia values throughout the experiment.  However as seen in 
Figure 7.4, a higher proportion of mice in the 5 and 10 mg/kg group survived to day 15 than 














































Table 7.4:  In vivo antimalarial activity (chemosuppression) of LF in reference formulation on day 8 




Figure 7.4: Kaplan-Meier survival estimate: Proportion surviving (S) vs. Time (days) plot for the LF 
in reference formulation treatment groups at 10, 5 and 1 mg/kg as well as the control groups. The 
survival plot for 10 mg/kg dose is identical to the 5 mg/kg plot. CQ; chloroquine, DMSO; 10% 
DMSO in water solution 
A Cox regression was performed to establish if LF in reference formulation at the 10 mg/kg 
treatment dose was able to prolong the survival of the infected mice when compared to the 
CQ treated group. The statistical term hazard ratio in survival analysis relates the rate that an 
event (e.g. death from malaria infection) may occur in one group compared to the rate that the 
same event occurs in the other group. A hazard ratio of 1 means there is no difference 
between the two groups. Results from the regression yielded a hazard ratio of 0.826 (95% 
confidence interval [CI] 0.31, 2.21; p= 0.704), which indicated no significant difference 
Treatment Dose Ave. %Parasitemia Chemosuppression
(mg/kg) (S.D) (%)
LF in Ref formulation 10 1 98
5 1 98
1 27 (3.08) 46
CQ (positvie control) 10 1 98





































between the survival efficacy of the LF in reference formulation, at the highest tested dose, 
and CQ in treating the infected mice. 
7.3.2 LF in Pheroid
™
 formulation 
A similar result to the reference formulation was seen in the experiment comparing the LF in 
Pheroid
™
 formulation to CQ treatment. The infected mice in this experiment survived for a 
longer period of time than in the reference experiment. The parasitemia values for the LF in 
Pheroid
™
 treatment and control groups are detailed in Table 7.5 and graphically shown in 
Figure 7.5. As expected the 10 mg/kg treatment group performed better than the 5 and 1 
mg/kg groups in suppressing the level of parasitemia. 
Table 7.5:  Average % parasitemia values for the LF in Pheroid
™
 formulation group at each treatment 
dose including the controls 
 
 
D2 D4 D8 D12 D16 D23
10 mg/kg Average 1 1 1 2 24.4 50
STDEV 0 0 0 0 6.95 0
5 mg/kg Average 1 1 12.3 29.5 50
STDEV 0 0 6.34 0.707 0
1 mg/kg Average 1 1 31.2 43.3 50
STDEV 0 0 4.92 5.77 0
CQ Average 1 1 1 5.32 36.7 50
positive control STDEV 0 0 0 6.36 15.3 0
DMSO Average 1 2.8 20.6 50


















Figure 7.5: Average % parasitemia vs. time graph for the LF in Pheroid
™
 formulation treatment 
groups at concentrations of 10, 5 and 1 mg/kg  as well as the control groups; CQ (positive control) 
and DMSO (negative control). 
As seen in Figure 7.5, for LF, the higher the dose the better the suppression of parasitemia. 
The 10 mg/kg and CQ treated groups survived till day 23 (Figure 7.6), however as 
demonstrated in Figure 7.5 it may be deduced that the 10 mg/kg treatment was more effective 
than CQ in suppressing the parasitemia. The activity (chemosuppression) of the treatment 
groups and CQ was calculated on day 12 of the experiment and the results are presented in 
Table 7.6. LF in Pheroid
™
 formulation at 10 mg/kg demonstrated a chemosuppression of 
96% which was higher than CQ‟s 89.4% chemosuppression. Figure 7.6 demonstrates the 
proportion of surviving mice, for each treatment and control group, for the duration of the 
experiment.   
Table 7.6:  In vivo antimalarial activity (chemosuppression) of LF in Pheroid
™






























Treatment Dose Ave. %Parasitemia Chemosuppression
(mg/kg) (S.D) (%)
LF in Pheroid™ formulation 10 2 96
5 29.5 (0.71) 41
1 43.3 (5.8) 13.4
CQ (positvie control) 10 5.32 (6.4) 89.4
















Figure 7.6:  Kaplan-Meier survival estimate: Proportion surviving (S) vs. Time (days) plot for the LF 
in Pheroid
™
 formulation treatment groups at 10, 5 and 1 mg/kg as well as the control groups. The 
survival plot for the 10 mg/kg group and CQ are indiscernible after day 15. CQ; chloroquine, DMSO; 
10% DMSO in water solution 
One of the mice in the 10 mg/kg treatment group died on day 4 for unexplained reasons. 
Toxicity has been ruled out as an explanation as previous bioavailability experiments have 
been performed in mice which were administered higher doses of LF (results not shown). 
One mouse in the 1 mg/kg group survived till day 21 despite high parasitemia and performed 
much better than the mice in the 5 mg/kg group which only survived till day 16. The mice in 
the 10 mg/kg group survived just as long as the CQ group. 
A Cox regression was performed to establish if LF in Pheroid
™
 formulation at the 10 mg/kg 
treatment dose was able to significantly prolong the survival of the infected mice when 
compared to the CQ treated group. Results from the regression yielded a hazard ratio of 0.935 
(95% confidence interval [CI] 0.27, 3.23; p= 0. 916), and a p value of 0.916 indicating that 
there was no significant difference between the survival efficacy of the LF in Pheroid
™
 








































The results from the modified Peters‟ 4-day suppressive test indicate that LF in the reference 
and Pheroid
™
 formulations, at 10 mg/kg, perform comparably to CQ in reducing parasitemia. 
This experiment was preliminary and higher dosing concentrations will have to be tested to 
determine an effective dose of LF in Pheroid
™
 formulation. The treatment doses used in this 
study were conservative as primary in vivo experiments are usually performed at dosing 
concentration of 50 or 100 mg/kg (Fidock et al., 2004, Kalra et al., 2006). As mentioned 
earlier Kiboi et al. reported an EC90 of 3.93 mg/kg for LF also using P. berghei ANKA strain 
however the mice were not cured in this experiment, even with a treatment dose of 10 mg/kg 
(Kiboi et al., 2009). 
The LF in reference formulation at 5 and 10 mg/kg performed similarly with respect to 
chemosuppression and duration of survival. This may be due to the variable bioavailability 
observed with the reference formulation as one would expect the higher concentration dose to 
perform more effectively. However this deduction is merely speculative as blood samples for 
analysis were not collected and the plasma concentration of LF was not determined when the 
level of parasitemia was determined. Throughout the experiment CQ performed better at 
suppressing the parasitemia than the LF in reference formulation at all the dose 
concentrations.  
The LF in Pheroid
™
 formulation treatment group showed good suppression of parasitemia 
and duration of survival, at the 10 mg/kg dose. Also the LF in Pheroid
™
 formulation at the 10 
mg/kg dose demonstrated a higher reduction in parasitemia on day 12 than CQ. However 
none of the treatment formulations, at the tested concentrations, were able to cure the 
infection.  Results from the Cox regression indicate that both the LF in reference formulation 
and LF in Pheroid
™
 formulation treatment groups were unsuccessful in significantly 
prolonging the survival of the infected mice when compared to the positive control, CQ. 
Further efficacy studies, should be done to determine the lowest effective dose and determine 
conclusively if the LF in Pheroid
™
 formulation would be more efficacious than the reference 
solution. Also if blood samples were collected for the determination of drug plasma levels as 
well as for the determination of parasitemia then one would be able to relate LF 
bioavailability to its efficacy or pharmacodymnamic effect, more accurately. 
As reported by Ezzet et al., the effect of LF when co-administered with artemether is to 
remove residual parasites, cure infection and prevent recrudescence (Ezzet et al., 1998). The 















antimalarial experiment for the testing of LF in Pheroid
™
 formulation compared to a 
reference formulation. The test procedure includes administering a single dose, three days 
after infection followed by daily monitoring and determining parasitemia levels. This test 
allows for the establishment of onset of activity, time to onset of recrudescence and survival 
time (Fidock et al., 2004).  
This study was primarily a proof of concept study and optimization of the LF in Pheroid
™
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Drug discovery and development is a time consuming and costly process and without 
sufficient financial support for scientific research, „neglected diseases‟ such as malaria will 
continue to claim lives in some of the poorest countries in the world. Malaria is a particularly 
devastating disease in Africa, with children and pregnant women being the most vulnerable to 
infection, disease complication and mortality. Currently, drug treatment strategies are 
challenged by the emergence of antimalarial drug resistant parasites therefore necessitating 
drug combination therapy to safeguard the longevity of clinically effective antimalarials. 
Continual efforts are being made to discover or synthesize novel antimalarial compounds 
with unique modes of action.  
LF was synthesized in the 1970‟s and is currently partnered with artemether as a fixed dose 
ACT for the treatment of uncomplicated malaria. As is the case with many „old‟ drugs, 
extensive pre-clinical investigation was not performed before clinical use, however, LF is still 
effective and well tolerated despite its poor aqueous solubility and variable bioavailability. 
The aim of this study was to improve the bioavailability of LF. It was hypothesized that by 
improving the solubility of LF with the application of Pheroid
™ 
technology we could produce 
a LF formulation with enhanced bioavailability and efficacy as well as predictable 
pharmacokinetics. 
The in silico tools predicted that LF had low solubility and good (Caco-2 cell membrane) 
permeability. Computational predictive models are usually used to explain experimental 
results or predict pharmacokinetic properties of new drug compounds. The low aqueous 
solubility of LF would result in inadequate dissolution and explain the slow, erratic 
absorption of LF. The fat in ingested food would facilitate the solubilisation and therefore 
improving the absorption of LF. It is thus relevant to describe the physicochemical factors of 
a test compound that may influence drug pharmacokinetics and efficacy. 
With the advantage of mass spectrometric detection, sensitive and selective LC-MS/MS 
methods were developed and validated for the quantitation of LF in mouse whole blood and 
plasma. Due to the short analytical run time and sensitivity of mass spectrometric detection, 
the developed methods are suitable for high throughput analysis using a 20 µl sample 















the two biological matrices and using the PPK model no substantial differences were found in 
the PK parameters. Blood-plasma ratio testing should be included into pre-clinical drug 
testing and when validating new quantitative LC-MS/MS methods, the validation should be 
performed in the same matrix as the test samples to minimize the risk of matrix effects and 
ensure accurate analysis.  
The bioavailability of LF with the application of Pheroid
™
 technology as a drug delivery 
system was 3.2 times higher when compared to LF in a reference (aqueous) solution in the 
starved state. LF dissolves completely in canola oil, results from the bioavailability study 
prove, and reiterates clinical findings, that the absorption of LF in the GI tract is limited by 
drug dissolution as LF in canola oil and Pheroid
™
 formulation produced similar 
bioavailability values. The concentration-time profiles for LF in canola oil and Pheroid
™
 
formulation differ, when in the Pheroid
™
 formulation WB/plasma levels of LF remain at a 
higher concentration for a longer period of time, suggesting that the Pheroid
™
 has a more 
complicated functionality than just improving the solubility of the lipophilic drug. This may 
be a valuable characteristic of the formulation as LF (when co-formulated with artemether) 
functions to remove residual parasites and cure malarial infection. Using Pheroid
™
 
technology, LF could be maintained at a therapeutic blood level for longer, minimising the 
risk of recrudescent infections.  
When dissolved and administered in the reference formulation, the bioavailability of LF was 
2.7 times higher in the fed compared to the fasted state. LF in Pheroid
™
 formulation is not 
associated with a positive food effect and produced similar bioavailability values in the fed 
and fasted state with reduced between-subject variability. Previous clinical studies found that 
very little dietary fat (1.6 g) is required to achieve optimum LF plasma levels and that the 
normal African diet contained sufficient quantities of fat to ensure optimum absorption of LF, 
yet LF is still associated with variable pharmacokinetics. Food did improve the absorption of 
LF in the reference formulation however the between subject variability was still high when 
compared to LF in Pheroid
™
 formulation. Unpredictable pharmacokinetics may favour the 
development of parasite drug resistance and undermine the efficacy of drug dosage regimens. 
The in vitro efficacy of LF in reference solution and Pheroid
™
 formulation was tested against 
a chloroquine sensitive (D10) strain of P. falciparum. The results indicated that LF in 
Pheroid
™
 formulation improved in vitro antimalarial efficacy by 46% when compared to LF 















conclusions. The mean IC50 values for LF in reference and Pheroid
™
 formulation were 50.9 
and 27.1 nM respectively. This improvement of antimalarial efficacy in vitro was not seen in 
vivo. Despite the enhancement in bioavailability of LF with the application of Pheroid
™
 
formulation, no significant improvement in antimalarial efficacy was seen in vivo.  
The in vivo efficacy experiment performed was a modified Peter‟s four day suppressive test; 
the test animals were inoculated with parasitized erythrocytes (P. berghei, ANKA strain) to 
induce an infection and were then treated with LF in reference solution or Pheroid
™
 
formulation for four consecutive days where after parasitemia levels were monitored until the 
experimental end point. The antimalarial efficacy of LF in both formulations was tested at 10, 
5 and 1 mg/kg dosage concentrations. None of the test or control animals survived the 
infection and LF in reference solution and Pheroid
™
 formulation performed comparably to 
CQ (positive control). Also the effective dose of LF, in reference and Pheroid
™
 formulation, 
was not determined. If the experiment was done testing LF at higher concentrations, 
investigating both formulations in the same experiment and if blood samples were collected 
for LF quantitation as well as for the determination of parasitemia, one would be able to 
make more conclusive deductions, relating the systemic concentration of LF to the 
antimalarial action rendered by LF in the Pheroid
™
 formulation compared to the reference 
formulation.  
It can be concluded that the primary experimental aims and objectives were achieved during 
this study. This study was intended as a „proof of concept‟ study, and it has been proven that 
Pheroid
™
 technology may be used to enhance the bioavailability of lipophilic drugs such as 
LF as well as reduce variability in bioavailability. With the application of Pheroid
™
 
technology, the bioavailability of oral administrated LF was not affected by food. This would 
be an important implication, especially for severely ill malaria patients as LF in Pheroid
™ 
formulation will be able to achieve optimum bioavailability irrespective of fed or fasted state.  
The LF in Pheroid
™
 formulation used in this study was preliminary and further optimization 
of the formulation should be performed. Future studies may involve an extensive 
pharmacokinetic evaluation of optimized LF in Pheroid
™
 formulation to determine the effect 
of the Pheroid
™
 on LF PK parameters such as volume of distribution, drug clearance and 
elimination half-life. Further pre-clinical efficacy studies should be performed to confirm that 
the Pheroid
™
 formulation improves the efficacy of LF more so than the reference formulation 
or canola oil. It would be advantageous to determine if LF in Pheroid
™















effective than LF in canola oil and thereby indicating that the Pheroid
™
 functions in 
improving LF solubility as well as delivering the drug to the target site.  
